---
document_datetime: 2023-09-21 20:35:52
document_pages: 126
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/varuby-epar-public-assessment-report_en.pdf
document_name: varuby-epar-public-assessment-report_en.pdf
version: success
processing_time: 127.6319153
conversion_datetime: 2025-12-30 12:51:35.096988
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

23 February 2017 EMA/239011/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Varuby International non-proprietary name: rolapitant Procedure No. EMEA/H/C/004196/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Medicinal product no longer authorised

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                  | 6                                                                                                      |
|---------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier .....................................................................................6     |                                                                                                        |
| 1.2. Steps taken for the assessment of the product                                                                        | ........................................................7                                              |
| 2. Scientific discussion................................................................................                  | 9                                                                                                      |
| 2.1. Problem statement...............................................................................................9    |                                                                                                        |
| 2.1.1. Disease or condition                                                                                               | ..........................................................................................9 authorised |
| 2.1.2. Epidemiology and risk factors                                                                                      | .............................................................................9                         |
| 2.1.3. Biologic features, aetiology and pathogenesis                                                                      | ..................................................... 10                                               |
| 2.1.4. Clinical presentation, diagnosis.                                                                                  | ........................................................................ 10                            |
| 2.1.5. Management...................................................................................................      | 11                                                                                                     |
| 2.2. Quality aspects ..................................................................................................   | 13                                                                                                     |
| 2.2.1. Introduction....................................................................................................   | 13                                                                                                     |
| 2.2.2. Active Substance.............................................................................................      | 13                                                                                                     |
| 2.2.3. Finished Medicinal Product................................................................................         | 15                                                                                                     |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................                        | 17                                                                                                     |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects longer                                          | ...................... 17                                                                              |
| 2.2.6. Recommendations for future quality development no                                                                  | ............................................... 18                                                     |
| 2.3. Non-clinical aspects............................................................................................     | 18                                                                                                     |
| 2.3.1. Introduction....................................................................................................   | 18                                                                                                     |
| 2.3.2. Pharmacology.................................................................................................      | 18                                                                                                     |
| 2.3.3. Pharmacokinetics ............................................................................................      | 22                                                                                                     |
| 2.3.4. Toxicology......................................................................................................   | 26                                                                                                     |
| 2.3.5. Ecotoxicity/environmental risk assessment......................................................... product         | 41                                                                                                     |
| 2.3.6. Discussion on non-clinical aspects .....................................................................           | 42                                                                                                     |
| 2.3.7. Conclusion on the non-clinical aspects                                                                             | ............................................................... 44                                     |
| 2.4. Clinical aspects ..................................................................................................  | 44                                                                                                     |
| 2.4.1. Introduction....................................................................................................   | 44                                                                                                     |
| 2.4.2. Pharmacokinetics ............................................................................................      | 45                                                                                                     |
| 2.4.3. Pharmacodynamics..........................................................................................         | 51                                                                                                     |
| 2.4.4. Discussion on clinical pharmacology...................................................................             | 52                                                                                                     |
| 2.4.5. Conclusions on clinical pharmacology................................................................. Medicinal    | 56                                                                                                     |
| 2.5. Clinical efficacy .................................................................................................. | 56                                                                                                     |
| 2.5.1. Dose response study(ies) .................................................................................         | 56                                                                                                     |
| 2.5.2. Main studies                                                                                                       | ................................................................................................... 61 |
| 2.5.3. Discussion on clinical efficacy............................................................................        | 95                                                                                                     |
| 2.5.4. Conclusions on the clinical efficacy ....................................................................          | 99                                                                                                     |
| 2.6. Clinical safety .................................................................................................... | 99                                                                                                     |
| 2.6.1. Discussion on clinical safety............................................................................          | 112                                                                                                    |
| 2.6.2. Conclusions on the clinical safety                                                                                 | .................................................................... 114                               |

<div style=\"page-break-after: always\"></div>

2.7. Risk Management Plan  ...................................................................................... 114

Summary of safety concerns

................................................................................ 114

2.8. Pharmacovigilance ........................................................................................... 119

2.9. New Active Substance ...................................................................................... 119

2.10. Product information ........................................................................................ 119

2.10.1. User consultation  ......................................................................................... 119

2.10.2. Additional monitoring  ................................................................................... 119

3. Benefit-Risk Balance ........................................................................... 119

3.1. Therapeutic Context ......................................................................................... 119

3.1.1. Disease or condition ...................................................................................... 119

3.1.2. Available therapies and unmet medical need  ..................................................... 120

3.1.3. Main clinical studies  ....................................................................................... 120

3.2. Favourable effects  ............................................................................................ 121

3.3. Uncertainties and limitations about favourable effects  ........................................... 121

3.4. Unfavourable effects  ......................................................................................... 122

3.5. Uncertainties and limitations about unfavourable effects ....................................... 122

3.6. Effects Table  .................................................................................................... 123

3.7. Benefit-risk assessment and discussion  ............................................................... 124

3.7.1. Importance of favourable and unfavourable effects  ............................................ 124

3.7.2. Balance of benefits and risks .......................................................................... 125

3.7.3. Additional considerations on the benefit-risk balance ......................................... 125

3.8. Conclusions  ..................................................................................................... 125

4. Recommendations  ............................................................................... 126

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## List of abbreviations

5-HT

Serotonin

ADME

Absorption, distribution, metabolism, excretion

AE

Adverse event

ALP

Alkaline phosphatase

ALT

Alanine aminotransferase Absolute neutrophil count Analysis of covariance Aspartate aminotransferase Area under the concentration x time curve Bioavailability Breast cancer resistance protein Biopharmaceutics Classification System Bioequivalence Concomitant emetogenic chemotherapy Committee for Medicinal Products for Human use Confidence interval Chronic idiopathic cough ? Chemotherapy-induced nausea and vomiting Maximum concentration Cochran-Mantel-Haenszel Critical process parameter Complete response Clinical study report Common Terminology Criteria for Adverse Events Cytochrome P450 Drug-drug interaction Differential Scanning Calorimetry European Commission Electrocardiogram European Union Functional Living Index-Emesis Fourrier Transform Infrared Spectroscopy Gas Chromatography Good Clinical Practice Good Manufacturing Practice Highly emetogenic chemotherapy High performance liquid chromatography Medicinal product no longer authorised

ANC

ANCOVA

AST

AUC

BA

BCRP

BCS

BE

CEC

CHMP

CI

CIC

CINV

Cmax

CMH

CPP

CR

CSR

CTCAE

CYP

DDI

DSC

EC

ECG

EU

FLIE

FT-IR

GC

GCP

GMP

HEC

HPLC

HRMS

High resolution mass spectrometry

ICH

International  Conference  on  Harmonisation  of  Technical  Requirements  for  Registration  of

Pharmaceuticals for Human Use

IPC

In-process control

IR

Infrared

IV

Intravenous

<div style=\"page-break-after: always\"></div>

<!-- image -->

Kb

Equilibrium dissociation constant

KF

Karl Fischer titration

Ki

Inhibition constant

LDPE

Low density polyethylene

LOD

Loss on drying

MEC

Moderately emetogenic chemotherapy

MedDRA

Medical Dictionary for Regulatory Activities

MITT

Modified intent-to-treat National Comprehensive Cancer Network National Formulary Neurokinin-1 Not more than Nausea Vomiting Proven Acceptable Range Pharmacodynamics Positron emission tomography P-glycoprotein European Pharmacopoeia Pharmacokinetic(s) Oral administration postoperative nausea and vomiting Particle Size Distribution Quality Control QT interval corrected using Bazett's formula QT interval corrected using Fridericia's formula Relative Humidity Serious adverse event Summary of Product Characteristics Standardized MedDRA Query System Organ Class Total Aerobic Microbial Count Treatment-emergent adverse event Treatment-emergent serious adverse event Terminal half life Time to maximum plasma concentration Transmissible Spongiform Encephalopathy Total Combined Yeasts/Moulds Count Upper limit of normal United States United States Pharmacopoeia Medicinal product no longer authorised

NCCN

NF

NK1

NMT

NV

PAR

PD

PET

P-gp

Ph. Eur.

PK

PO

PONV

PSD

QC

QTcB

QTcF

RH

SAE

SmPC

SMQ

SOC

TAMC

TEAE

TESAE

t½

Tmax

TSE

TYMC

ULN

US

USP

VAS

Visual analogue scale

Vd

Volume of distribution

WBC

White blood cell

XRPD

X-Ray Powder Diffraction

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Tesaro UK Limited submitted on 2 March 2016 an application for marketing authorisation to the European Medicines Agency (EMA) for Varuby, through the centralised procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 26 March 2015.

The applicant applied for the following indication: Prevention of nausea and vomiting associated with initial and repeat courses of highly and moderately emetogenic cancer chemotherapy in adults Varuby is given as part of combination therapy. The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC - complete and independent application. The applicant indicated that rolapitant was considered to be a new active substance. The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies). Information on Paediatric requirements Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0047/2016 on the agreement of a paediatric investigation plan (PIP). At the time of submission of the application, the PIP P/0047/2016 was not yet completed as some measures were deferred. Information relating to orphan market exclusivity Similarity Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication. Medicinal product no longer authorised

## New active Substance status

The applicant requested the active substance rolapitant contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

<div style=\"page-break-after: always\"></div>

## Scientific Advice

The applicant received Scientific Advice from the CHMP on 26 January 2006. The Scientific Advice pertained to quality, non-clinical and clinical aspects of the dossier.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: Pierre Demolis (up to February 2017) and Alexandre Moreau (from February 2017 onwards) Co-Rapporteur:  Patrick Salmon · The application was received by the EMA on 2 March 2016. · The procedure started on 24 March 2016. · The Rapporteur's first Assessment Report was circulated to all CHMP members on 10 June 2016. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 10 June 2016. The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on 24 June 2016. · During the meeting on 7 September 2016, the PRAC agreed on the PRAC Assessment Overview and Advice to CHMP. The PRAC Assessment Overview and Advice was sent to the applicant on 6 July 2016. · During the meeting on 21 July 2016, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 22 July 2016. The applicant submitted the responses to the CHMP consolidated List of Questions on 9 September 2016. · In cases when a pre-authorisation inspection has been conducted, please reflect the following steps (include/delete information as applicable): · The following GCP inspection were requested by the CHMP and their outcome taken into consideration as part of the Quality/Safety/Efficacy assessment of the product: -A GCP inspection at one investigator site in Korea and the sponsor site in US between 1 and 26 August 2016.  The outcome of the inspection carried out was issued on 12 October 2016. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 18 October 2016. · During the PRAC meeting on 27 October 2016, the PRAC agreed on the PRAC Assessment Overview and Advice to CHMP. The PRAC Assessment Overview and Advice was sent to the applicant on 25 October 2017. Medicinal product no longer authorised

- The Rapporteurs circulated the updated Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 4 November 2016.
- During the CHMP meeting on 10 November 2016, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant.
- The applicant submitted the responses to the CHMP List of Outstanding Issues on 24 January 2017.

<div style=\"page-break-after: always\"></div>

- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Outstanding Issues to all CHMP members on 8 February 2017.
- During the meeting on 20-23 February 2017, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Varuby on 23 February 2017.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

Despite the availability of effective prevention, many patients still suffer from chemotherapy-induced nausea and vomiting (CINV), particularly delayed and often in the form of nausea. CINV can interfere with treatment adherence, functional activity and quality of life in patients treated with cytotoxic chemotherapy.

2.1.1. Disease or condition CINV plays a significant role in cancer patients' morbidity and is associated with significant clinical, social and economic burden. Although the direct mortality of CINV is low, there is significant morbidity, including premature or inadequate termination of effective chemotherapy as well as negative impact on quality of life and daily functioning and increased healthcare costs (National Cancer Institute (NCI, 2015);Wiser W, 2005; Bloechl-Daum B, 2006; Navari RM, 2007). 2.1.2. Epidemiology and risk factors Emetogenicity classification of chemotherapeutic agents The  frequency  of  chemotherapy  induced  emesis  depends  on  the  emetogenic  potential  of  the  specific chemotherapeutic agents used. A 1997 classification scheme gained broad acceptance and was utilized as the basis  for  treatment  recommendations  by  guideline  panels.  Chemotherapy  agents  were  divided  into  five levels:  level  1  (&lt;10%  of  patients  experience  acute  [&lt;or  =  24  hours  after  chemotherapy]  emesis  without antiemetic prophylaxis); level 2 (10% to 30%);level 3 (30% to 60%); level 4 (60% to 90%); and level 5 (&gt;90%). For combinations, the emetogenic level was determined by identifying the most emetogenic agent in the combination and then assessing the relative contribution of the other agents. (Hesketh PJ 1997) A modification of this scheme was proposed at the 2004 Perugia Antiemetic Consensus Guideline meeting that reflected the likelihood of emesis developing following treatment (Roila et al 2006) and was incorporated into  the  most  recent    MASCC/ESMO  2010  guidelines  for  the  prevention  CINV  .This  modified  classification divides chemotherapy agents into four categories · Highly emetic - &gt;90 percent risk of emesis · Moderately emetic - &gt;30 to 90 percent risk of emesis · Low emetogenicity - 10 to 30 percent risk of emesis · Minimally emetic - &lt;10 percent risk of emesis Medicinal product no longer authorised

The objective of antiemetic therapy is the complete prevention of CINV, and this should be achievable in the majority of patients receiving chemotherapy, even with highly emetic agents.

## Incidence and risk factors for CINV

<div style=\"page-break-after: always\"></div>

More than 90% of patients receiving highly emetic chemotherapy (HEC) will have episodes of vomiting. With prophylactic antiemetic therapy, vomiting will be prevented or substantially decreased in about 70% of cases. Nausea is however more difficult to control.

Multiple  factors  influence  the  incidence  and  severity  of  CINV  (Grunberg  SM,  2004;  Hesketh  PJ,  2008), including:

- -Chemotherapy regimen (type of agent and dosage, route of administration.)

## 2.1.4. Clinical presentation, diagnosis.

-Females and patients aged &lt;65 and particularly those &lt;50yrs are at high risk for CINV compared to males and patients aged ≥65 -Poorly managed CINV during the 1st cycle (significantly increased the risk for subsequent CINV by 68 fold) -Incomplete control of CINV during cycle 1 (increased the risk for incomplete response by 6 fold during the cycle 2) -Incomplete control of CINV during cycle 2 (further increased the risk for incomplete response by 8 times during cycle 3) -History of pregnancy-induced nausea and vomiting; -History of limited alcohol intake; -History of motion sickness; -History of anxiety-related disorder. 2.1.3. Biologic features, aetiology and pathogenesis Two phases of CINV mediated by neurotransmitter- driven mechanisms have been defined. The acute emesis is mediated in part by chemotherapy-induced increases in serotonin (5-HT) release and activation of 5-HT3 receptors on vagal afferent neurons located primarily in the gastrointestinal tract. The 5HT3 receptors have been shown to play a significant role in acute-onset CINV. 5-HT3 receptor antagonists such as granisetron and ondansetron are clinically effective in reducing the incidence of CINV in the acute phase, particularly when given in combination with a corticosteroid such as dexamethasone. Delayed emesis, involves the production of substance P, which binds to NK1 receptors in the vomiting centre of the brain, leading to nausea and vomiting. Although NK-1 signalling has some role in acute chemotherapyinduced nausea and vomiting (≤24 h), delayed emesis has primarily been linked with substance P mediated stimulation  of  neurokinin  1  receptors  within  the  central  and  peripheral  nervous  systems.  Blocking  both receptors is required to achieve optimal control of CINV (Hesketh et al., 2003). Medicinal product no longer authorised

The acute phase, which most commonly begins within one to two hours of chemotherapy and usually peaks in the first four to six hours which represents the first 24 hours following chemotherapy,

The delayed phase of CINV, occurs more than 24 hours after chemotherapy - usually 2 to 5 days following the initiation of chemotherapy.

<div style=\"page-break-after: always\"></div>

## 2.1.5. Management

## Current recommendations for antiemetics used to prevent CINV

Antiemetic therapy should be initiated before chemotherapy. Three categories of drugs are routinely used for the management of CINV: type three 5-hydroxytryptamine (5-HT3) receptor antagonists, the neurokinin-1 receptor  antagonists  (NK1  RA),  and  glucocorticoids  to  prevent  acute  nausea  and  vomiting  following chemotherapy of high emetic risk.

| Risk Level         | Chemotherapy            | Antiemetic Guidelines                                                                                   |
|--------------------|-------------------------|---------------------------------------------------------------------------------------------------------|
| High (>90%)        | Cisplatin and other HEC | Day 1: 5-HT3 receptor antagonist + DEX 12 mg + (fos)aprepitant Days 2-3: DEX + aprepitant Day 4: DEX no |
| Moderate (30%-90%) | AC                      | Day 1: 5-HT3 receptor antagonist + DEX + (fos)aprepitant Days 2-3: aprepitant                           |
|                    | Non-AC MEC product      | Day 1: Palonosetron + DEX 8mg                                                                           |

A three-drug regimen including single doses of a 5-HT3 receptor antagonist, dexamethasone and aprepitant given before chemotherapy is recommended. A number of agents are licensed for the prevention of CINV including  the  first-  and  second  generation  5HT3  receptor  antagonists  ondansetron,  granisetron  and palonosetron and NK1 receptor antagonists aprepitant, fosaprepitant, and netupitant. Evidence-based  guidelines  for  CINV  prophylaxis  have  been  published  by  different  contemporary  sources, (ESMO/MASCC  2010;  NCCN  2016;ASCO.There  are  some  differences  between  these  guidelines  but  they generally  recommend  a  5HT3  receptor  antagonists  plus  corticosteroid  for  patients  receiving    moderately emetogenic chemotherapy ( MEC), and combination treatment with an NK-1RA and 5HT3 receptor antagonist plus a corticosteroid for patients receiving HEC. Chemotherapy Antiemetic guidelines MASCC /ESMO Recommendation (Roila 2010) DEX, dexamethasone; AC, combination of an anthracycline (doxorubicin or epirubicin) and cyclophosphamide. (fos)aprepitant: either i.v. or oral form of the NK1 receptor antagonist. No  differences  between  the  5-HT3  receptor  antagonists,  dolasetron,  granisetron,  ondansetron,  tropisetron exist in terms of efficacy. There is no consensus on the dose of dexamethasone to be used in delayed emesis. A single 20-mg dose before chemotherapy is recommended based on the observations that the 20-mg dose had the highest numerical efficacy. Unmet need Medicinal product no longer authorised

Although  antiemetic  prophylaxis  has  been  improving  continuously,  significant  numbers  of  patients  still continue  to  experience  CINV.  Compliance  with  current  emetic  guidelines  can  be  suboptimal.  Treatment  of nausea remains a challenge.

Currently approved treatments have limitations. NK1 receptor antagonists, aprepitant and netupitant are inhibitors of cytochrome P450 (CYP) 3A4, with aprepitant also having CYP3A4 and CYP2C9 induction potential

<div style=\"page-break-after: always\"></div>

and inhibition of other CYP enzymes induction potential. Dosage adjustment of concomitantly administered drugs is required including dexamethasone.

## About the product

Rolapitant  is  a  potent,  selective,  competitive  NK1  receptor  antagonist  with  no  known  activity  at  other pharmacologic targets. It is proposed to be given as part of a regimen that includes dexamethasone and 5HT3 receptor antagonist.

8

mg daily

|                  | Day 1                                               | Day 2                                                                                               | Day 3   | Day 4       |
|------------------|-----------------------------------------------------|-----------------------------------------------------------------------------------------------------|---------|-------------|
| Rolapitant       | 180 mg; approx. 1 to 2 hours prior to chemotherapy  | None                                                                                                |         |             |
| Dexamethasone    | 20 mg; 30 min prior to chemotherapy                 | None                                                                                                |         |             |
| 5-HT3 antagonist | receptor Standard dose of 5-HT3 receptor antagonist | See the prescribing information for administered 5-HT3 receptor antagonist appropriate information. |         | the co- for |

An agreement of a paediatric investigation plan (PIP) and on the granting of a deferral and on the granting of a waiver for rolapitant (EMEA-001768-PIP02-15) is addressed in March 2016. PIP is not required for this application concerning the adults.

twice

Two tablets should be administered orally approximately 1 to 2 hours prior to initiation of each chemotherapy cycle but at no less than 2-weeks intervals. The  following  regimens  are  recommended  for  the  prevention  of  nausea  and  vomiting  associated  with emetogenic cancer therapy: Highly Emetogenic Chemotherapy Regimen: Day 1 Day 2 Day 3 Day 4 Rolapitant 180  mg;  approx.  1  to  2  hours prior to chemotherapy Dexamethasone 20 mg; 30 min prior to chemotherapy 8 mg  twice daily 8 mg twice daily 5-HT3 receptor antagonist Standard dose of 5-HT3 receptor antagonist Moderately Emetogenic Chemotherapy Regimen: Day 1 Day 2 Day 3 Day 4 Rolapitant 180  mg;  approx.  1  to  2  hours prior to chemotherapy None Dexamethasone 20 mg; 30 min prior to chemotherapy None 5-HT3 antagonist Standard dose of 5-HT3 receptor antagonist See  the  prescribing  information  for  the  coadministered 5-HT3 receptor antagonist for appropriate information. Type of Application and aspects on development Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product is presented as film coated tablets containing 90 mg rolapitant (as hydrochloride salt monohydrate) as active substance.

<!-- image -->

The chemical structure of rolapitant was confirmed by a combination of  1 H and  13 C nuclear magnetic resonance spectroscopy, mass spectrometry, elemental analysis, infrared spectroscopy and ultraviolet spectroscopy. Absolute control of stereochemistry is inferred from the known absolute configurations of raw materials.  Epimerisation has been shown not to occur. Chiral HPLC methods have been developed to control starting materials and the active substance. Relative stereochemistry around the piperidine ring was confirmed by  1 H nuclear magnetic resonance spectroscopy.

Other ingredients are: Tablet content: lactose monohydrate, pregelatinised starch, microcrystalline cellulose (E460), povidone K-30, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate. Tablet coating: partially hydrolysed polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, FD&amp;C Blue No. 2 Indigo Carmine Lake (E132) and polysorbate 80. The product is available in polyvinyl chloride/polychlorotrifluoroethylene/aluminium foil twinned blister as described in section 6.5 of the SmPC. 2.2.2. Active Substance General information The chemical name of rolapitant hydrochloride is (5 S ,8 S )-8-[[(1 R )-1-[3,5bis (trifluoromethyl)phenyl] ethoxy]methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one hydrochloride monohydrate corresponding to the molecular formula C25H26F6N2O2.HCl.H2O. It has a relative molecular mass of 554.96 g/mol and the following structure: Figure 1 - Structure of rolapitant hydrochloride Medicinal product no longer authorised

The active substance is a white to off-white, slightly hygroscopic crystalline powder. It exhibits pH dependent solubility in aqueous media with maximum solubility between pH 2-4. It is a BCS class II molecule, exhibiting dissolution rate-limited absorption when dosed orally.

<div style=\"page-break-after: always\"></div>

Rolapitant exhibits stereoisomerism due to the presence of three chiral centres, all of which originate in raw materials. Enantiomeric purity is controlled routinely by chiral HPLC in both the active substance and starting materials' specifications.

Polymorphism has not been observed for rolapitant hydrochloride monohydrate. Two non-hydrated forms have been detected by DSC but convert back to the hydrated form in the presence of moisture. The crystallisation process ensures routine production of the monohydrate form which is conformed routinely by XRPD.

The active substance specification includes tests for description, identification (IR, HPLC), chloride identity (precipitation) and assay (titration), assay (HPLC), impurities (HPLC), stereomeric impurities (chiral HPLC), residual solvents (GC), water content (KF), heavy metals (turbidimetric), residue on ignition (gravimetric), particle size (laser diffraction) and polymorphic form (XRPD).

Rolapitant is considered to be a new active substance. The applicant demonstrated that neither it, nor its derivatives and salts have ever been active substances in products authorised in Europe. Manufacture, characterisation and process controls Rolapitant is synthesized from well-defined starting materials with acceptable specifications. The starting material was re-defined during the procedure in responses to a major objection from CHMP as not enough of the process had been included for the regulator to understand the control and fate of impurities. The revised process, along with impurity (including genotoxic impurities) fate and purge studies ensures that sufficient steps are included in the process description, and that the control strategy is adequate to ensure the quality of the active substance. Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented. The starting material specifications contain tests for genotoxic impurities with limits set to ensure these are not carried through to the active substance. The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of active substances. Potential and actual impurities were well discussed with regards to their origin and characterised. The commercial manufacturing process for the active substance was developed in parallel with the clinical development program. A new process to that used to provide material for phase I and II clinical trials was introduced to facilitate the increased material requirements needed for phase III. The same process will be used commercially. Changes introduced have been presented in sufficient detail and have been justified. It has been demonstrated that the changes did not have a significant impact on the quality of the product. The active substance is packaged in LDPE bags which comply with the EC directive 2002/72/EC and EC 10/2011 as amended. Specification Medicinal product no longer authorised

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

<div style=\"page-break-after: always\"></div>

Batch analysis data on 13 production scale batches of the active substance manufactured by the proposed route were provided, 7 of which were manufactured by the proposed commercial manufacturer. The results are within the specifications and consistent from batch to batch. The microbiological quality of 13 batches of active substance was consistently below 100 cfu/g (TAMC) and 10 cfu/g (TYMC) and given the oral route of administration, no routine test is required. Impurities limits are all set below the qualification threshold.

## Stability

Phase 1-3 clinical trials were carried out using a 50 mg capsule formulation. Following identification of the efficacious dose as 200 mg, development began on a solid dosage form with higher active substance content. A series of prototype dosage forms were investigated in order to identify a bioequivalent formulation. The final commercial formulation is a 100 mg film coated tablet, shown to be bioequivalent following optimisation of content for manufacturability. All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur. standards. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.1.1 of this report.

Stability data from three pilot scale batches of active substance from the proposed manufacturer stored in a container closure system representative of that intended for the market for up to 36 months under long term conditions (25 ºC / 60% RH) and for up to 6 months under accelerated conditions (40 ºC / 75% RH) according to the ICH guidelines were provided. The following parameters were tested: description, identity, water content, assay, impurities, particle size (only for long term batches) and microbial limits. The analytical methods used were the same as for release, except for the microbial limit tests which use the Ph. Eur. method, and are stability indicating. The polymorphic form had already been shown to be stable so no testing was deemed necessary. Particle size remained constant under long term conditions so was not tested under accelerated conditions. All tested parameters were within the specifications and no significant trends were observed. Photostability testing following the ICH guideline Q1B was performed on one batch showing that the active substance is not photosensitive. Forced degradation studies were carried out by exposing the active substance to heat, light, acid, base and oxidative conditions. Rolapitant hydrochloride monohydrate is stable in the solid state but degrades in aqueous solution at high pH or when treated with an oxidant. The stability results indicate that the active substance manufactured by the proposed supplier is sufficiently stable. The stability results justify the proposed retest period in the proposed container under the proposed conditions. 2.2.3. Finished Medicinal Product Description of the product and pharmaceutical development Varuby is a blue film coated immediate release tablet, debossed with T0101 on one side and 100 on the other, containing 100 mg rolapitant hydrochloride monohydrate, equivalent to 90 mg rolapitant free base. Studies were aimed at developing a robust and stable formulation allowing immediate release and dissolution of the active substance. Rolapitant hydrochloride is a stable BCS class II molecule with absorption limited by its dissolution rate. Accordingly, the active substance is micronized. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

The dissolution method was developed using compendial apparatus. Various parameters were optimized resulting in a method able to achieve sink conditions. The QC method was shown to be discriminatory with respect to manufacturing changes shown to impact the performance of the finished product and is considered to have sufficient discriminatory power.

Additional process development studies were carried out and process parameters optimized using a series of design of experiment studies to study the granulation, drying and milling, and lubrication, compression and coating steps. Target set-points were thus defined for individual process parameters and proven acceptable ranges set. Active substance batches with particle size distributions at the extremes of the proposed specification were also investigated and the proposed limits shown to be suitable. This series of experiments also demonstrated the robustness of the process. Scale up of the process was shown to deliver finished product of adequate quality.

A bioequivalence study was performed showing bioequivalence between the 50 mg capsule used in clinical trials and the proposed commercial 100 mg tablets. The primary packaging is polyvinyl chloride/polychlorotrifluoroethylene/aluminium foil twinned blisters. The materials comply with Ph. Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product. Manufacture of the product and process controls The manufacturing process consists of six main steps: de-lumping and mixing of intra-granular materials, wet granulation followed by  drying and  milling, blending  with extra-granular excipients and  lubrication, compression  to  form  tablets,  film  coating  and  packaging.  The  process  is  considered  to  be  a  standard manufacturing process. Major  steps  of  the  manufacturing  process  have  been  validated  by  manufacturing  three  consecutive production  scale  batches  using  the  intended  processing  conditions.  It  has  been  demonstrated  that  the manufacturing  process  is  capable  of  producing  the  finished  product  of  intended  quality  in  a  reproducible manner. The in-process controls  are  adequate  for  this  type  of  manufacturing  process  and  pharmaceutical form. Product specification The finished product release specifications are appropriate for this kind of dosage form and comprise tests for description,  identity  (FT-IR,  HPLC),  assay  (HPLC),  impurities  (HPLC),  uniformity  of  dosage  units  (USP), dissolution (HPLC), moisture (KF) and microbial enumeration (USP). The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented. Medicinal product no longer authorised

Batch analysis results were provided for the three production scale validation batches confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification. In addition, batch analysis data from 23 previous batches of a range of tablet and capsule strengths (from 2.25-180 mg) used throughout clinical development was provided as supporting information.

<div style=\"page-break-after: always\"></div>

## Stability of the product

Stability data from 3 pilot scale batches of finished product (and an additional batch with a white film coat) stored for up to 24 months under long term conditions (25 ºC / 60% RH) and for up to 6 months under accelerated conditions (40 ºC / 75% RH) according to the ICH guidelines were provided. Other than the white batch, the batches of Varuby are identical to those proposed for marketing, except that they were printed with black ink rather than debossed, and were packed in the primary packaging proposed for marketing. The difference in appearance was not considered likely to enhance stability. Samples were tested for description, water content, dissolution, assay, related substances and microbial enumeration. The analytical procedures used are stability indicating. No significant changes to any of the measured parameters were observed, other than a slight increase in water content over time under long term conditions. Since this doesn't impact any of the other quality attributes, it is not a concern.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

In addition, one batch was exposed to light as defined in the ICH Guideline on Photostability Testing of New Drug Substances and Products. No significant changes to any of the measured parameters were observed under the above conditions. Therefore, Varuby is photostable. Samples were also exposed to freeze/thaw cycles (between -20 and 50  o C) and thermal stress (85  o C). A bulk storage study was carried out on one batch packaged in double LDPE bags for up to 12 months under ambient conditions. No degradation was observed other than under thermal stress where some minor degradants were observed. Based on available stability data, the proposed shelf-life of 36 months without special storage conditions as stated in the SmPC (section 6.3) is acceptable. Adventitious agents It is confirmed that the lactose is produced from milk from healthy animals in the same condition as those used to collect milk for human consumption and that the lactose has been prepared without the use of ruminant material other than calf rennet according to the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents Via Human and veterinary medicinal products. The magnesium stearate is of plant origin. 2.2.4. Discussion on chemical, pharmaceutical and biological aspects Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use. Medicinal product no longer authorised

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

<div style=\"page-break-after: always\"></div>

## 2.2.6. Recommendations for future quality development

Not applicable.

## 2.3. Non-clinical aspects

2.3.1. Introduction The majority of pharmacokinetic studies and all primary pharmacology studies were non-GLP studies. All pivotal toxicology studies and the safety pharmacology studies were carried out in compliance with Good Laboratory practice (GLP) regulations except in vitro hERG in mouse L-929 cells (SN-08107, SN-46553)  and cardiovascular isolated canine Purkinje fibers study (SN05255), cardiovascular study in cynomolgus monkeys ( SN-08107, SN-46553) and central nervous system and respiratory renal and gastrointestinal studies in rats (SN-46553). CHMP Scientific advice was sought regarding the nonclinical programme. 2.3.2. Pharmacology Primary pharmacodynamic studies In vitro studies ( D-46896, GR 73632, 100000503) Table  1:  in  vitro  pharmacology  studies:  Affinity  of  rolapitant  and  it  major  metabolite (M19) for NK1, NK2 and NK3 receptor Medicinal product no longer authorised

<!-- image -->

| GLP aspect             | Type of study                                                                   | Test system                                                                                                                                                                          | Noteworthy Findings                                                                                                                                                                                                                                                                                                             |
|------------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| no GLP D-46896 study   | Affinity of rolapitant for NK1 receptor Medicinal                               | Gerbil, rabbit and monkey striata and cells expressing cloned rat mouse and guinea pig NK receptors. Chinese hamster ovary cells transfected with the recombinant human NK1 receptor | Human recombinant NK1 : Ki = 0.66 nM Gerbil NK1 receptor : Ki = 0.13 nM Guinea pig NK1 receptor : Ki = 0.72 nM Monkey NK1 receptor : Ki = 2.5 nM Rabbit NK1 receptor : Ki = 31.7 nM Mouse NK1 receptor : Ki = 64.4 nM Rat NK1 receptor : Ki = 78.6 nM Human recombinant NK2 : Ki > 1200 nM Human recombinant NK3 : Ki = 4050 nM |
| no GLP 100000503 study | Affinity of major metabolite (M19) of rolapitant for NK1, NK2 and NK3 receptors | Human NK1, NK2 and NK3 receptor                                                                                                                                                      | NK1 : IC50<10 nM (Ki = 0.42 nM) NK2 : IC50=20 000 nM NK3 : IC50=1700 nM                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

## In vivo studies

Table 2: In vivo pharmacology studies with rolapitant

| Type of study No of animals/dose GLP aspect                                             | Doses (mg/kg)                                         | Major findings                                                                                                                                                                                                                                 |
|-----------------------------------------------------------------------------------------|-------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Induced Foot-Thumping in Gerbils                                                        | Induced Foot-Thumping in Gerbils                      | Induced Foot-Thumping in Gerbils                                                                                                                                                                                                               |
| Foot thumping induced by an NK1 agonist (GR 73632) 3F /group No GLP D-46896 SN04917     | Oral by Gavage 0.03- 1 mg/kg                          | Rolapitant blocked NK1 agonist induced foot thumping => ED90 = 0.3 mg/kg. Plasma concentration of rolapitant (4 hours after administration of the ED90 dose of 0.3 mg/kg) = 34 ng/ml (68 nM). authorised                                       |
| Foot thumping induced by an NK1 agonist (GR 73632) 3F/group No GLP D-46896              | Oral by gavage and IV 0.3 mg/kg PO 1.0 mg/kg IV       | Rolapitant blocked NK1 agonist induced foot thumping for up to 24 hours. longer                                                                                                                                                                |
| Emesis studies in Ferrets                                                               | Emesis studies in Ferrets                             | Emesis studies in Ferrets                                                                                                                                                                                                                      |
| Ferrets Acute apomorphine induced retching and vomiting 4M/group No GLP D-46833         | Oral by Gavage 0.01 - 0.3 mg/kg + apomorphine product | Rolapitant produced a significant dose related inhibition of emesis induced by apomorphine =>ED50 = 0.03 mg/kg. no                                                                                                                             |
| Ferrets Acute cisplatin-induced retching and vomiting 4M/group No GLP D-46833 Medicinal | Oral by Gavage 0.03 - 0.3 mg/kg + cisplatin           | Rolapitant produced a significant dose related inhibition of emesis induced by cisplatin => ED50 = 0.07 mg/kg.                                                                                                                                 |
| Ferrets Acute and delayed cisplatin-induced retching and vomiting                       | Oral by Gavage 1 mg/kg                                | A single dose of rolapitant at 1 mg/kg administered 4 hours prior to cisplatin produced 95% inhibition of retching and vomiting over 72 hours. Daily treatment with rolapitant produced 95% inhibition of retching and vomiting over 72 hours. |

<div style=\"page-break-after: always\"></div>

| 4M/group   | + cisplatin   |
|------------|---------------|
| D-46833    |               |

## Secondary pharmacodynamic studies

In vitro pharmacology assays, rolapitant has &gt; 1000-fold lower affinity for a panel of 115 other receptors, transporters, enzymes, or channels. Rolapitant has a little affinity for norephinephrine or dopamine transporters or Cl- channel.  Rolapitant has &gt; 200-fold lower affinity for glucocorticoid receptor, the closest receptor by affinity, than for the NK1 receptor. The major active metabolite M19 has &gt; 1000-fold lower affinity for a panel of 86 other receptors, transporters, enzymes, or channels against which it was tested. The secondary pharmacodynamics experiments indicate that rolapitant and M19 are selective for NK1 over the related NK2 and NK3 receptors (&gt;1000-fold lower affinity). Furthermore, rolapitant and the metabolite M19 were screened against a large panel of other receptors, enzymes and ion channels, the results of which indicate  that  based  on  lower  affinity,  rolipitant  is  unlikely  to  achieve  sufficient  clinical  concentrations  in humans  to  affect  other  receptor/ion  channel  activity,  including  the  closest  receptor  by  affinity,  the glucocorticoid receptor (&gt;200-fold lower affinity). Safety pharmacology programme Table 3: Safety pharmacology studies with rolapitant and its metabolite M19 Medicinal product no longer authorised

| Type of study GLP aspect                                                                                             | Doses/concentrations                                           | Major findings                                                                                                                                                                    |
|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ex vivo                                                                                                              | Ex vivo                                                        | Ex vivo                                                                                                                                                                           |
| Cardiovascular Isolated, canine Purkinje fibers Non-GLP SN05255                                                      | ROLAPITANT 1.19 and 8.04 μM product                            | 8.04 µM: small but statistically significant shortening of action potential duration at all pacing frequencies (APD60 and APD90: - 14.0% and -9.5%, respectively). NEL = 1.19 μM. |
| In vitro                                                                                                             | In vitro                                                       | In vitro                                                                                                                                                                          |
| Cardiovascular hERG: Mouse L- 929 cells stably transfected with human hERG Non-GLP SN-46553 SN-08107 (M19) Medicinal | ROLAPITANT: 0, 0.4, 2.46, 7.18 µM M19: 0.3, 1.0, 3.0, 10, 20μM | hERG : IC50 = 1.05 μM (rolapitant) and = 5.8 μM (M19) Rolapitant at 1.05 µΜ  Safety margin = 278                                                                                 |
| In vivo                                                                                                              | In vivo                                                        | In vivo                                                                                                                                                                           |
| Cardiovascular Cynomolgus Monkeys (Telemetry) Cardiovascular: 5M/group                                               | Oral, by gavage ROLAPITANT Cardiovascular: 0, 1, 2, 5 mg/kg    | Cardiovascular: No treatment related effects on blood pressure, heart rate, ECG. At 6 hours post-dose, plasma drug levels at 2 and 5 mg/kg were 290 and 820 ng/mL, respectively.  |

<div style=\"page-break-after: always\"></div>

| Non-GLP SN-08107 SN-46553                                                                                     |                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cardiovascular Cynomolgus Monkeys Telemetry 6M/Group GLP SN03125                                              | Oral, by gavage ROLAPITANT Single dose : 0, 5, 15 mg/kg                                                                                                                                                                                                                                                     | No changes in heart rate, blood pressure, or ECG intervals or ECG morphology NOEL =15 mg/kg                                                                                                                                                                                                                                                                                                                                                                        |
| CNS, Respiratory, Renal, GI: Sprague-Dawley Rats 6/sex/group SN-03124 (GLP) SN-03123 (GLP) SN-46553 (Non-GLP) | Oral, by gavage CNS (Irwin), Respiratory, Renal, GI (SN-46553) : ROLAPITANT : 0, 5, 10 mg/kg in M only Respiratory (SN-03123): ROLAPITANT single oral dose in M 5, 25, or 100 mg/kg or in F 1, 5, or 25 mg/kg CNS (SN-03124): ROLAPITANT single oral dose :1, 5, or 25 mg/kg in F; 5, 25, or 100 mg/kg in M | CNS: No significant findings in behavioral or autonomic endpoints. Respiratory: No test-article-related effects on respiratory rate, tidal volume, minute volume or arterial pH, blood gases, or bicarbonate levels. Renal: No test-article-related effects on urine volume, urinary electrolyte excretion, serum creatinine, or 24-hour creatinine clearance. GI: No test-article-related effects on gastric emptying or intestinal transit. no longer authorised |

Furthermore,  a  canine  Purkinje  fiber  assay  indicated  that  small  but  statistically  significant  shortening  of action potential duration at all pacing frequencies occurred in fibers exposed to the high concentration of 8.04 μM of rolapitant (APD60 and APD90 were shortened slightly by 14.0% and 9.5%, respectively) but no test article related effects were reported at lower concentrations or on other action potential parameters at any concentration.

6M/Group GLP SN03125 CNS, Respiratory, Renal, GI: Sprague-Dawley Rats 6/sex/group SN-03124 (GLP) SN-03123 (GLP) SN-46553 (Non-GLP) M: male ; F: female; PK: pharmacokinetic; plasma fu : free fraction of drug in plasma; NEL: no effect level The  SN05255,  SN46553  and  SN08107  studies  concern  also  the  evaluation  of  the  potential  for  delayed ventricular repolarization (QT interval prolongation) regarding rolapitant or it major metabolite M19 and were not conducted under GLP conditions. For that reason, the Applicant performed two new studies in December 2016 and in January 2017 for both rolapitant (SN 1000-09-003) and its M19 metabolite (SN 1000-09-004) under GLP conditions (subject to pending final report). The results of all studies are consistent. In addition, a QTc study of rolapitant in humans was conducted at 4x the therapeutic dose, and no QT signal was observed in this study. In vitro rolapitant and M19 weakly inhibited hERG (potassium) current with an IC50 of 1.05 μM and 5.8 μM, respectively. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

In  vivo  safety  pharmacology  studies  were  conducted  to  evaluate  the  safety  of  rolapitant  in  core  organ systems including rat studies of central nervous, respiratory, renal/urinary and gastrointestinal systems and a  monkey  cardiovascular  study.  No  test-article  related  effects  of  concern  were  observed  on  neurologic  or respiratory function at doses up to 25 mg/kg in female rats and 100 mg/kg in male rats or on gastrointestinal or  renal  function  in  male  rats  at  single  oral  doses  of  up  to  10  mg/kg  rolapitant  (SN03123,  SN03124,  D46553). However, the binding affinity of rolapitant for rat NK1 receptor is &gt;100-fold less than for human NK1 receptor.

| Reference   | Species           | Analyte           | Range (ng/mL)   |   LLOQ (ng/mL) | Accuracy (% Diff)   | Precision (% CV)   |
|-------------|-------------------|-------------------|-----------------|----------------|---------------------|--------------------|
| DM27321     | Mouse             | Rolapitant        | 50 to 50000     |             50 | -3.5 to 3.0         | 2.5 to 7.7         |
| Non-GLP     |                   | M19               | 5 to 5000       |              5 | -2.4 to 3.0         | 2.0 to 9.5         |
| DM27320     | Rat               | Rolapitant        | 50 to 50000     |             50 | -5.0 to 2.8         | 1.7 to 12.5        |
| Non-GLP     |                   | M19               | 5 to 5000       |              5 | -4.2 to 4.0         | 2.5 to 12.0        |
| DM27322     | Monkey Rolapitant | Monkey Rolapitant | 50 to 50000     |             50 | -6.0 to 6.0         | 1.8 to 9.1         |
| Non-GLP     | M19               | M19               | 5 to 5000       |              5 | -4.7 to 6.5         | 1.2 to 11.8        |

Rolapitant administered at doses ranging from 1 to 15 mg/kg to male conscious telemetered cynomolgus monkeys did not affect arterial blood pressure, heart rate, ECG intervals or ECG morphology in vivo (D46553, SN03125). In addition, no ECG intervals or morphology changes including QTc intervals were observed in repeat-dose GLP toxicity studies up to an oral dose of 30 mg/kg/day for 9 months and up to an IV dose of 15 mg/kg/day for 14 days in monkeys. Taken together with the in vitro study results, these data suggest that rolapitant does not delay cardiac ventricular repolarization. Pharmacodynamic drug interactions Non clinical studies on pharmacodynamic drug interactions were not submitted. 2.3.3. Pharmacokinetics Quantitative  methods  using  protein  precipitation  followed  by  reverse  phase  HPLC  coupled  with  triple quadruple  mass  spectrometry  (MS/MS)  was  developed  and  validated  for  the  quantitatively  analyses  of rolapitant  and  the  metabolite  M19  in  several  nonclinical  matrices  (mouse  plasma,  rat  plasma,  monkey plasma). Table 4: Representative Validated LC-MS/MS Assays Used to Determine Rolapitant and Metabolite M19 (M19) Concentration in Mouse, Rat, and Monkey Plasma Absorption Single dose studies: Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 5:  Bioavailability of rolapitant after single dose in preclinical species

| Species   | Formulation                      | Dose (mg/kg) Route   | Gender (N)   | Cmax (ng/mL)   | Tmax (hr)   | AUC 0- ∝ (ng*hr/mL)   | F (%)    |
|-----------|----------------------------------|----------------------|--------------|----------------|-------------|-----------------------|----------|
| Rat       | Amorphous HCl Salt               | 5 i.v.               | M (3)        | ND             | ND          | 10400                 |          |
| Rat       | Amorphous HCl Salt               | 5 p.o.               | M (17)       | 556            | 3.6         | 4840 - 7000           | 47 -71 % |
| Rat       | Crystalline HCl monohydrate salt | 5 p.o.               | M (20)       | 379            | 5.0         | 5410 (0-24 hr)        |          |
| Rat       | Crystalline HCl monohydrate salt | 5 p.o.               | F (10)       | 723            | 8.0         | 14900 (0-24 hr)       |          |
| Monkey    | Amorphous HCl Salt               | 2 i.v.               | M (3)        | ND             | ND          | 5200                  |          |
| Monkey    | Amorphous HCl Salt               | 2 p.o.               | M (3)        | 467            | 2.7         | 6540 authorised       | ≈100%    |
| Monkey    | Crystalline HCl monohydrate salt | 2.5 p.o.             | M (3)        | 590            | 4.0         | 11700 (0-72 hr)       |          |

A quantitative whole-body autoradiography (QWBA) study was conducted following a single oral dose of 14Crolapitant (25 mg/kg) to both the albino (Sprague-Dawley) and pigmented rats (Long-Evans). 14C-rolapitant was absorbed rapidly into the blood. The majority of tissues reached peak radiocarbon concentrations at the 8-hr time point, the tissues that had the highest radiocarbon concentrations, at this time point were the liver, lung, pancreas harderian, adrenal, and the wall of the small intestine (range; 18100 to 88900 SCH 619734 ng equiv/g). The lens of the eye had fallen below the limit of quantification in all genders and strains at the 8-hr time point and the tissue-to-blood concentration ratios were on average between 3.5- and 6.2-fold higher than the time-matched blood concentrations. Since the amount of radioactivities was one of the lowest in the ocular tissues among all solid tissues examined in both pigmented and albino rats, the binding affinity of rolapitant to melanin-containing tissues appears to be negligible. Radioactivities were not detected in ocular tissues after 48 hours postdose.

Distribution In Vitro Protein Binding- Plasma Protein Binding Rolapitant is highly plasma protein-bound (99.7-99.9% in mice, rabbits, rats, dogs, monkeys, and humans). Consistently, the metabolite M19 exhibits the same marked binding with the rat, monkey and human plasma proteins (≥ 99.0%). Both rolapitant and the active metabolite M19 are highly non-specifically bound, resulting in the free fraction available for the potential interactions with biological targets likely in the order of 1% or less of the total compounds in the brain. In Vivo Studies The volume of distribution (Vdss) of rolapitant is considered high in rats (Vdss =7.7 L/kg) and moderate in monkeys (Vdss =3.9 L/kg). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Brain Distribution

Table 6 : Brain distribution in gerbils and rats

| Studies       | Rolapitant brain to plasma concentration ratio         | M19 brain to plasma (AUC) ratio   |
|---------------|--------------------------------------------------------|-----------------------------------|
| RAT 5 mg/kg   | 2.4 to 5 ( 24 h post dose) 0.2 to 2.5 (48 h post dose) |                                   |
| RAT 10 mg/kg  | 1.2 (48 h post dose)                                   | 0.682 (24 h post dose)            |
| RAT 25 mg/kg  |                                                        | 0.627 1.2 (24 h post dose)        |
| RAT 100 mg/kg | 1.2 (48 h post dose)                                   |                                   |

| Species   | Formulation   |   Dose (mg/kg) Per os |   Duration (day) | Gender (N)   |   Cmax (ng/mL) |   Tmax (hr) |   AUC 0-24h (ng*hr/mL) |
|-----------|---------------|-----------------------|------------------|--------------|----------------|-------------|------------------------|
| Rat       | Crystalline   |                     5 |                7 | M (20)       |            417 |         2   |                   4680 |
| Rat       | HCl           |                     5 |                7 | F (10)       |           1118 |         2   |                  22500 |
| Rat       | monohydrate   |                     5 |               30 | M (10)       |            551 |         8   |                   8660 |
| Rat       | salt          |                     5 |               30 | F (10) no    |            551 |         8   |                  40600 |
| Monkey    | Amorphous     |                     5 |               15 | M (4)        |           1300 |         1.8 |                  12700 |
| Monkey    | HCl Salt      |                     5 |               30 | M (4)        |           1353 |         2.5 |                  14054 |

The elimination kinetics appeared to be comparable between brain (t½ ~ 4.2-4.4 hr) and plasma (t½ ~ 4.55.3 hr) in rats. Multiple dose studies Table 7: Rolapitant Pharmacokinetic Parameters after Repeated Oral Dosing to Rats and Monkeys Metabolism In vitro studies: 14C-rolapitant  metabolism  was  investigated,  in  a  cofactor  NADPH-dependent  manner,  using  human  liver subcellular  fractions  (microsomal  preparations,  S9  and  cytosolic  fractions),  and  human  recombinant metabolic  enzymes  including  19  recombinant  P450  members  and  3  human  flavin  monooxygenases. Recombinant human CYP3A4 and CYP3A5, to a less extent, catalyzed the formation of M19 from rolapitant. In vivo studies: None of the metabolites detected appear to possess discernible structural alerts for bioactivation specifically, glutathione (GSH) or acyl glucuronide conjugates formed with rolapitant and the metabolites in the nonclinical species (rats and monkeys) were not evidently detected. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table  8:  Comparaison  of  plasma  metabolites  in  mice,  rats  and  monkeys  given  a  single dose of rolapitant

| Metabolite                           | Peak Area Relative to Rolapitant (%)   | Peak Area Relative to Rolapitant (%)   | Peak Area Relative to Rolapitant (%)   | Peak Area Relative to Rolapitant (%)   | Peak Area Relative to Rolapitant (%)   |
|--------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
|                                      | Mouse                                  | Rat                                    | Rat                                    | Monkey                                 | Human                                  |
|                                      | Male                                   | Male                                   | Female                                 | Male + Female                          |                                        |
| M4 Dihydroxy -O- desalkyl-SCH 619734 | NR                                     | 24.5                                   | ND                                     | ND                                     | NA*                                    |
| M4a Hydroxy -O- desalkyl- SCH 619734 | NR                                     | 24.5                                   | ND                                     | ND                                     | NA*                                    |
| M6 Hydroxy -O- desalkyl- SCH 619734  | NR                                     | 26.0                                   | ND                                     | ND                                     | NA*                                    |
| M19 (M19) Hydroxy- SCH 619734        | 1.1                                    | 50.4                                   | 3.8                                    | 11 -17                                 | 50                                     |
| M21 Hydroxy- SCH 619734              | 5.8                                    | 4.0                                    | 5.0                                    | ND                                     | NA*                                    |
| ROLAPITANT                           | 100                                    | 100                                    | 100                                    | 100                                    | NA*                                    |

| Species   | N   | Dose (mg/kg)       | Route   | Urine (% dose)   | Faeces (% dose) no   | Bile (% dose)   | Recovery (% dose)   | Time (h)   |
|-----------|-----|--------------------|---------|------------------|----------------------|-----------------|---------------------|------------|
| Rat       | 2a  | 5                  | IV      | 14.9             | NC                   | 25.5            | 40.3                | 0-24       |
| Rat       | 3   | 5                  | IV      | 34.1             | 54.6                 | NC              | 92.9                | 0-168      |
| Rat       | 2a  | 15.6               | PO      | 10.1             | NC                   | 22.3            | 32.4                | 0-24       |
| Rat       | 3   | 5                  | PO      | 31.3             | 51.8                 | NC              | 87.8                | 0-168      |
| Monkey    | 2a  | 2                  | IV      | 7.5              | NC                   | 48              | 55.5                | 0-48       |
| Monkey    | 3   | 2                  | IV      | 18.6             | 58.4                 | NC              | 77.3                | 0-240      |
| Monkey    | 2a  | 10                 | PO      | 5.2              | NC                   | 31.8            | 37.0                | 0-48       |
| Monkey    | 3   | 2                  | PO      | 18.1 product     | 56.9                 | NC              | 75.7                | 0-240      |
| Humans    |     | 180 mg Single dose | PO      | 14.2             | 73                   |                 |                     | 6 weeks    |

|                           |   Blood |   Plasma |   Milk |   Blood |   Plasma |
|---------------------------|---------|----------|--------|---------|----------|
| Cmax (ng equiv/g)         |    4470 |     5990 |  14100 |     356 |      369 |
| Tmax (hr)                 |       8 |        8 |     12 |      22 |       22 |
| AUCo-48hr (ng equiv*hr/g) |  124000 |   156000 | 331000 |   11500 |    12000 |

ND, not detected on Day 1 but detected in Day 5 plasma ; NR, not reported as detected by either MS or online 14C radiometric detection NA*: No details available in Humans, wathever the other metabolites their plasma exposure are &lt; 10% Excretion Table 9 : Excretion of rolapitant (SN04917 (No GLP)) a : bile duct-cannulated animals Milk excretion Table 10 : Pharmacokinetic Parameters of Rolapitant in Dams and Pups after Oral Administration (25 mg/kg) to Postpartum Female Rats Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 2.3.4. Toxicology

## Single dose toxicity

Table 11 : Summary of acute toxicity studies performed with rolapitant

| Species/ Sex/Number/Gr oup Study ID GLP aspect   | Dose/Route (mg/kg)                                                        | Approx. Lethal dose / observed max non- lethal dose                                                          | Major findings                                                                                                                                                                                                                                                                                                                                                                                         |
|--------------------------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Mouse 3 days 5M & 5F SN 05220 GLP                | Oral, by gavage 300, 450, 900, 1800                                       |                                                                                                              | Mortality: 2M & 3F at 450 mg/kg, 4M & 4F at 900 mg/kg, 5M & 3F at 1800 mg/kg found dead after single dose. 1F at 300 mg/kg and 2F at 1800 mg/kg euthanized after single dose. Physical Signs: In M & F at all doses, convulsions, hypoactivity, impaired equilibrium, intermittent tremors and/or convulsions, partial closure of eyes, prostration. authorised                                        |
| Rat 3M & 3F SN 03101 GLP                         | Oral, by gavage M: 0, 0, 100, 500, 1000, 2000 F: 0, 0, 50, 250, 500, 1000 | Observed Maximum Non lethal Dose (mg/kg) F: 100 M: 1000 Approximate Lethal Dose (mg/kg) F: 500 M: 2000 no    | Mortality: 1/3 F at 500 mg/kg, 3/3 F at 1000 mg/kg; 1/3 M at 2000 mg/kg Physical Signs: Hunched appearance, hypoactivity, tremors in F at ≥250 mg/kg and M at ≥500 mg/kg. Ataxia, abnormal stool M&F at 500 and 1000 mg/kg and M at 2000 mg/kg. Labored breathing, coolness to touch, chromorhinorrhea and salivation in M at 2000 mg/kg. longer                                                       |
| Rat 3M&3F SN 03102 GLP                           | Intraperitoneal M: 0, 125, 250, 500, 1000 F: 0, 125, 250, 500 Medicinal   | Observed Maximum Nonlethal Dose (mg/kg) F: 250 M: 500 Approximate Lethal Dose (mg/kg) F: 500 M: 1000 product | Mortality: 1/3 F at 500 mg/kg; 3/3 M 1000 mg/kg. Physical Signs: Hypoactivity ≥250 mg/kg. Ataxia and hunched posture F at 250 mg/kg, M&F at 500 mg/kg, and M at 1000 mg/kg. Abnormal stool. Chromodacryorrhea and fecal M at 500 mg/kg. Labored breathing and urogenital staining in F at 500 mg/kg. Tremors in M&F at 500 mg/kg and M at 1000 mg/kg. clonic convulsions, prostration M at 1000 mg/kg. |

<div style=\"page-break-after: always\"></div>

| Monkey/ Cynomolgus 1M&1F SN 03126 GLP   | Oral, by gavage 25, 50, 75, 100, 150, 200   | Observed Maximum Nonlethal Dose (mg/kg) F: 100 M: 200 Approximate Lethal Dose (mg/kg) F: 100 M: 200   | Mortality: F at 200 mg/kg Clinical Signs: F at 200 mg/kg: convulsions, emesis, hypothermia, prostration, and morbidity. At 150 mg/kg, excessive vocalization in M, hyperactivity in F, face rubbing in M&F.   |
|-----------------------------------------|---------------------------------------------|-------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Monkey/ Cynomolgus 8F SN 08134 GLP      | Oral, by gavage 100                         | Observed Maximum Nonlethal Dose (mg/kg) F: 100                                                        | Emesis, hypoactivity, and abnormal posture.                                                                                                                                                                   |

| Species/Sex/ Number/Group Study ID/ GLP aspects                               | Dose (mg/kg/da y) / Duration /Route    | NOAEL (mg/kg/day )   | Major findings no                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------------------------------------------------|----------------------------------------|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IV INFUSION                                                                   | IV INFUSION                            | IV INFUSION          | IV INFUSION                                                                                                                                                                                                                                                                                                                                                 |
| Rat 14 days toxicity study Tox 10M&10F TK: 12M&12F SN 07395 GLP 18, Medicinal | IV infusion Saline, Vehicle, 4.5, 36   | NOAEL = 18 product   | - At 36 mg/kg/day: sacrificed after the first dosing due to inability to infuse such volume (20 mL/kg) reliably. - in 4.5 and 18 mg/kg/day group : no findings                                                                                                                                                                                              |
| Monkey/ Cynomolgus 14 days toxicity study 4M&4F SN 07393                      | IV infusion Saline, vehicle, 5, 10, 20 | NOAEL : F = 5 M < 5  | Mortality: 14 monkeys pre-terminally euthanized due to clinical observation findings: 4M/4 at the 5 mg/kg, 8/8 at 20 mg/kg; 1M/4 +1 F/4 at 10 mg/kg : hunched posture, prostration, hypoactivity, ataxia, pulling hair, no food consumption, coughing/gagging, vomitus, excessive salivation, and retching. 2M sacrificed on D10 at 5 mg/kg : ↓ in red cell |

BWG = body weight gain, F = female, M = male, NA = not applicable, TK = toxicokinetics a All rolapitant doses as hydrochloride monohydrate salt Repeat dose toxicity Table 12 : Summary of repeat-dose toxicity studies Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| GLP                                                                                                             |                                                |                                                                | mass and albumin with ↑ cholesterol and triglycerides, 1M with notable ↓ in reticulocyte and platelet counts.                                                                                                                                                                                                                                                               |
|-----------------------------------------------------------------------------------------------------------------|------------------------------------------------|----------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Monkey/ Cynomolgus 14 days toxicity study Main study: 4M&4F Recovery: 2M&2F for Groups 2 and 5 only SN-2013-009 | IV infusion Saline, vehicle, 3, 10, 20/15      | NOAEL =10 (30 minute infusion) NOAEL = 15 (45 minute infusion) | 20mg/kg/day: convulsions, decreased activity, recumbency, and ataxia  resulted in a dose reduction to 15mg/kg/day and a lengthening of the infusion time to 45 minutes (20/15 mg/kg, 45 minutes infusion). authorised                                                                                                                                                      |
| ORAL (GAVAGE) no longer                                                                                         | ORAL (GAVAGE) no longer                        | ORAL (GAVAGE) no longer                                        | ORAL (GAVAGE) no longer                                                                                                                                                                                                                                                                                                                                                     |
| Mouse 3 months toxicity study Toxicity: 10M&10F TK: 30M&30F SN 03665 GLP Rat                                    | Oral, by gavage 0, 25, 75, 150 Oral, by gavage | NOAEL = 75 product                                             | Organ wt (changes listed as relative to body wt) • ↑ Liver wt in M&F at ≥75 mg/kg • ↓ Uterine wt (-19%) at 150 mg/kg Histopathology • Liver: centrilobular hepatocellular hypertrophy in M at ≥25 mg/kg and F at ≥75 mg/kg P450 Gene Expression • Induction of CYP 2B1/2B2 and CYP 3A1 in M (~7-fold for both) and F (~4- and ~9-fold, respectively) - only HD investigated |
| 3 months toxicity study Toxicity : 10M&10F TK : 30M&30F SN 03409 GLP                                            | M : 0, 5, 25, 100 F : 0, 1, 5, 25 Medicinal    | NOAEL = 5                                                      | Body weights: ↓ BWG: in M at 100 mg/kg Biochemistry: ↑ protein, albumin, and globulin at 25 mg/kg; ↓ A/G and ↑ calcium at 100 mg/kg Organ weights: ↑ liver wt. in M at 100 mg/kg. Histopathology: Epididymes: vacuolation of epithelium at ≥25 mg/kg                                                                                                                        |
| Rat 3 months toxicity study                                                                                     | Oral, by gavage                                | NOAEL M = 75                                                   | Clinical signs: dose-related peri-oral food-like material associated with salivation at ≥50 mg/kg, convulsions on F43 to termination in 1F at 125                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Toxicity: 10M&10F TK: 15M&15F P450 Gene Expression : 5M&5F control and high dose only SN 03664 GLP     | 0, 50, 75, 125                | (based on histo- pathology & organ wt) F = 50 (based on organ wt).   | mg/kg Body weights: ↓ BWG in F at 125 mg/kg Food consumption: transient ↓ on D7 at ≥ 50 mg/kg. Hematology: slight ↓ RBC, Hb, Hct, microcytosis ( ↓ MCV, MCH) in F at 125 mg/kg Biochemistry: ↑ protein, ↑ globulin at 125 mg/kg in M and at ≥75 mg/kg in F, ↓ TG at 125 mg/kg in M and at ≥50 mg/kg in F Organ weights: ↑ Liver at ≥50 mg/kg, ↑ Thyroid and adrenal in M at 125 mg/kg, ↑ Kidney wt in M at ≥50 mg/kg, ↓ Uterus wt in F at 125 mg/kg. Histopathology: • Liver: centrilobular hypertrophy at ≥50 mg/kg, multinucleated hepatocytes in 2/10 M at 125 mg/kg • Thyroid: follicular cell hyperplasia in M at 125 mg/kg • Adrenal gland: hyperplasia of zona fasciculate in 1/10 M at 125 mg/kg • Kidney: focal hyperplasia of tubular cells in outer stripe of kidney in M at ≥75 mg/kg Ultrastructural Pathology (selected control and high-dosed M only): proliferation of smooth endoplasmic reticulum in tubular epithelial cells of pars recta of kidney, compatible with enzyme induction. P450 Gene Expression: induction of hepatic CYP 2B1/2B2 (~7- to 13-fold) and CYP 3A1 (~12- to no longer authorised   |
|--------------------------------------------------------------------------------------------------------|-------------------------------|----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Rat 6 months toxicity study Toxicity : 15/sex/group TK 3/sex/group/tim e point SN 03115. GLP Medicinal | oral by gavage 0, 25, 50, 100 | NOAEL = 100 product                                                  | - Physical signs: ↑ incidence of salivation in M&F 50 and 100 mg/kg/day. - ↓ BWG on D184 in F 25, 50, and 100 mg/kg/day (-20.4, -21.4. and -20.6%, respectively) - Serum Biochemistry: a slight to mild ↓ in total and conjugated bilirubin in all dosage level in M&F, with a dose-related trend only in M. Minimal ↑ Cholesterol F all dose groups. Mildly ↓ TG in all doses with dose-related trend only in males. - Organ wt: ↑ liver weight correlated with hepatocellular hypertrophy. ↓ absolute uterus weight in all dosage level. - Histopathological findings : • Liver: minimal to moderate centrilobular hepatocellular hypertrophy with an apparent dose-related increase in incidence and severity, multinucleated hepatocytes at 50 and 100 mg/kg/day, single cell necrosis at 50 and 100 mg/kg/day, eosinophilic cell focus at 100 mg/kg/day in                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

A/G  =  albumin/globulin  ratio,  BWG  =  body  weight  gain,  ECG  =  electrocardiogram,  F  =  female,  Hb  = hemoglobin, Hct = hematocrit, M = male, MCH = mean corpuscular hemoglobin, MCV = mean corpuscular volume, PBS = phosphate buffered saline, RBC = red blood cells, TK = toxicokinetics WBC = white blood cells, wt = weight, w/v = weight to volume ratio. D: day

<!-- image -->

|                                                                             |                                |                   | M, ↑ incidence of minimal to slight hepatocellular vacuolation in M. • Thyroid: minimal to slight follicular cell hypertrophy at 50 and 100 mg/kg/day in M&F • Epididymes: a minimal vacuolation of the tubular epithelium (in all M at all doses)  Vacuolation of epithelial cells is a common degenerative change in the epididymis of aged rats.                                                                                                                                                                                                                                                                                                                                                          |
|-----------------------------------------------------------------------------|--------------------------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Monkey/ Cynomolgus 28 days toxicity study 4M&4F SN 05015 GLP                | Oral, by gavage 0, 30, 60, 100 | NOAEL =30         | Mortality: All animals at 60 and 100 mg/kg euthanized after 2 and 3 day dosing due to treatment-related clinical signs. At ≥60 mg/kg, loose/soft stool, emesis, hypoactivity, weakness, coolness to touch, hunched appearance, ataxia, prostration, and/or convulsions. Stress-related ↑ WBC, neutrophils and ↓ lymphocytes ≥60 mg/kg. Histopathology: • Pancreas: at ≥60 mg/kg, vacuolar degeneration of pancreatic acinar cells and • Stomach: vacuolar degeneration of glandular epithelium of stomach. • Heart : Multifocal arteriolar degeneration of the heart in 1 M at 60 mg/kg possibly secondary to seizures.  Traumatic injuries secondary to convulsive activity ≥60 mm/kg. no longer authorised |
| Monkey/ Cynomolgus 3 months toxicity study 4M&4F SN 03098                   | Oral, by gavage 0, 1, 5, 15    | NOAEL =15 product | None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| GLP Monkey/ Cynomolgus 9 months toxicity study 4M&4F SN 03663 GLP Medicinal | oral by gavage 0, 2.5, 15, 30  | NOAEL =30         | Minimal focal necrosis in the liver of 3 out of 4 high-dose (30 mg/kg/day) in M.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

In rodents, rolapitant was tested in repeated dose oral toxicity studies up to 26-weeks in duration, and the liver, thyroid, kidneys, epidymis and uterus were identified as target organs.

<div style=\"page-break-after: always\"></div>

Liver  weight  increased  with  dose-dependent,  which  correlated  with  histopathological  findings  such  as hepatocellular  hypertrophy.  In  the  thyroid,  the  incidence  of  follicular  cell  hypertrophy  was  increased  at  all doses and relative thyroid weights were increased at the high dose. The changes in the liver and thyroid appear  to  be  related  to  the  activation  of  drug  metabolizing  enzymes  (increased  CYP  gene  expression (CYP2B1/2B2 and CYP 3A1) and may not be relevant to humans. In the 3-month dose range-finding study, additional observations in males at 125 mg/kg/day consisted of hyperplasia of the tubular cells of the outer stripe of the kidney that was associated with endoplasmic reticulum proliferation, and minimal hyperplasia of the  zona  faciculata  in  the  adrenal  gland,  both  considered  consistent  with  enzyme  induction.  Moreover treatment-related minimal vacuolation in the epididymis was not considered adverse since the changes were minimal and did not increase in severity with longer duration treatment. Decreased absolute uterus weight occurred in 3-months repeated doses studies in mice from dose of 1 mg/kg/day and in rats from dose of 50 mg/kg/day and in 6-months repeated doses study in rat from dose of 25 mg/kg/day.

<!-- image -->

| Type of test/study ID/GLP                              | Test system Method of administration                               | Concentrations/ Concentration range/ Metabolising system                                                                                                            | Results   |
|--------------------------------------------------------|--------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| In vitro                                               |                                                                    |                                                                                                                                                                     |           |
| Ames Gene mutations in bacteria SN 03113 GLP Medicinal | Salmonella typhimurium TA 1535, TA97a, TA98, TA100, TA102, WP2uvrA | 31.2 to 5000 µg/plate +/- S9                                                                                                                                        | negative  |
| Chromosome aberration SN 03114 GLP                     | Human peripheral blood lymphocytes                                 | -S9: 2.93 to 23.4 µg/mL (4-hour treatment) and 10 to 40 μg/mL (19-hour treatment). +S9: 5.86 to 46.9 μg/mL (4-hour treatment) and 40 to 70 μg/mL (4-hour treatment) | negative  |
| In vivo                                                |                                                                    |                                                                                                                                                                     |           |
| Micronucleus test                                      | Mouse                                                              | 0, 31.25, 62.5, 125 mg/kg for 2                                                                                                                                     | negative  |

In monkeys, the oral administration of rolapitant at dosage levels as high as 15 mg/kg/day for 3 months and 30 mg/kg/day for 9 months resulted in no treatment-related findings. However in an oral one month study, all  animals  in  the  60  and  100  mg/kg/day  dosage  levels  were  euthanized  due  to  treatment-related  clinical signs, including convulsions. In addition, convulsions were observed in mice, oral doses of 300 mg/kg/day and intraperitoneal doses of 125 mg/kg/day. In rats, convulsions occurred following a single IP dose of 1000 mg/kg and in a single animal given 125 mg/kg/day in a 3-month oral toxicity study. Given the differences in half-lives and the difference in dosing in animals (repeated daily dosing) and in humans (single dose per treatment cycle), the Applicant considered for the safety margin calculation that direct comparison of steady-state AUC0-24h values in animals to AUC0-∞ values following a single dose in humans to be misleading. Thus, to allow for a comparison of cumulative total exposure in animals relative to the total exposure in humans over the same timeframe, animal ' AUC Projected ' values by multiplying the daily, steady state AUC0-24h values for rolapitant and metabolite M19 in animals by a factor of  14. This approach, comparing projected human steady state exposure for two weekly dosing intervals to cumulative exposure in the non-clinical species over the same time period is reasonable when considering the significant difference in half-lives of the drug and major metabolite M19 between non-clinical species and humans. Genotoxicity Table 13 : Summary of genotoxicity studies performed with rolapitant: Type of test/study ID/GLP In vitro Ames Gene mutations bacteria SN 03113 GLP Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| SN 03261 GLP   | 6 M + 6F /group IP Micronuclei in marrow cells   | days Mortality at ≥ 250 mg/kg, Clinical signs at ≥ 62.5 mg/kg/day : hypoactivity and/or flattened posture Bone marrow toxicity at 125 mg/kg/day at the 48-hour harvest.   |
|----------------|--------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Type of test/study ID/GLP                    | Test system Method of administration                                       | Concentrations/ Concentration range/ Metabolising system no                                                             | Results                                |
|----------------------------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|----------------------------------------|
| In vitro                                     |                                                                            |                                                                                                                         |                                        |
| Ames Gene mutations in bacteria SN 08101 GLP | Salmonella typhimurium TA 1535, TA97a, TA98, TA100, TA102, WP2uvrA product | 78 (strain 1535 -S9) to 5000 µg/plate +/- S9                                                                            | negative                               |
| Chromosone aberration SN 08102 GLP           | Human peripheral blood lymphocytes                                         | -S9: 15 to 23.4 µg/mL (4-hour treatment) and 7.5-60 μg/mL (19- hour treatment). +S9: 30 to 100 μg/mL (4-hour treatment) | Negative Doses limited by cytotoxicity |

| Species/Sex/ Number/Group Study ID/ GLP aspects   | Dose (mg/kg/day ) / Duration /Route                          | NOAEL (mg/kg/d ay)    | Major findings                                                                                                                                                            |
|---------------------------------------------------|--------------------------------------------------------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Mouse (CD-1) Two-Year Oral Carcinogenicity Study  | oral gavage once daily 0 (control), 0 (control), 25, 75, 150 | NOAEL = 150 mg/kg/day | - Non-neoplastic findings : - Glandular stomach : ↑ incidence/severity of lymphoid aggregates in F at 150 mg/kg, ↑ incidence/severity of mucosal hyperplasia at 150 mg/kg |

The dose ranges evaluated in the GLP bacterial gene mutation study were based on an exploratory study which  identified  excessive  cytotoxicity  in  Salmonella  typhimurium  strains,  at  higher  doses.  Rolapitant  was negative for revertant colony counts in all strains tested with or without metabolic activation indicating that rolapitant is negative for bacterial gene mutations. Rolapitant was also negative for chromosome aberrations in  human  peripheral  blood  lymphocytes  with  or  without  metabolic  activation  in  a  GLP-compliant  assay.  A dose-range finding study was performed for the in vivo bone marrow micronucleus assay and doses of 15.6, 31.3, 62.5, and 125 mg/kg/day were selected for the definitive micronucleus assay based on the significant mortality  observed at ≥ 250mg/kg/day. Rolipitant was negative in the in vivo bone marrow micronucleus study in CD1 mice dosed with rolapitant ip. The pharmacologically active primary metabolite, M19 was also assessed for genotoxicity in a GLP-compliant bacterial mutagenicity test and a GLP compliant chromosomal aberration study. M19 was negative in the bacterial mutagenicity study with or without metabolic activation and negative for chromosomal aberrations in cultured in human peripheral blood lymphocytes with or without metabolic activation. Table 13b : Summary of M19 genotoxicity studies Type of test/study ID/GLP In vitro Ames Gene bacteria SN 08101 GLP Chromosone aberration SN 08102 GLP Carcinogenicity Table 14 :  Summary of carcinogenicity studies Species/Sex/ Number/Group Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| age 7-week old Toxicology groups (50/sex/group) Toxicokinetic groups (20/sex/group)                                                                                                                                          | mg/kg/day                                                                                                                                                                                                                                                            |                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| SN 03662 GLP Rat SD Two-Year Carcinogenicity Study age 6-7 weeks Toxicology groups (50/sex/group except for group 250 mg/kg only 50 M) Toxicokinetic groups (10/sex/group except for group 250 mg/kg only 10 M) SN 03361 GLP | Oral gavage once daily 0, 0, 25, 50, or 100 mg/kg. On study days 0 through 10, rats in the 25, 50, and 100 mg/kg dose groups received 5, 25, and 75 mg/kg, respectively. An additional group of male rats was administred with 250 mg/kg daily for 9 days. Medicinal | NOAEL = 25 mg/kg/day for male NOAEL = 50 mg/kg/day for female | - ROLAPITANT-related mortality only in males dosed at 250 mg/kg/day. This group was terminated and carcasses discarded without necropsy or tissue collection on study Day 9 due to mortality and adverse clinical signs including hypoactivity, impaired equilibrium, intermittent tremors, dermal atonia, thin body, cool to touch, and rales. - Lower mean body weights and cumulative body weight gains noted at Week 104 in the 50 and 100 mg/kg/day M&F, compared to controls. - ROLAPITANT-related increased survival was statistically significant at 50 mg/kg/day in M and at 25, 50, and 100 mg/kg/day in F. - ROLAPITANT-related decreases in the incidences of palpable masses and animals with multiple masses, and ROLAPITANT-related increases in the mean number of days to first mass at 25, 50, and 100 mg/kg/day in F. - Macroscopically: • Benign pheochromocytomas (adrenal glands) : ↑ incidence at 50 and 100 mg/kg/day in M and • Thyroid glands: ↑ incidence at 100 mg/kg/day in M&F; follicular cell adenomas : ↑ incidence of follicular cell carcinomas at 100 mg/kg/day in M. ROLAPITANT-related non-neoplastic findings: • adrenal glands at 100 mg/kg/day in M. Cystic cortical degeneration at 100 mg/kg/day M • liver of both sexes at all doses. Findings included multinucleated hepatocytes in both sexes at 50 and 100 mg/kg/day, focus(i) of cellular alteration, eosinophilic cell, in females at all doses, focus(i) of cellular alteration, basophilic cell, in M at all doses and centrilobular hypertrophy in both sexes at all doses. However, these non-neoplastic findings in the liver were not accompanied by higher incidences of liver tumors. product no longer authorised |

D = day; M = mâle; F = female

<div style=\"page-break-after: always\"></div>

Table 15 : SD Rat 140 weeks carcinogenic study: principal neoplastic findings according to tissue or organ of origin

<!-- image -->

<!-- image -->

<!-- image -->

Table 16: Estimated exposure multiples for rolapitant at the highest doses in the mouse carcinogenicity study vs. the single 200 mg oral dose in humans. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 17: Estimated exposure multiples for rolapitant at the highest doses in the rat carcinogenicity study vs. the single 200 mg oral dose in humans.

<!-- image -->

| Species   | Study    | Study   | Dose        | Steady State Mean Values atVariedDose   | Steady State Mean Values atVariedDose   | Rolapitant     | ExposureMultiple atVariedDose   | ExposureMultiple atVariedDose   |
|-----------|----------|---------|-------------|-----------------------------------------|-----------------------------------------|----------------|---------------------------------|---------------------------------|
|           | Duration | Number  | (mg/kg/day) | Cmax (μg/mL)                            | AUCo-24hr (μg·hr/mL)                    | AUC Projected\" |                                 | AUC Projected                   |
| Rat       |          |         |             |                                         |                                         |                |                                 |                                 |

In mice, no carcinogenic findings were associated with rolapitant following 2 years daily oral administration of doses  up  to  150mg/kg/day  in  CD-1  mice.  In  rats,  non-neoplastic  findings  were  observed  in  the  adrenal glands  of  males  (cystic  cortical  degeneration)  at  100mg/kg/day  and  in  the  liver  of  males  and  females (multinucleated  hepatocytes,  foci  of  cellular  alteration,  eosinophilic  cell  and  basophilic  cell,  centrilobular hypertrophy) at all  doses  but  liver  findings  were  not  associated  with  higher  incidence  of  liver  tumour  and were considered a result of P450 enzyme induction. Rolapitant-related neoplastic findings included a decrease in absolute incidence of mammary gland neoplasms (fibroadenomas, adenomas and malignant adenocarcinomas)  and  adenomas  of  the  pituitary  gland  (benign  pars  distalis  adenoma),  attributed  to  the decrease in body weight and body weight gain. A higher absolute incidence of benign pheochromocytomas in the  adrenal  gland  of  rolapitant-dosed  50  mg/kg/day  and  100  mg/kg/day  males  and  a  higher  absolute incidence of follicular  cell adenomas in the thyroid glands in 100 mg/kg/day-dosed males and females, as well  as  follicular  cell  carcinomas  (malignant)  in  the  thyroid  glands  of  100  mg/kg/day-dosed  males  were reported  but  these  findings  were  not  statistically  significant.    Hyperplasia  of  follicular  cells  of  the  thyroid gland was previously noted in rats in a 3-month dose range-finding study at 125 mg/kg/day and in  a 6month study at 50 and 100 mg/kg/day. In both of these previous studies as well as in the present study, this change  was  associated  with  centrilobular  hypertrophy  in  the  liver,  consistent  with  P450  induction.  The administration of rolapitant has been shown to result in a significant elevation of cytochrome P450s in rats. The  association  of  follicular  cell  hypertrophy/hyperplasia  and  subsequent  thyroid  gland  neoplasia  with centrilobular  hepatocellular  hypertrophy  is  a  well-known  rat-specific  phenomenon  that  occurs  secondarily after P450 enzyme induction and was considered of no clinical relevance. The safety margin (AUC) at NOAEL for rat carcinogenicity study is estimated at 8 for males and 13.9 for females. Reproductive and Developmental Toxicity Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 18 : Summary of Fertility and early embryonic development studies

| Species (number) Study ID                                                                                                                                                               | Route/ Duration/ Dose                                                                                                                                           | NOAEL (mg/kg/d)                                                                                                                      | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| GLP aspect Male Rats Fertility and Early Embryonic Developmental Toxicity Study (22 M+F/group) SN 05078 GLP                                                                             | Oral by Gavage 0, 5, 25, 100 mg/kg/day For 4 weeks prior to cohabitation period through the day prior to schedule sacrifice. Females (22/group) were not dosed. | NOAEL for paternal toxicity = 25 mg/kg/ NOAEL for male mating and fertility and early embryonic development =100 mg/kg/day           | - ≥25 mg/kg/day: peri-oral substance. -100 mg/kg/day from Day 0 to 3: ↓ transient mean body weight with an associated ↓ in food consumption, but was not affected during the remainder of dosing period. -100 mg/kg/day: ↓ mean absolute weights of the prostate gland and seminal vesicles  No effects on male mating and fertility indices and early embryonic development. authorised                                                                                                                                                                                                                                                                                                                    |
| Female Rats Fertility and Early Embryonic Developmental Toxicity Study 25F/group SN 03117 GLP                                                                                           | Oral by Gavage 0, 1, 5, 10 mg/kg/day oral gavage for at least two weeks prior to and during the cohabitation period and through gestation Day 7                 | NOAEL for maternal toxicity = 5 mg/kg/day. NOAEL for female fertility =1 mg/kg/day NOAEL for early embryonic development = 5 product | - 10 mg/kg/day: ↑ pre- and post-implantation losses ( ↑ in early resorptions) - 5 and 10 mg/kg/day: Significant ↓ in the number of corpora lutea compared to the control group, but below the historical control range (15.3 to 16.6). - 5 mg/kg/day: ↓ in the number of implantation sites attributed to the decrease in the number of corpora lutea. no longer                                                                                                                                                                                                                                                                                                                                             |
| Rat (SD) Investigative Study of the Effects on Rat Hormone Levels during Pregnancy: Reversibility of Effects on Female Fertility and Early Embryonic Development 20F/group SN 06533 GLP | Oral by gavage 0, 25 mg/kg/day Male rats not dosed. Female rats dosed once on GD 0-7 (Phase 1) or on GD 0-7 after the first mating (Phase 2). Medicinal         | mg/kg/day                                                                                                                            | • Phase 1 and 2: ↓ in BWG and ↓ food consumption, relative to control rats. After re-mating (Phase 2), without administration of rolapitant did not affect BWG or food consumption  reversible. • Phase 1 : ↓ pregnancies, ↓ implantation sites, ↓ numbers of corpora lutea, and probable pre- implantation loss. • Phase 2: administration of rolapitant: ↓ pregnancies ↓ litters. Prolongation of gestation (≈ 8 days). After re-mating (Phase 2), without administration of rolapitant: no persistent effects on fertility and development => reversible. • Prolactin, estradiol, and progesterone levels unaffected by rolapitant on gestation Day 5 during Phase 1 and after re-mating during Phase 2. |

<div style=\"page-break-after: always\"></div>

|         |                |              |                  | Steady State Values   | Steady State Values   | Mean   | Rolapitant   | ExposureMultiple   | ExposureMultiple   |
|---------|----------------|--------------|------------------|-----------------------|-----------------------|--------|--------------|--------------------|--------------------|
| Species | Study Duration | Study Number | Dose (mg/kg/day) | Cmax (μg/mL)          | AUCo-24hr (μg·hr/mL)  | AUC    | Projected?   | Cmax               | AUC Projected      |
| Rat     | 3-month        | 03409        | F=1              |                       |                       |        | 154.7        |                    | 1.3                |

Table 19 : Estimated exposure multiples for rolapitant at 1 mg/kg/day in the rat female fertility study vs. the single 200 mg oral dose in humans.

| Species (number) Study ID GLP aspect                                                                                 | Route/ Duration/ Dose                                               | NOAEL (mg/kg/d)                                                                                                                                                       | Major findings                                                                                                                                                                                                                                                                                                                                                                                                       |
|----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pregnant rats Embryo-Fetal Developmental Toxicity Study (25/group) SN 03118 GLP                                      | oral gavage 0, 5, 15 or 25 mg/kg/day on GD 6 - 17                   | NOAEL for maternal toxicity = 5 mg/kg/day based on the effects on body weight and food consumption NOAEL for embryo and fetal toxicity in rats = 25 mg/kg/day product | - 15 or 25 mg/kg/day exhibited evidence of maternal toxicity: ↓ BWG and/or BW loss and concomitant ↓ in food consumption during the first week of dosing. -No test article-related effects on placental findings, reproductive parameter findings, fetal body weight, fetal sex determination, fetal external findings, fetal visceral findings, and fetal skeletal examination findings. no longer                  |
| Pregnant Rabbits (NZW) Embryo-Fetal Developmental Toxicity and Toxicokinetic study (20/group) SN 03119 GLP Medicinal | oral gavage 0 (vehicle control), 5, 15 or 30 mg/kg/day on GD 7 - 19 | NOAEL for maternal toxicity in rabbits = 15 mg/kg/day NOAEL for embryo-fetal toxicity = 30 mg/kg/day                                                                  | - 30 mg/kg/day: 2 rabbits exhibited maternal toxicity: ↓ food consumption and concomitant ↓ in fecal output. - All doses: no observations of embryo-fetal toxicity or teratogenicity. No test article-related effects on placental findings, reproductive parameter findings, fetal body weight, fetal sex determination, fetal external findings, fetal visceral findings, and fetal skeletal examination findings. |

Table 20 : Summary of embryo-foetal development studies Medicinal product no longer authorised

GD: gestation day

<div style=\"page-break-after: always\"></div>

Table 21 : Estimated exposure multiples for rolapitant at NOAEL rat and rabbit embryofetal toxicity study vs. the single 200 mg oral dose in humans.

|         |             |                  | SteadyStateMeanRolapitantValues   | SteadyStateMeanRolapitantValues   | SteadyStateMeanRolapitantValues   | ExposureMultiple   | ExposureMultiple   |
|---------|-------------|------------------|-----------------------------------|-----------------------------------|-----------------------------------|--------------------|--------------------|
| Species | StudyNumber | Dose (mg/kg/day) | Cmax (μg/mL)                      | AUCo-24hr (μg-hr/mL)              | AUC Projecteda                    | Cmax               | AUC Projected      |
| Rat     | SN03118and  | 25               | 4.45                              | 60.7                              | 728.4                             | 4.6                | 6.0                |

In an oral fertility and early embryonic development study, male mating and fertility indices were not affected at 100 mg/kg/day. However the decreased female fertility was identified at dose of 10 mg/kg/day in rats. The critical period for the reproductive effects (no viable fetuses, decreased number corpora lutea resulting in increased pre-implantation loss at 25 mg/kg/day) was identified at GD 0-7. In a separate fertility and early embryonic  development  study,  rolapitant  was  administered  for  at  least  2  weeks  prior  to  and  during cohabitation  and  through  GD  7.  At  the  time  of  implantation  no  changes  in  maternal  serum  prolactin, estradiol, and progesterone levels were found. These changes in fertility were shown to be reversible, i.e., when the dams are re-mated after the first pregnancy and are not dosed, no adverse effect on fertility are observed. The female decreased fertility is rolapitant dose related and the mechanism was not identified. The potential embryo and fetal toxicity of rolapitant was assessed in pregnant rats administered daily oral doses up to 25 mg/kg/day. The NOAEL for maternal toxicity is 5 mg/kg/day based on the effects on body weight and food consumption. As no embryo and fetal toxicity are occurred, the NOAEL for embryo and fetal toxicity in rats is 25 mg/kg/day. The estimated exposure multiple based on the maternal AUC (projected) as compared to that after a single 200 mg oral dose in human is 6. In  pregnant  rabbits,  the  potential  maternal,  embryo  and  fetal  toxicity  of  rolapitant  was  further  assessed administered daily  oral  doses  up  to  30  mg/kg/day.  At  all  doses  examined,  there  were  no  observations  of embryo-fetal toxicity or teratogenicity. The NOAEL for maternal toxicity in rabbits is 15 mg/kg/day, and the NOAEL for embryo-fetal toxicity is 30 mg/kg/day. The estimated exposure multiple based on the maternal AUC as compared to that after a single 200 mg oral dose in human is 1.2. In  an  oral  pre-  and  postnatal  development  study  in  rats,  the  NOAEL  for  F0  maternal  toxicity  was  10 mg/kg/day  rolapitant  based  on  mortality/moribund  condition,  total  litter loss, prolonged  parturition, decreased gestation length, increased number of unaccounted-for implantation sites. The NOAEL for offspring (F1) effects was 2.5 mg/kg/day rolapitant based on decreased postnatal survival and body weight gain at 25 mg/kg/day, decreased pup body weights at 10 and 25 mg/kg/day (at this one all pups was euthanized), and effects on memory (Biel swim maze) at 10 mg/kg/day. Medicinal product no longer authorised dose

## Toxicokinetic data

Comparative systemic exposure ratios

<div style=\"page-break-after: always\"></div>

Table 22 : Estimated Exposure Multiples for Rolapitant at the Oral NOAEL in Animals vs. the Single 200 mg Oral Dose in Humans .

<!-- image -->

|         |                |              | NOAEL       | Steady State Mean ValuesatNOAEL   | Steady State Mean ValuesatNOAEL   | Rolapitant     | Exposure Multiple at the NOAEL   | Exposure Multiple at the NOAEL   |
|---------|----------------|--------------|-------------|-----------------------------------|-----------------------------------|----------------|----------------------------------|----------------------------------|
| Species | Study Duration | Study Number | (mg/kg/day) | max (μg/mL)                       | AUC0-24hr (μg·hr/mL)              | AUC Projecteda |                                  | AUC Projected                    |
| Mouse   | 3-month        | 03665        | M≥150       | 13.50                             | 128.0                             | 2,688          | 13.8                             | 22.2                             |
| Rat     |                |              |             |                                   |                                   |                |                                  |                                  |

<!-- image -->

Table  23 :  Estimated  Exposure  Multiples  for  M19  at  the  Oral  NOAEL  in  Animals  vs.  the Single 200 mg Oral Dose in Humans. Local Tolerance An independent local tolerance study was performed in male rabbits for the clinical intravenous formulation. This local tolerance study for the IV formulation is not relevant to the oral administration of the proposed market product in humans Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Other toxicity studies

Table 24 : Summary of other toxicity studies

| Species (number) Study ID GLP aspect                                                             | Dose                                                              | Major findings                                                                                                                                                       |
|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| In vitro Human Blood Compatibility Study 3M+3F SN 6000033 GLP                                    | Rolapitant : 0.01, 0.025, 0.1 mg/mL Incubated at 37oC for 1 hour. | No hemolysis was observed for the test article, placebo and saline control while significant hemolysis was observed for the positive control 20% saponin. authorised |
| Chemical solutions of rolapitant and M19 UV-Visible absorption spectrum Scan SN XBL 11073 No-GLP |                                                                   | Rolapitant and its major metabolite M19 do not absorb UVB, UVA, or visible radiation longer                                                                          |

<!-- image -->

Antigenicity Rolapitant  is  a  small  molecule  and  no  antigenicity  is  expected.  Therefore,  no  antigenicity  study  was performed. Immunotoxicity No immunotoxic effects (histopathologic examination of the spleen, mandibular and mesenteric lymph nodes, gut-associated lymphoid tissue, and thymus) were observed in the toxicology program, including the pivotal 6 month rat study and 9 month monkey study. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Dependence

Table 25 : Summary of dependence studies

| Species (number) Study ID GLP aspect   | Route/ Duration/ Dose                                                                  | NOAEL (mg/kg/d)   | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|----------------------------------------|----------------------------------------------------------------------------------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Rhesus Monkey 4M SN 2013-001 GLP       | IV Self- administration 0, 0.1, 0.5, 1.0, 1.5 mg/kg /injection 3-5 Days per dose cycle |                   | Rhesus monkeys were conditioned to self-administer 0.18 mg/kg/injections of cocaine under a fixed-ratio 30 schedule of drug deliveries in daily 2-hour unlimited access. The reinforcing properties of rolapitant were assessed from a saline-extinction baseline. Rolapitant did not initiate, sustain, or maintain lever- press responding for rolapitant drug deliveries for 3 or 5 daily sessions preceded by saline extinction trials  low potential for abuse. authorised |
| Rhesus Monkey 4M SN 2013-002 GLP       | Oral (once daily) 0, 7.5, 25 mg/kg/day for 28 days                                     |                   | No significant clinical change within the activity/arousal, neuromuscular, sensory motor, or autonomic domains of a standardized and validated non-human primate functional observational battery. Abrupt cessation of daily dosing did not induce a measurable or definable discontinuation syndrome in male rhesus monkeys . longer                                                                                                                                            |

| Substance : ROLAPITANT                                                        | Substance : ROLAPITANT         | Substance : ROLAPITANT      | Substance : ROLAPITANT                     |
|-------------------------------------------------------------------------------|--------------------------------|-----------------------------|--------------------------------------------|
| CAS-number : 5522922-08-7                                                     | CAS-number : 5522922-08-7      | CAS-number : 5522922-08-7   | CAS-number : 5522922-08-7                  |
| PBT-assessment                                                                | PBT-assessment                 | PBT-assessment              | PBT-assessment                             |
| Parameter                                                                     | Result relevant for conclusion |                             | Conclusion                                 |
| Bioaccumulation                                                               | Log P partition coefficient    | 5.3 in n- octanol/0.15N KCI | Above 4.5 threshold Consider PBT screening |
| Phase I                                                                       | Phase I                        | Phase I                     | Phase I                                    |
| Calculation                                                                   | Value                          | Unit                        | Conclusion                                 |
| PEC surfacewater , default or refined (e.g. prevalence, literature) Medicinal | 0.0081                         | µ g/L                       | > 0.01 threshold (Y) Phase II not required |

2.3.5. Ecotoxicity/environmental risk assessment Table 26: Summary of main study results Substance : ROLAPITANT CAS-number : 5522922-08-7 Medicinal product no longer authorised

Rolapitant  PEC surfacewater  is  below  the  action  limit  of  0.01µg/L  but  log  Kow  exceeds  4.5  therefore  an estimation of Persistence, Bioaccumulation and toxicity (PBT index) is required and will be submitted as a post-authorisation measure.

<div style=\"page-break-after: always\"></div>

With reference to the guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (European Medicines Agency, 2006 [EMEA/CHMP/SWP/4447/00]), the applicant is recommended to conduct a specific risk with regard to a step-wise fashion for Persistence, Bioaccumulation and toxicity (PBT index), since log Kow value for rolapitant is above 4.5 and provide a planning for these studies.

## 2.3.6. Discussion on non-clinical aspects

Primary  and  secondary  pharmacodynamic  in  vitro  studies  completed  by  the  sponsor  demonstrate  that rolapitant (SCH 619734) is a potent, highly selective and competitive NK1 receptor antagonist that binds with high affinity  to  the  human NK1 receptor, as does its primary metabolite M19 (SCH 720881) which is also pharmacologically  active.  Rolipitant  shows  similar  affinity  toward  the  gerbil,  guinea  pig  and  monkey  NK1 receptor,  while  it  is  significantly  less  potent  toward  the  rabbit,  rat  and  mouse  NK1  receptor.  In  vivo, rolapitant is  active  in  ferret  models  of  chemotherapy-induced emesis, supporting proof of principle for the proposed indication for rolapitant. Two additional studies showed consistent results. In addition, a QTc study of rolapitant in humans was conducted at 4x the therapeutic dose, and no QT signal was observed in this study. Safety  pharmacology  studies  performed  in  rats  evaluated  central  nervous,  respiratory,  renal/urinary  and gastrointestinal  systems  and  indicated  no  cause  for  concern  following  the  administration  of  rolapitant. Cardiovascular safety pharmacology was completed in the monkey and similarly did not indicate a cause for concern. From  the  pharmacokinetic  point  of  view,  the  monkey  was  the  most  relevant  species  for  non-clinical assessment based on the similarities in binding affinity, oral bioavailability and metabolism. The rat is also a relevant species, despite the evidence that the binding affinity of rolapitant for rat NK1 receptor is &gt;100-fold less than for human NK1 receptor. The M19 metabolite is also the primary metabolite in rats. Rolapitant is rapidly absorbed after oral administration in mice, rats, and monkeys with maximum plasma concentrations (Cmax) being reached within 8 hours. The bioavailability across a series of single dose studies was approximately 50-70% in rats and was higher in monkeys, consistent with the near 100% bioavailability observed  in  humans.  Gender-related  differences  in  exposure  were  found  in  rats,  with  an  exposure consistently higher in the female than the male (4 fold in average) following repeated dosing of rolapitant. The gender differences in the pharmacokinetics of rolapitant observed are likely due to the gender differences in CYP3A isoenzyme concentrations in rats. In addition, this is not observed in humans. The half-lives of rolapitant are markedly longer in humans (t1/2= 7 days) than in cynomolgus monkeys and rat (t1/2= 6-8 h). The in vitro intrinsic clearance or lipophilicity alone cannot fully explain the significant difference of half-life. In the SmPC it is stated that the mechanism of the significant difference of half-lives observed between the rat and monkey (6-8 h) and human (7 days) is not elucidated. Medicinal product no longer authorised

Rolapitant  is  highly  plasma  protein-bound  (99.7-99.9%  across  rat,  monkey,  and  human).  In  rat  studies, rolapitant was found to be extensively distributed. The distribution to ocular tissues is very low and transient, suggesting  lack  of  melanin  binding.  Rolapitant  crosses  the  blood-brain  barrier  (BBB)  and  supports  the proposed mechanism of action of NK1 receptor antagonism. Liver metabolism, largely oxidative biotransformation,  appeared  to  be  the  major  clearance  mechanism  of  rolapitant  in  rats  and  monkeys.  A common major circulating active metabolite is M19 in both rat and human. Biliary excretion into the faeces was  the  major  route  of  elimination  for  rolapitant  in  rats  and  monkeys  following  oral  and  intravenous administration.  Rolipitant  was  also  rapidly  transferred  to  the  milk  of  lactating  rats  and  section  4.6  of  the

<div style=\"page-break-after: always\"></div>

SmPC appropriately reports the presence of rolipitant in the milk of lactating rats treated orally with rolipitant and breast-feeding is not recommended during treatment with Varuby. Rolapitant pass through the placenta.

All pivotal toxicology studies were GLP compliant and included repeat-dose toxicity studies of up to 6 months in duration rats and 9 month duration in monkeys. Supportive toxicokinetic analyses were also performed for these studies. Mortality was reported in mice at ≥450mg/kg, in rats at 500mg/kg and 1000mg/kg for females and males respectively, and in monkeys at 200mg/kg. Target organs for toxicity identified included the liver and  uterus  in  mice  and  rats,  with  increased  weight  and  histopathological  findings  also  reported  in  the kidneys, adrenal and thyroid glands in rats. The effect on liver was considered a result of enzyme induction leading to centrilobular hypertrophy and similarly the findings in the kidney, adrenal and thyroid glands were considered associated with P450 enzyme induction after repeated dosing. Clinical signs in rats at ≥ 250mg/kg included  hunched  appearance,  hypoactivity,  tremors,  ataxia,  dehydration  and  abnormal  stool.  Similarly  in monkeys, abnormal stool and decreased food consumption occurred at ≥ 75mg/kg with convulsions, emesis, hypothermia, morbidity and prostration occurring at the highest dose of 200mg/kg. Severe acute toxicity, including convulsions, was reported at 60 and 100mg/kg/day in one month repeat-dose toxicity testing in monkeys. The mechanism underlying the convulsions is likely to be common in all species. The finding is probably  due  to  reversible  interaction  with  target  sites  in  the  central  nervous  system.  However  since  the target site in brain involved in the convulsions is not identified, the relevance of these findings in humans is unknown.  (See  SmPC  point  5.3.)  The  calculations  for  safety  margins  is  based  on  body  surface  area comparison between human and non-clinical species, producing approximate 6x and 5.8x margins based on convulsive doses in rat and monkey studies respectively. Potential  M19  related  toxicity  has  been  assessed  as  part  of  the  toxicology  studies  is  not  justified  when considering that the proportion of M19 exposure relative to rolapitant+M19 exposure in terms of AUC ranges from  6-15%  in  the  non-clinical  species  in  these  studies,  whereas  in  humans,  the  reported  M19  exposure relative to rolapitant+M19 based on AUC is from 36- 37% (P04328, P04852) following the 180mg  dose. A  complete  package  of  genotoxicity  and  carcinogenicity  studies  indicated  rolipitant  was  negative  for genotoxicity  and  2  year  carcinogenicity  studies  in  rats  and  mice  did  not  reveal  a  carcinogenic  risk  of relevance  to  humans.  The  pharmacologically  active  primary  metabolite,  M19  was  also  negative  in  2  GLP compliant genotoxicity tests for bacterial mutagenicity, mammalian chromosomal aberration. In a fertility and early embryonic development study in female rats, rolapitant hydrochloride at an oral dose equivalent to 9 mg/kg per day free base (approximately 0.5 times the recommended human dose on a body surface area basis) caused a transient decrease in maternal body weight gain and increases in the incidence of pre- and post-implantation loss. At a dose equivalent to 4.5 mg/kg per day free base (approximately 0.2 times the recommended human dose on a body surface area basis), there were decreases in the number of corpora lutea and implantation sites (See section 5.3. of the SmPC). Medicinal product no longer authorised

In a pre- and post-natal development rat study, maternal toxicity was evident based on mortality/moribund condition, decreased body weight and food consumption, total litter loss, prolonged parturition, decreased length of gestation, and increased number of unaccounted for implantation sites at a dose equivalent to 22.5 mg/kg per day free base (approximately 1.2 times the recommended human dose on a body surface area basis). Effects on offspring at this dose included decreased postnatal survival, and decreased body weights and body weight gain, and may be related to the maternal toxicity observed. At a maternal dose equivalent to 9 mg/kg per day rolapitant free base (approximately 0.5 times the recommended human dose on a body surface area basis), there was a decrease in memory in female pups in a maze test and a decrease in pup body weight.

<div style=\"page-break-after: always\"></div>

Overall, the toxicology programme revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, teratogenic potential and carcinogenic potential. Relevant information has been reflected in the SmPC indicating the relevance of these findings to clinical use.

## 2.3.7. Conclusion on the non-clinical aspects

Overall, the non-clinical pharmacology studies provided adequate evidence that rolapitant (SCH 619734) is a potent, highly selective and competitive NK1 receptor antagonist. The general pharmacology studies showed proof of principle for the proposed indication for rolapitant in the prevention of CINV for highly or moderately emetogenic chemotherapy. Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity, teratogenic potential, and carcinogenic potential. The CHMP considered the following recommendations for further development on non-clinical aspects: · The  applicant  is  recommended  to  perform  an  estimation  of  Persistence,  Bioaccumulation  and  toxicity (PBT index) in accordance with the guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (European Medicines Agency, 2006 [EMEA/CHMP/SWP/4447/00]) 2.4. Clinical aspects 2.4.1. Introduction GCP The Clinical trials were performed in accordance with GCP as claimed by the applicant The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC. Table 27: Tabular overview of clinical studies Medicinal product no longer authorised

| Study ID   | Design                                     | Study Posology                                                                                                               | Study Objective                                      | Subjs by arm planned/actual/ compl.                               | Duration                                                                                                              | Gender M/F Median Age                           |
|------------|--------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|-------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| P04351     | Phase MC, DB, Active control, dose finding | 2, R, Rolapitant 10, 25, 100, or 200mg single dose or placebo in combination with ondansetron and dexamethasone PO Medicinal | Efficacy: Prevention of CINV Safety and tolerability | Overall: 450/454/416 Rolapitant: 360/363/332 Control: 90/91/84    | Maximum: 6 cycles Median number of cycles: NR Cycle length (range): 16 to 78 days                                     | Overall: M=244; F=210 Overall: 53.7 yrs (18-86) |
| P04832     | Phase 3, MC, R, DB, Active control         | Rolapitant 200 mg single dose or placebo in combination with granisetron and dexamethasone PO                                | Efficacy: Prevention of CINV Safety and tolerability | Overall: 530/526/491 Rolapitant: 265/264/251 Control: 265/262/240 | Maximum: 6 cycles Median number of cycles: 2.0 Median cycle duration: 21-22 days Cycle length (range): 13 to 70- days | Overall: 57.3 yrs (20-90) Overall: M=304; F=222 |
| P04833     | Phase                                      | 3, Rolapitant 200 mg single                                                                                                  | Efficacy:                                            | Overall:                                                          | Maximum: 6                                                                                                            | Overall:                                        |

<div style=\"page-break-after: always\"></div>

|        | MC, DB, Active control       | R,    | dose or placebo in combination with granisetron and dexamethasone PO                           | Prevention of CINV Safety and tolerability           | 530/544/518 Rolapitant: 265/271/259 Control: 265/273/259             | cycles Median number of cycles: 3.0 Median cycle duration: 21-23 days Cycle length (range): 13 to 42 days    | 58.5 yrs (18-83) Overall: M=369; F=175           |
|--------|------------------------------|-------|------------------------------------------------------------------------------------------------|------------------------------------------------------|----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| P04834 | Phase MC, DB, Active control | 3, R, | Rolapitant 200 m g single dose or placebo in combination with granisetron and dexamethasone PO | Efficacy: Prevention of CINV Safety and tolerability | Overall: 1350/1332/1276 Rolapitant: 675/666/636 Control: 675/666/640 | Maximum: 6 cycles Median number of cycles: 4.0 Median cycle duration: 21 days Cycle length (range): 12 to 62 | Overall: 56.7 yrs (22-88) Overall: M=265; F=1067 |

## Influence of food

Abbreviations:  CINV  =  chemotherapy-induced nausea and vomiting; CR = complete response; DB = double-blind, F = female;  HEC  =  highly  emetogenic  chemotherapy;  IV  =  intravenous;  M  =  male;  MC  =  multicentre;  MEC  =  moderately emetogenic  chemotherapy;  MITT  =  modified  intent-to-treated;  NR  =  not  reported;  PO  =  oral  administration;  R  = randomised a Duration of treatment is presented maximum number of cycles planned, median number of cycles administered, and actual range of days per cycle reported. b Actual refers to the MITT population for Studies P04832, P04833 and P04834 and for Study P04351 was based on all randomised subjects who received cisplatin-based chemotherapy and a dose of study medication and had at least  one post-treatment efficacy assessment in Cycle 1 recorded. c Completed primary endpoint of Cycle 1. d Subjects were to receive a first course of one or more of the following agents IV: cyclophosphamide (&lt;1500 mg/m2), or doxorubicin, epirubicin, carboplatin, idarubicin, ifosfamide, irinotecan, daunorubicin, or cytarabine (&gt;1 g/m2). 2.4.2. Pharmacokinetics Absorption Orally administered rolapitant was completely bioavailable (~100%), rapidly absorbed, and slowly metabolised and eliminated. Following single oral dose administration of 5 to 200 mg in the fasted state, mean time to maximum plasma concentration (Tmax) of rolapitant ranged from 2 to 4 hours. At the 200 mg dose, the mean maximum plasma concentration (Cmax) is approximately 1000 ng/mL. The variability in exposure (Cmax and AUC) was low to moderate with coefficients of variation ranging from 10% to 47%. Following multiple oral doses (9 to 45 mg once daily) of rolapitant, accumulation of rolapitant is approximately 5-fold. Medicinal product no longer authorised

An Open-Label, Randomized, Pivotal Bioequivalence and Food Effect Study of Oral Rolapitant carried out an analysis of the effect of food on the PK of the 100-mg tablet formulation. For the comparison of 2 x 100-mg tablets fed vs. 2 x 100-mg tablets fasting, the geometric mean ratios were 1.16, 1.05, 1.04, and 1.06 for Cmax, AUC0-t, AUC0-∞ and AUC0-120, respectively. The rolapitant peak exposure (Cmax) was increased when 2 x 100-mg tablets were administered with food; however, for overall exposure (AUC0-t, AUC0-∞ and days

<div style=\"page-break-after: always\"></div>

AUC0-120), there was no effect when rolapitant was administered with or without food. The 90% CIs for the test/reference ratios were within the acceptable range of 80% to 125% for the comparison for AUC0-t, AUC0∞ and AUC0-120, and outside the range for Cmax.

## Distribution

Rolapitant and its metabolite M19 are highly protein-bound to human plasma with unbound (free) fractions of &lt;1%. The apparent volume of distribution (Vd) of rolapitant is high (~ 460 L). Given a 100% absolute bioavailability observed, the apparent Vd would be representative of true Vd, indicating an extensive tissue distribution of rolapitant. Human NK1 receptor occupancy study indicates that rolapitant crosses blood brain barrier. Elimination Rolapitant is extensively biotransformed via oxidation, primarily to M19, a pharmacologically active metabolite exhibiting an inhibitory potency similar to the parent compound against human neurokinin-1 (NK1) receptor. The pharmacokinetics of the major metabolite M19 were well characterised in humans. Following administration of a single oral 200-mg dose of [14C]-rolapitant (180 mg of rolapitant monohydrate), total radioactivity recovered in the urine accounted for 14.2% (range 9.11% to 20.0%) of the dose and total radioactivity recovered in the faeces was 72.7% (range 51.8% to 88.7%) of the dose based on interpolation of the excreta data. Rolapitant is slowly eliminated, primarily through the hepatic/biliary route. Renal elimination represents a minor route, which is consistent with non-clinical studies demonstrating no significant changes in exposure of rolapitant in 5/6 nephrectomised rats. Following single oral doses (4.5 to 180 mg) of rolapitant, the mean terminal half-life (t1/2) ranges from 169 to 183 hours (~7 days) and is independent of dose. In the human ADME study following administration of a single oral 200-mg dose of [14C]-rolapitant, the mean terminal half-life (t1/2) is 186 hours and apparent total clearance of rolapitant is 1.74 L/hr. Given the 7-day half-life of rolapitant, the accumulation of rolapitant is expected to be minimal following either once every two weeks (q2w) or once every three weeks (q3w) regimen. Metabolism Hepatic metabolism is the major clearance mechanism in nonclinical species. Oxidation appears to be the primary metabolic pathways in rats, monkeys and human. Rolapitant is extensively metabolised by CYP3A4 via oxidation primarily to M19. This metabolite is structurally elucidated as a C4-pyrrolidine-hydroxylated rolapitant. In human ADME study, M19 was identified as the major circulating metabolite of rolapitant in plasma. The exposure ratio of M19 to rolapitant was approximately 50% in plasma. Medicinal product no longer authorised

## Dose proportionality and time dependencies

After oral administration, rolapitant was rapidly and completely absorbed with a dose-proportional increase in exposure . The PK of rolapitant is approximately linear across the dose range of 5 to 200 mg. Exposure to

<div style=\"page-break-after: always\"></div>

rolapitant (Cmax and area under the concentration - time curve [AUC]) following single or multiple oral doses was dose-proportional).

## Intra- and inter-individual variability

The inter-individual variability of plasma rolapitant concentrations was low to moderate

Population pharmacokinetics A population PK study was performed in 482 subjects who received Rolapitant. One objective of the analysis was to develop a population pharmacokinetic model for Rolapitant and its metabolite and to identify factors that may influence the disposition of the drug in cancer patients. The data consisted of 8858 valid Rolapitant concentration measurements from 482 adult subjects. Measures of organ function were also considered in the analysis and included clinical chemistries such as ALT, AST, alkaline phosphatase, albumin, total bilirubin, and creatinine clearance. In addition, Karnofsky performance score, rescue medication, and neutrophil counts were also evaluated. The relationship between concentrations of Rolapitant (predicted AUC) and efficacy measures was investigated graphically. The demographic subpopulations showed that the majority of the population was male (54.6 %). The majority of subjects were Caucasian (62%) or Multiracial (27.4%), followed by Asian (6%), American Indian (1.7%), Black (0.4%), and Native Hawaiian (0.2%). A one-compartment sub-model was used to describe the PK of the metabolite, M19. The typical estimate for the apparent CL of M19 was 1.83 L/hr. Rolapitant disposition was characterized by a two-compartment model with an estimated typical value for apparent CL of 0.962 L/hr and a large apparent V2, estimated to be 214 L. The apparent Q and apparent V4 were estimated to be 2.79 L/hr and 164 L, respectively, indicating extensive tissue distribution. None of the covariates investigated (body surface area, age, gender, race, chemotherapy regimen, Karnofsky performance score, creatinine clearance, ALT, AST, alkaline phosphatase, albumin, bilirubin, rescue medication, and neutrophil count) had a significant impact on the pharmacokinetics of Rolapitant. Subject body weight did influence the volume of distribution parameters. The covariate analysis showed a 39% decrease in V2/F for subjects at the low end of the weight range (38 kg) compared to subjects at the median weight (68.8 kg). A 67% increase in V2/F was evident for the heaviest subjects (WT=128 kg). Similarly, over the weight range seen in the studies, V4/F was 71% lower for the lightest subjects (WT=38 kg) and was 263% higher for patients at the highest weight (128 kg) when compared to subjects with median weight Special populations Medicinal product no longer authorised

## Impaired renal function

In population pharmacokinetic analyses, creatinine clearance (CLcr) at baseline did not show a significant effect on rolapitant pharmacokinetics in cancer patients with mild (CLcr: 60 to 90 mL/min) or moderate (CLcr: 30 to 60 mL/min) renal impairment compared to cancer patients with normal kidney function. Information is insufficient for the effect of severe renal impairment. The pharmacokinetics of rolapitant was not studied in patients with end-stage renal disease requiring haemodialysis.

<div style=\"page-break-after: always\"></div>

## Impaired hepatic function

The PK profiles of rolapitant were evaluated in subjects with mild and moderate hepatic impairment as compared to normal healthy subjects. The PK profiles and exposure parameters were generally similar in subjects with mild impairment compared to normal subjects. The PK profiles and exposure parameters in subjects with moderate impairment were slightly lower, especially for Cmax, than those in normal subjects.

The ratio of the geometric means of Cmax and AUCs (i.e. AUC0-120hr and AUC0-last) comparing subjects with mild impairment to normal subjects ranged from 92% to 96%. The ratio of the geometric means of Cmax and AUCs comparing subjects with moderate impairment to normal subjects ranged from 75% to 100%. Although the 90% CIs for these parameters (moderate vs. normal) were not fully contained within the 80% to 125% interval, the possible effect of moderate hepatic impairment on the elimination of rolapitant was not considered clinically meaningful. There was no formal study of rolapitant in patients with severe hepatic impairment (Child-Pugh score &gt;9), however baseline serum albumin, AST, total bilirubin, and ALT levels did not have a clinically important effect on rolapitant pharmacokinetics in patients with various degrees of hepatic impairment. Gender Based on the population PK analysis from pooled CINV studies (P04351, TS-P04832 and TS-P04833), gender had no significant impact on the pharmacokinetics of rolapitant. Therefore, no dosing adjustments based on any patient variables are recommended. Race Based on the population PK analysis from pooled CINV studies (P04351, TS-P04832 and TS-P04833), race had no significant impact on the pharmacokinetics of rolapitant. Therefore, no dosing adjustments based on any patient variables are recommended for rolapitant. Weight Based on the population PK analysis from pooled CINV studies (P04351, TS-P04832 and TS-P04833), age, gender, and race had no significant impact on the pharmacokinetics of rolapitant. Body weight was shown to have an influence on the central and peripheral volume of distribution, with heavier subjects exhibiting a larger volume of distribution. However, no clear trend was observed between body weight and rolapitant clearance. Therefore, no dosing adjustments based on any patient variables are recommended for rolapitant. Elderly Table 28: Number of elderly patients included in clinical pharmacology studies Medicinal product no longer authorised

|           | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|-----------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| PK Trials | 85/95                                             | 9/95                                              | 1/95                                            |

## Pharmacokinetic interaction studies

In  vitro,  CYP3A4 is  the  main  enzyme involved in rolapitant metabolism. According to the results, CYP2B6, 2C8  and  2J2  are  also  implicated  since  the  inhibition  of  these  enzymes  decreases  more  than  50  %  the

<div style=\"page-break-after: always\"></div>

metabolism  of  rolapitant.  Furthermore,  the  estimated  high  bioavailability  of  rolapitant  in  vivo  (F~100%), translates the low impact of the first pass metabolism and the low hepatic extraction ratio of rolapitant. This is confirmed by a DDI study performed with ketoconazole, a strong CYP3A4 inhibitor, that shows a slight but significant effect of ketoconazole on rolapitant exposure (increase of rolapitant exposure ca-20%) stressing the low involvement of CYP3A4 in rolapitant hepatic clearance. Therefore, the co-administration of rolapitant with strong and moderate CYP3A4 inhibitors is not expected to be clinically relevant.

Rolapitant is competitive inhibitor for most of CYP450, CYP3A4, 2C8, 2C9, 2C19, 2D6 and 2B6, except for CYP1A2, and a time-dependent inhibitor for CYP1A2, CYP2A6, CYP2D6, and CYP3A4/5. As regards its active metabolite, it does not exhibit any inhibitory potential towards these CYPs except CYP2B6. Nonetheless, at therapeutic concentrations, this effect is unlikely: its IC50 is far higher the worst estimated concentrations of 50*Cmax,u or 0,15 µM. Based on these data, the Applicant carried out dedicated clinical DDI studies with probe CYP3A (midazolam and  ondansetron),  2D6  (dextromethorphan),  CYP2C  (tolbutamide,  omeprazole  for  CYP2C9  and  CYP2C19 respectively), CYP2C8 (repaglinide) and CYP2B6 (efavirenz) substrates. Rolapitant and its active metabolite, M19, are not P-gp, BCRP, OATP1B1 and 1B3 substrates. Despite some limits in the dedicated in vitro studies, it can be concluded that rolapitant is a P-gp and BCRP inhibitor with an IC50= 7,4µM and =0,172 µM, respectively. No additional in vitro investigation is requested since clinical studies have been carried out (see in vivo part). In vivo Based on in vitro data, clinical interaction studies were conducted to assess the magnitude of the potential interactions with rolapitant: Table 29: Rolapitant as a perpetrator Medicinal product no longer authorised

| Midazolam ( CYP3A4 substrate)                                                  | Midazolam ( CYP3A4 substrate)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| + rolapitant low dose (study P03670) + rolapitant 200 mg (study PR-10- 5002-C) | With rolapitant low dose, midazolam exposure slightly decreases but with a single dose of 20 mg, no induction or inhibition of CYP3A4 by rolapitant or its active metabolite is evidenced. product                                                                                                                                                                                                                                                                                                                                                                                                            |
| Dexamethasone (CYP3A4 substrate) Medicinal                                     | No significant effect of rolapitant on dexamethasone exposure.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Ondansetron (CYP3A4 substrate)                                                 | No significant effect of rolapitant on ondansetron exposure.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Digoxin (P-gp substrate)                                                       | Rolapitant significantly alters digoxin C ss,max about 71 %, and its AUC about 30%. Even though no pharmacodynamics effect was observed in healthy volunteers, in the clinical setting, this effect may be clinically relevant notably in women patients in whom the therapeutic margin for digoxin is narrower than in men. Furthermore, rolapitant will be administered to patients the renal status of whom would be probably altered either due to the age and/ or to combined chemotherapies (e.g. cisplatin). Therefore, it cannot be ruled out that digoxin exposure may increase in a greater extent. |

<div style=\"page-break-after: always\"></div>

| Dextromepthorphan (CYP2D6 substrate)                         | Rolapitant is a CYP2D6 inhibitor since its increases about 2,6-fold dextromethorphan exposure at D7 and about 3,3-fold at day 14. However, the clinical relevance of this increase is questionable. This is far lower than the effect of cinacalacet, a well-known strong CYP2D6 inhibitor, on dextromethorphan exposure, the latter increasing about 11- fold in extensive metabolisers (Nakashima D. and al; J Clin Pharmacol 2007).   |
|--------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Efavirenz ( CYP2B6 substrate)                                | In vitro both rolapitant and its active metabolite inhibit CYP2B6. Even though this effect is expected to be low in vivo, a clinical DDI study has been carried out in order to invalidate or confirm it. Based on the observed results, rolapitant does not exhibit any clinically relevant CYP2B6 inhibition. authorised                                                                                                               |
| Omeprazol (CYP2C19 substrate) Tolbutamide (CYP2C9 substrate) | When rolapitant is co-administered with omeprazole or tolbutamide, no significant change in their AUC and Cmax is observed. It can be concluded that rolapitant is not expected to alter the pharmacokinetics of drugs the metabolism of which is CYP2C9 or CYP2C19-dependant.                                                                                                                                                           |
| Repaglinide (CYP2C8 substrate)                               | AUC and C max of repaglinide does not significantly change when rolapitant is co-administered simultaneously. Interestingly, 7 days after the co- administration with rolapitant, repaglinide AUC and C max significantly increase, about 24% and 29%. longer                                                                                                                                                                            |
| Sulfasalazine (BCRP substrate)                               | Rolapitant increases sulfasalazine (a BCRP substrate) exposure about-2- fold and about 32 % 7 days after the co-administration compared to sulfasalazine given alone. no                                                                                                                                                                                                                                                                 |

| Ketoconazole          | Rolapitant AUC significantly increases with a strong CYP3A4 inhibitor, about 21% with a 90% CI of [1,04- 1,41], nonetheless this is not expected to be clinically relevant.                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Rifampicine Medicinal | Results show a substantial decrease in both rolapitant and its metabolite M19 about 87% and 89% respectively. Based on the data available on rolapitant metabolism and absorption (notably, its high bioavailability and low hepatic extraction ratio likely < 0,3), and according to outcomes observed with ketoconazole, these results are puzzling. Therefore, the Applicant should further discuss the mechanisms behind this interaction since CYP3A4 induction does not appear to be the main explanation. Rifampicin is a well-known potent inducer and does not limit its inducing effect, via PXR activation, to CYP3A. |

Table 30: Rolapitant as a victim drug Rolapitant AUC significantly increases with a strong CYP3A4 inhibitor, about 21% with a 90% CI of [1,04- 1,41], nonetheless this is not expected to be clinically relevant. Results show a substantial decrease in both rolapitant and its metabolite M19 about 87% and 89% respectively. Based on the data available on rolapitant metabolism and absorption (notably, its high bioavailability and low  hepatic  extraction  ratio  likely  &lt;  0,3),  and  according  to  outcomes observed  with  ketoconazole,  these  results  are  puzzling.  Therefore,  the Applicant  should  further  discuss  the  mechanisms  behind this  interaction since  CYP3A4  induction  does  not  appear  to  be  the  main  explanation. Rifampicin is a well-known potent inducer and does not limit its inducing effect, via PXR activation, to CYP3A. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Others DDI comments / issues

Two NK1 receptor antagonists are currently launched in the prevention of nausea and vomiting induced by highly and moderate emetogenic cancer chemotherapy, netupitant (fixed-does combination with palonosetron)  and  aprepitant.  Since  no  efficacy  and  safety  data  allows  NT1  receptor  antagonists  to  be combined,  the  mention  of  a  statement  that  not  recommend  the  simultaneous  use  of  these  drugs  with rolapitant is raised in order to avoid any off-label use.

<!-- image -->

As a result, for the largest time-matched difference (QTcF), which is the main endpoint of the study, its one sided  confidence  interval  was  always  constrained  within  10  ms.    The  time  matched  analysis  for  the  QTcF endpoint revealed that the moxifloxacin group met the assay sensitivity criteria outlined in the statistical plan with several time points &gt; mean of 5 ms, as moxifloxacin duly prolonged the QTcF ~ 10 ms at its estimated Cmax (with an upper limit of the 95 CI between 10 and 13 ms).

Pharmacokinetics using human biomaterials N/A 2.4.3. Pharmacodynamics Mechanism of action No specific clinical pharmacology studies have been performed to qualify the suggested mechanism of action of rolapitant. Primary and Secondary pharmacology Two studies were performed to evaluate the PK and PD effects of rolapitant, including a PET study (P04078) and a thorough QT/QTc study (P04852). PET Study in Healthy Volunteers This study showed that the NK1 receptor occupancy in the cortex was related with rolapitant dose and the plasma concentration This study showed that at rolapitant dose of 200 mg, mean NK1 receptor occupancy was over 90% for at least 120 hour. Thorough QT Study in Healthy Volunteers A thorough QT study investigated the effect of rolapitant on corrected QT interval. The study was designed according to the ICH E14 guidance, according to a parallel group design and using moxifloxacin as a positive control. The  resulting  study  is  a  randomized,  double-blind,  parallel-group,  placebo-controlled  study  involving  four study groups (placebo, SCH 619734 50mg ; SCH 619734 200 mg ; SCH 619734 800 mg) A total of 184 subjects were enrolled. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

The time matched results for QTcF (as well as QTcI) showed that at no time point did rolapitant dose groups exceed the upper confidence interval of 10 ms. As for categorical values with QTcF there was no subject with ≥ 30 ms change from baseline in the low or high dose or placebo groups. One volunteer had [30-60] ms change from baseline with moxifloxacin. QTcI are matching these results. There was no significant gender effect.

The relationship between concentrations of Rolapitant and efficacy measures was investigated graphically using the data available from the Phase 2 and 3 studies. Measures of exposure (predicted AUC) for Rolapitant were correlated with efficacy (as measured by complete response, emesis, nausea, significant nausea, and complete protection) variables via a graphical exploratory approach to visually determine if any correlations between drug exposures and these parameters were evident. These plots demonstrate that there does not appear to be any overt relationship or trend between exposure parameters for Rolapitant and response for the subjects in the Phase 2 and 3 studies included in this population analysis. 2.4.4. Discussion on clinical pharmacology Following a single dose administration of 180 mg rolapitant under fasting conditions to healthy subjects, rolapitant was measurable in plasma between 30 minutes and the peak plasma concentration (Cmax) for rolapitant which was reached in about 4 hours and mean Cmax was 968 ng/mL (%CV:28%). It was rapidly absorbed with mean time to maximum plasma concentration (Tmax) ranging from 2 to 4 hours. At the 200 mg dose, the mean maximum plasma concentration (Cmax) is approximately 1000 ng/mL. The mean terminal half-life (t1/2) following single oral doses ranged from 169 to 183 hours (~7 days) and was independent of dose. Following multiple oral doses 9 to 45 mg once daily of rolapitant; accumulation of rolapitant was approximately 5-fold. In the human ADME study following administration of a single oral 200 mg dose of [14C]-rolapitant, the mean terminal half-life (t1/2) was 186 hours and apparent total clearance was 1.74 L/hr. The terminal halflife (t1/2) is consistent with the intended single oral dose application when used in combination with a 5-HT3 receptor antagonist and dexamethasone. The PK of rolapitant is approximately linear across the dose range of 5 to 200 mg with exposures increased in a dose-proportional manner. Exposure to rolapitant (Cmax and area under the concentration - time curve [AUC]) following single or multiple oral doses was dose-proportional. Rolapitant is slowly eliminated with mean terminal half-life of approximately 7 days. Rolapitant is eliminated mainly through the hepatic/biliary route, with minor contributions from renal elimination. Rolapitant is metabolised primarily by CYP3A4 to form a major active metabolite, M19. In vitro studies suggest that rolapitant is not an inhibitor of CYP2E1. Rolapitant was highly protein bound to human plasma (99.8%). The apparent volume of distribution (Vd/F) was 460 L in healthy subjects, indicating an extensive tissue distribution of rolapitant. In a population pharmacokinetic analysis of rolapitant, the Vd/F was 387 L in cancer patients. Medicinal product no longer authorised

Following multiple oral dose administration of 10 to 50 mg once daily, accumulation of rolapitant was approximately 5-fold, consistent with its long t1/2. Given the 7-day half-life of rolapitant, the accumulation is expected to be minimal following either once every two weeks or once every three weeks dosing.

Following single oral doses (4.5 to 180 mg) of rolapitant, the mean terminal half-life (t1/2) of rolapitant ranged from 169 to 183 hours (approximately 7 days) and was independent of dose. In a population pharmacokinetic analysis the apparent total clearance (CL/F) of rolapitant was 0.96 L/hour in cancer patients.

<div style=\"page-break-after: always\"></div>

Rolapitant is eliminated primarily through the hepatic/biliary route. Following administration of a single oral 180-mg dose of [ 14 C]-rolapitant, on average 14.2% (range 9% to 20%) and 73% (range 52% to 89%) of the dose was recovered in the urine and feces, respectively over 6 weeks. In pooled samples collected over 2 weeks, 8.3% of the dose was recovered in the urine primarily as metabolites and 37.8% of the dose was recovered in the feces primarily as unchanged rolapitant. Unchanged rolapitant or M19 were not found in pooled urine sample.

The systemic exposures (Cmax and AUC) to rolapitant increased in a dose-proportional manner when the dose of rolapitant increased from 4.5 mg to 180 mg. With an increase in dose by 4 times from the recommended clinical dose of 180 mg, the Cmax and AUC of rolapitant increased by 3.1 fold and 3.7 fold, respectively. The absolute bioavailability of rolapitant is approximately 100%, indicating minimal first pass effect. The apparent volume of distribution (Vd) is high (~ 460 L). Given the nearly 100% absolute bioavailability observed, the apparent Vd would be representative of true Vd, indicating extensive tissue distribution of rolapitant. Concomitant administration of a high fat meal did not significantly affect the pharmacokinetics of rolapitant, had minimal effects on the rate or extent of absorption of rolapitant when administered as 50 mg capsules, 100 mg tablets, or 2 × 100 mg high shear tablets Rolapitant is metabolised primarily by CYP3A4 to form a major active metabolite, M19 (C4-pyrrolidinehydroxylated rolapitant). In a mass balance study, the metabolite M19 was the major circulating metabolite. The formation of M19 was significantly delayed with the median Tmax of 120 hours (range: 24-168 hours) and the mean half-life of M19 was 158 hours. The exposure ratio of M19 to rolapitant was approximately 50% in plasma. No specific clinical pharmacology studies have been performed to qualify the suggested mechanism of action of rolapitant. In a study examining NK1 receptor occupancy, the PK profile of oral rolapitant was similar to that observed in other studies and the study described the relationship of the plasma concentration of rolapitant and brain NK1 receptor occupancy using sigmoid Emax model. Based on model predictions, plasma rolapitant concentrations above 348 ng/mL correspond to &gt;90% NK1 receptor occupancy. At rolapitant dose of 200 mg, mean NK1 receptor occupancy was over 90% for at least 120 hours. A separate study looking at QTc, rolapitant was well tolerated at single doses up to 800 mg administered as a single  oral  dose,  and  confirmed  that  QTc  was  evaluated  at  the  Cmax  of  rolapitant.  Administration  of rolapitant at doses up to 800 mg does not prolong the QT interval compared to the administration of placebo control,  based  on  QTcF  analysis.  Results  of  the  other  QT  analyses  (ie,  QTcB,  QTcI,  and  uncorrected  QT interval) were consistent with the results of the QTcF analysis. In addition, categorical summaries of numbers of subjects with changes in QT/QTc interval of &lt;0, 0 to 30, 31 to 60, and &gt;60 msec and/or with a QT/QTc interval &gt;480 msec were concordant with the above conclusions. Medicinal product no longer authorised

The thorough QT Study fulfilled the requirements to conclude that rolapitant meets the ICH E14 criteria of a negative TQT. However, even though the M19 metabolite is said to be a weaker blocker of hERG (higher IC50) it takes time to appear, possibly way after 24 hours of rolapitant intake. Therefore, caution should be taken  and  surveillance  exerted  on  lay  patients  prone  to  vomiting  (or  with  other  causes  of  electrolyte disturbancies/hypokaliemia) at distance from rolapitant intake.

Population pharmacokinetic analyses indicated that age, sex and race had no significant impact on the pharmacokinetics of Varuby. There are limited data in patients aged 75 years and older.

<div style=\"page-break-after: always\"></div>

Following administration of a single dose of 180 mg rolapitant to patients with mild hepatic impairment (Child-Pugh Class A), the pharmacokinetics of rolapitant were comparable with those of healthy subjects. In patients with moderate hepatic impairment (Child-Pugh Class B), the mean Cmax was 25% lower while mean AUC of rolapitant was similar compared to those of healthy subjects. The median Tmax for M19 was delayed to 204 hours in patients with mild or moderate hepatic impairment compared to 168 hours in healthy subjects. The pharmacokinetics of Varuby was not studied in patients with severe hepatic impairment (Child-Pugh Class C).

In population pharmacokinetic analyses, creatinine clearance (CLcr) at baseline did not show a significant effect on rolapitant pharmacokinetics in cancer patients with mild (CLcr: 60 to 90 mL/min) or moderate (CLcr: 30 to 60 mL/min) renal impairment compared to cancer patients with normal kidney function. Information is insufficient for the effect of severe renal impairment. The pharmacokinetics of Varuby was not studied in patients with end-stage renal disease requiring haemodialysis. A human Positron Emission Tomography (PET) study with rolapitant demonstrated that rolapitant crosses the blood brain barrier and occupies brain NK1 receptors. A dose-dependent increase in mean NK1 receptor occupancy was observed in the dose range from 4.5 mg to 180 mg of rolapitant. At rolapitant plasma concentrations of &gt;15 ng/mL and 348 ng/mL, the NK1 receptor occupancies in the cortical regions were approximately &gt;50% and 90% respectively. At the 180 mg dose of rolapitant, the mean NK1 receptor occupancy in the cortical regions was greater than 90% for at least 120 hours. The clinical pharmacology data with Varuby have been reflected in the SmPC (see section 5.2). Rolapitant is a moderate CYP2D6 inhibitor. Increased plasma concentration of CYP2D6 substrates may result in potential adverse reactions. A 3-fold increase in the exposure of dextromethorphan, a CYP2D6 substrate, was observed 7 days after a single oral dose of rolapitant and may last longer. In the SmPC section 4.5 caution is advised when rolapitant is combined with a medicinal product metabolised by CYP2D6, notably those having a narrow therapeutic margin (e.g. propafenone, tamoxifen, metoprolol used in heart failure, thioridazine, pimozide). Rolapitant is an inhibitor of Breast-Cancer-Resistance Protein (BCRP). Increased plasma concentrations of BCRP substrates (e.g. methotrexate, irinotecan, topotecan, mitoxantrone, rosuvastatin, sulfasalazine, doxorubicin, bendamustine) may result in potential adverse reactions. Co-administration of a single dose of 180 mg rolapitant with sulfasalazine, a BCRP substrate, resulted in an approximately 2-fold increase in Cmax and AUC of sulfasalazine. Close monitoring is advised In the SmPC  if the combination cannot be avoided; the lowest effective dose of rosuvastatin is to be used. Rolapitant is an inhibitor of P-glycoprotein (P-gp). A 70% increase in Cmax and 30% increase in AUC of digoxin, a P-gp substrate, were observed when administered with a single dose of 180 mg rolapitant. Therefore, clinical monitoring of adverse reactions is recommended in section 4.5 of the SmPC when rolapitant is combined with digoxin or with other P-gp substrates (e.g.  dabigatran or colchicine), and in particular in patients with renal impairment. Medicinal product no longer authorised

In vitro studies suggest that rolapitant is not expected to inhibit OATP1B1 at clinically relevant concentrations, whereas it is unknown whether it inhibits OATP1B3. Therefore, caution should be observed when rolapitant is combined with an OATP1B3 substrate (e.g. statins, bosentan, fexofenadine).

In vivo , rolapitant is not expected to exhibit any inhibitory or inducing effect on CYP3A4. A single dose of 180 mg rolapitant had no significant effects on the pharmacokinetics of midazolam compared to oral midazolam 3 mg alone on Day 1, Day 8 and Day 11.

<div style=\"page-break-after: always\"></div>

Rolapitant had no significant effects on the pharmacokinetics of intravenous ondansetron when concomitantly administered with a single 180 mg dose of rolapitant on the same day.

Rolapitant had no significant effects on the pharmacokinetics of dexamethasone when oral dexamethasone was administered on Days 1 to 3 after a single 180 mg dose of rolapitant was co-administered on Day 1.

No clinically significant interaction is expected with the following medicinal products when administered with a single dose of 180 mg rolapitant on Day 1 and without rolapitant on Day 8: repaglinide 0.25 mg (a CYP2C8 substrate), efavirenz 600 mg (a CYP2B6 substrate), tolbutamide 500 mg (a CYP2C9 substrate) or omeprazole 40 mg (a CYP2C19 substrate).

Concomitant administration of rifampicin, a strong enzyme inducer significantly decreased the systemic exposure to rolapitant and to its active metabolite. When 600 mg rifampicin was administered once daily for 7 days before and 7 days after administration of a single dose of 180 mg rolapitant, the mean AUC was reduced by 87% and its active metabolite by 89% compared to administration of rolapitant alone. Varuby in patients who require chronic administration of strong inducers (e.g. rifampicin, carbamazepine, enzalutamide, phenytoin) is not recommended (see SmPC section 4.4 and 4.5). The effect of moderate inducers (e.g. efavirenz, rifabutin) is not established; therefore, the use of rolapitant in patients already given a moderate inducer is not recommended (see section 4.4). Due to its strong inducing effect, St John's wort is contraindicated with rolapitant (see SmPC section 4.3). No clinically significant effect was seen on the pharmacokinetics of rolapitant when ketoconazole, a strong CYP3A4 inhibitor was administered with rolapitant. Concurrent administration of 400 mg ketoconazole once daily for 21 days following a single 90 mg dose of rolapitant, did not significantly affect the Cmax of rolapitant while the AUC increased by 21%. This is not expected to be clinically relevant. Therefore, no dose adjustment is recommended when rolapitant is combined with a strong CYP3A4 inhibitor (e.g. ketoconazole, itraconazole, posaconazole, ritonavir, cobicistat, clarithromycin). The efficacy and safety of rolapitant with concurrent use of another NK1 receptor antagonist is not established and therefore not recommended (see section 4.4). Further pharmacology studies are requested (see RMP) and the Applicant agreed to perform: · a DDI study assessing the effect of rolapitant on CYP1A2 substrate as caffeine or theophylline, and taking into account the half-life of rolapitant (dosage of the tested substrate should be made, at least, at day 7 and 14 after rolapitant administration). · an in vitro study assessing the ability for rolapitant to be a BSEP and MRPs substrate. · in vitro studies to clarify uncertainties on enzymes or transporters in order to anticipate potential DDI. · an in vitro study assessing the effect of rolapitant as an inhibitor of OCT1 and OATP1B3 at 20µM · an in vitro study assessing the effect of rolapitant as an inhibitor of UGTs Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 2.4.5. Conclusions on clinical pharmacology

Pharmacodynamics  data  collected  are  considered  adcequate.  The  Pharmacokinetic  of  rolapitant  has  been sufficiently  characterized  in  healthy  volunteers  and  cancer  patients.  A  number  of  pharmacology  studies described in the RMP will be submitted post authorisation.

## 2.5. Clinical efficacy

2.5.1. Dose response study(ies) Study P04351 This was a Phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel-group, dose rangefinding study of rolapitant 200mg in subjects receiving HEC (≥70 mg/m2 cisplatin-based chemotherapy). The study was conducted at 75 sites in 21 countries, across Asia, Europe (CZ, PL, and EL), Central and South America, South Africa and Canada. The study was conducted between 13 October 2006 to 27 March 2008. Doses from 10 to 200 mg were evaluated. The primary objective of the study was to determine if administration of rolapitant in combination with ondansetron and dexamethasone prevented CINV in the overall phase (0 to 120 hours) compared to administration of placebo in combination with ondansetron and dexamethasone. Rolapitant 10, 25, 100, and 200 mg was administered orally as 2.5, 10, or 50 mg capsules. It was administered approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1. Ondansetron 32mg IV and dexamethasone 20mg PO were administered concurrently with Rolapitant 0.5 hour before initiation of chemotherapy on Day 1. Dexamethasone 8 mg PO was administered twice daily on Days 2, 3, and 4. Treatment could be administered for up to six   chemotherapy cycles. Subjects recorded nausea, emesis, and use of rescue therapy in the SP Nausea and Vomiting (SPNV) Subject Diary daily from Days 1 to 6. Study population Patients were cisplatin treatment naïve and about to receive their first course of cisplatin-based chemotherapy (≥70 mg/m2). Tumour type is not specified. Karnofsky performance score of ≥60. The primary analysis was based on all randomized subjects who received cisplatin-based chemotherapy and a dose of study medication and had at least one posttreatment efficacy assessment in Cycle 1 recorded. Safety was evaluated in all randomized subjects who received at least one dose of study treatment. Symptoms of nausea were self-reported by the study subjects in the Nausea Vomiting (NV) Subject Daily Diary through Day 6 of Cycle 1. Concomitant medications Medicinal product no longer authorised

<!-- image -->

Prior and concomitant medications that may have influenced the assessment of efficacy were restricted. 5HT3 receptor antagonists, phenothiazines, benzamides, domperidone, cannabinoids, NK1 receptor antagonists and benzodiazepines were prohibited within 48 hours prior to the start of study treatment. Subjects who experienced intolerable nausea and/or vomiting during the study were permitted to take rescue medication. A subject who required rescue medication was allowed to continue participating in the study however, this subject was considered to have failed the primary endpoint of complete response.

<div style=\"page-break-after: always\"></div>

## Primary and key secondary efficacy endpoints

The primary endpoint was the overall complete response rate (no emesis and no use of rescue medication 0 through 120 hours following initiation of cisplatin-based chemotherapy).

Across cycles 2-6 a different primary endpoint was used. Subject's response to questions regarding episodes of emesis/retching or nausea (based on subject recall) on Days 6, 7, or 8 in Cycles 2 to 6 was assessed.

| Endpoint               | Definition                                                                             |
|------------------------|----------------------------------------------------------------------------------------|
| Complete response (CR) | No emesis, no use of rescue medication                                                 |
| No emesis              | No vomiting, retching, or dry heaves (includes subjects who receive rescue medication) |
| No nausea              | Maximum VAS <5 mm                                                                      |
| No significant nausea  | Maximum VAS <25 mm                                                                     |
| Complete protection    | No emesis, no rescue medication, and maximum VAS <25 mm                                |
| Total control          | No emesis, no rescue medication, and maximum VAS <5 mm                                 |

Approximately 450 subjects were planned. A total of 533 subjects were screened, and 454 were randomized in a 1:1:1:1:1 ratio to one of the five treatment arms: doses of 10, 25, 100, and 200 mg or matching placebo. Randomization occurred centrally using an interactive voice response system. Treatment was stratified according to the following factors:

The key secondary endpoint was CR for the acute (0 through 24 hours) and delayed (&gt;24 through 120 hours) phases of CINV. Table 31: Definitions of Efficacy Endpoints in Study P04351 Secondary Endpoints Secondary efficacy endpoints included no emesis, no nausea, no significant nausea, total control, and complete protection overall and each assessed in the acute and delayed phases. In addition, the time to first emesis or use of rescue medication was assessed along with impact of CINV on daily life using the FLIE Questionnaire. Statistical approach The primary endpoint of overall CR rate was evaluated using a logistic regression model with treatment, gender, and use of CEC (yes/no). The key secondary endpoints of CR for the acute (0 through 24 hours) and delayed (&gt;24 through 120 hours) phases of CINV were evaluated using the same logistic regression model. To control for the type I error rate, testing for the primary and key secondary endpoints was conducted in a stepwise fashion. Sequential lower dose comparison against placebo was to be carried out only if the previous comparison was statistically significant (p &lt; 0.049). Methodology Cycle 1 Medicinal product no longer authorised

- Gender
- Use of concomitant emetogenic chemotherapy (CEC) (yes/no).

<div style=\"page-break-after: always\"></div>

An interim analysis was carried out after approximately the first 50% of randomized subjects (n≈225) had completed Cycle 1.

Subjects recorded nausea, emesis, and use of rescue therapy in the SP Nausea and Vomiting (SPNV) Subject Diary daily from Days 1 to 6. The duration of each cycle was 29 days (median duration of 24-27 days.). In Cycle 2-6 subjects were questioned about their symptoms of vomiting/retching and nausea on day 6, or 8.

## Exposure and patient disposition

A total of 454 subjects were randomised into the study including 91 subjects who were randomised to placebo or 10, 25 or 100 mg rolapitant and 90 subjects who were randomised to 200 mg rolapitant Participants were distributed across the various regions as follows Asia/South Africa 8.65%, Central South America 53. % Europe 33.5% Canada 4.4%).Two subjects (one in the placebo group and one subject in the 200 mg rolapitant group) were randomised but did not receive study medication. A total of 416 (91.6%) completed Cycle 1. Thirty-eight (8.4%) subjects discontinued from the Cycle 1 treatment phase. More subjects discontinued during the Cycle 1 treatment phase in the 25-mg dose group (12/91, 13%) compared with the other treatment groups (5%-8%). The primary reason for discontinuation across all groups was adverse events. Median duration of each treatment cycle across all subjects ranged from 24 to 27 days. All Cycles (Cycles 1 to 6) Overall, 61% to 65% of subjects administered placebo or SCH 619734 10, 25, or 200 mg continued from the Cycle 1 through 6 treatment phase. The lowest overall discontinuation rate was observed at 100 mg (50/91, 55%).In all treatment groups across all cycles, the primary reason for discontinuation was that subjects did not wish to continue for reasons unrelated to treatment. Across all treatment groups 8% to 12% discontinued because of adverse events. Demographic and Baseline Characteristics In Cycle 1, 244 (54%) were male, 256 (56%) were white, and 251 (55%) were Hispanic or Latino. The median age was 55 years (range, 18 to 86 years). Demographics (weight, concomitant emetogenic therapy and Karnofsky Performance Status were comparable across treatment groups in cycle 1 and all treatment cycles. The study enrolled a broad cancer population. A total of 389 (86%) subjects were receiving CEC at Baseline. Median cisplatin dose was 78.5 mg/m2 in Cycle 1. Efficacy Primary efficacy endpoint was the overall complete response rate (no emesis and no use of rescue medication from 0 through 120 hours following initiation of cisplatin-based chemotherapy); The Rolapitant 200-mg dose group had significantly greater complete response rates overall than the placebo group. The overall complete response rate was 62.5% compared with 46.7% for placebo (odds ratio [OR] = 1.94; P = 0.032). Medicinal product no longer authorised

Rolapitant 200mg was statistically superior to control for the key secondary endpoints  complete response rates for the acute (0 through 24 hours) and delayed (&gt;24 through 120 hours) phases of CINV. For the acute phase, the response was 87.6% vs 66.7% (OR = 3.60; P = 0.001); for the delayed phase, the response was 63.6% vs 48.9% (OR = 1.86; P = 0.045). Complete response rates for the other Rolapitant dose groups (10, 25 and 100 mg) did not achieve statistical significance when compared with placebo. A positive trend across doses was noted.

<div style=\"page-break-after: always\"></div>

Secondary endpoints were also supportive of an effect of rolapitant 200 mg. The 200-mg dose group had significantly greater rates of no emesis overall and in the acute and delayed phases than the placebo group. (Acute: 91.0% versus 67.8%, respectively, p &lt;0.001), (delayed: 68.2% versus 48.9%, respectively, p =0.008) and (overall 67.0% versus 46.7%, respectively, p =0.006). A dose-response trend for no emesis was generally observed for each time interval; the 200-mg dose had the highest response, and the 10-mg dose had the lowest response.

No emesis. 200-mg dose group had significantly greater rates of no emesis overall and in the acute and delayed phases than the placebo group. (Acute: 86.5% versus 73.3% p = 0.029), (delayed 64.4% versus 47.8%, p = 0.026) and (overall 63.2% versus 42.2%p = 0.005) No significant nausea The SCH 619734 200-mg dose group had significantly greater rates of no significant nausea overall and in the acute and delayed phases, than the placebo group. Significant nausea was significantly higher in the rolapitant 200 mg dose group compared to control during the acute (86.5% versus 73.3%, respectively, p = 0.029), delayed (64.4% versus 47.8%, respectively, p = 0.026) and overall (63.2% versus 42.2%, respectively, p = 0.005) phases. Total control overall and no nausea Response rates for total control overall (no emesis, no rescue medication, and a maximum nausea VAS score of &lt;5 mm on a 0- to 100-mm scale) and for no nausea overall and in the acute and delayed phases did not achieve statistical significance for any SCH 619734 dose group when compared with placebo. Longer time to first emesis or need for rescue medication was reported by patients taking 200mg (p=0.011) but not for the other dose groups. Complete protection (no emesis, no rescue medication, and a maximum nausea VAS score of &lt;25 mm on a 0- to 100-mm scale.) A significantly greater rate of complete protection was observed for the SCH 619734 200-mg dose group in the acute phase (p=0.009), but not in the delayed phase or overall. Time to first emesis or to rescue medication use was significantly longer during Cycle 1 for subjects administered rolapitant 200 mg compared to control (p = 0.011), but not for the other dose groups. Kaplan-Meier Plot for Time to First Emesis or Rescue Medication Use: Cycle 1 (Efficacy Population, Study P04351) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

<!-- image -->

| Efficacy Variable     | CINV Phase        | Rolapitant Dose product   | Rolapitant Dose product   | Rolapitant Dose product   | Rolapitant Dose product   | Rolapitant Dose product   | Rolapitant Dose product   | Rolapitant Dose product   | Rolapitant Dose product   | Rolapitant Dose product   | Rolapitant Dose product   | P-Value 200 mg vs.   |                   |
|-----------------------|-------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|----------------------|-------------------|
|                       |                   | Placebo                   | Placebo                   | Placebo                   | 25                        | 25                        | 100 mg                    | 100 mg                    | 200 mg                    | 200 mg                    |                           |                      |                   |
|                       |                   | n                         | %                         | n                         | %                         | n                         | %                         | n                         | %                         | n                         | %                         | Control              |                   |
| Primary Medicinal     | Primary Medicinal | Primary Medicinal         | Primary Medicinal         | Primary Medicinal         | Primary Medicinal         | Primary Medicinal         | Primary Medicinal         | Primary Medicinal         | Primary Medicinal         | Primary Medicinal         | Primary Medicinal         | Primary Medicinal    | Primary Medicinal |
| Complete Response a   | Overall           | 90                        | 46.7                      | 91                        | 48.4                      | 88                        | 53.4                      | 91                        | 53.8                      | 88                        | 62.5 *                    | 0.032                |                   |
| Key Secondary         | Key Secondary     | Key Secondary             | Key Secondary             | Key Secondary             | Key Secondary             | Key Secondary             | Key Secondary             | Key Secondary             | Key Secondary             | Key Secondary             | Key Secondary             | Key Secondary        | Key Secondary     |
| Complete Response a   | Acute             | 90                        | 66.7                      | 90                        | 66.7                      | 89                        | 70.8                      | 91                        | 74.7                      | 89                        | 87.6 *                    | 0.001                |                   |
|                       | Delayed           | 90                        | 48.9                      | 91                        | 50.5                      | 88                        | 54.5                      | 91                        | 58.2                      | 88                        | 63.6 *                    | 0.045                |                   |
| Secondary             | Secondary         | Secondary                 | Secondary                 | Secondary                 | Secondary                 | Secondary                 | Secondary                 | Secondary                 | Secondary                 | Secondary                 | Secondary                 | Secondary            | Secondary         |
| No Emesis b           | Overall           | 90                        | 46.7                      | 91                        | 54.9                      | 88                        | 58.0                      | 91                        | 61.5                      | 88                        | 67.0 **                   | 0.006                |                   |
| No Emesis b           | Acute             | 90                        | 67.8                      | 91                        | 74.7                      | 90                        | 77.8                      | 91                        | 76.9                      | 89                        | 91.0 ***                  | <0.001               |                   |
| No Emesis b           | Delayed           | 90                        | 48.9                      | 91                        | 58.2                      | 88                        | 59.1                      | 91                        | 67.0                      | 88                        | 68.2 **                   | 0.008                |                   |
| No Significant Nausea | Overall           | 90                        | 42.2                      | 91                        | 49.5                      | 89                        | 57.3 *                    | 91                        | 56.0                      | 87                        | 63.2 **                   | 0.005                |                   |
| No Significant Nausea | Acute             | 90                        | 73.3                      | 91                        | 74.7                      | 90                        | 77.8                      | 91                        | 74.7                      | 89                        | 86.5 *                    | 0.029                |                   |

Functional Living Index-Emesis Questionnaire (18 questions on how nausea and vomiting affected their QoL over the last 5 days using a 7-point VAS scale.) The 100- and 200-mg doses achieved statistically significantly better vomiting- and nausea-related QoL scores than those of the placebo group. QoL scores increased as the dose increased. A higher proportion of subjects treated with 200 mg rolapitant reported no impact on daily life (FLIE total score &gt; 108) compared with subjects who were treated with control (p = 0.005) Table 32: Overview of Efficacy Analysis: Statistical Significance for Between Group Comparisons (Efficacy Population, Study P04351 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| c                                                               | Delayed   |   90 |   47.8 |   91 |   52.7 |   89 | 59.6   |   91 | 60.4          |   87 | 64.4 *   |   0.026 |
|-----------------------------------------------------------------|-----------|------|--------|------|--------|------|--------|------|---------------|------|----------|---------|
| No Nausea d                                                     | Overall   |   90 |   24.4 |   91 |   20.9 |   89 | 21.3   |   91 | 27.5          |   89 | 30.3     |   0.386 |
| No Nausea d                                                     | Acute     |   90 |   52.2 |   91 |   48.4 |   90 | 55.6   |   91 | 47.3          |   89 | 51.7     |   0.927 |
| No Nausea d                                                     | Delayed   |   90 |   25.6 |   91 |   23.1 |   89 | 23.6   |   91 | 28.6          |   89 | 32.6     |   0.308 |
| Complete Protection e                                           | Overall   |   90 |   38.9 |   91 |   39.6 |   88 | 46.6   |   91 | 44.0          |   87 | 52.9     |   0.058 |
| Complete Protection e                                           | Acute     |   90 |   63.3 |   90 |   63.3 |   89 | 64.0   |   91 | 61.5          |   89 | 80.9 **  |   0.009 |
| Complete Protection e                                           | Delayed   |   90 |   42.2 |   91 |   41.8 |   88 | 47.7   |   91 | 48.4          |   87 | 52.9     |   0.151 |
| Total Control f                                                 | Overall   |   90 |   23.3 |   91 |   18.7 |   88 | 19.3   |   91 | 25.3          |   89 | 30.3     |   0.297 |
| Total Control f                                                 | Acute     |   90 |   48.9 |   90 |   40   |   89 | 44.9   |   91 | 42.9          |   89 | 51.7     |   0.722 |
| Total Control f                                                 | Delayed   |   90 |   24.4 |   91 |   20.9 |   88 | 21.6   |   91 | 26.4          |   89 | 32.6     |   0.233 |
| Median Time (hours) to 1st emesis or use of rescue medication g | Overall   |   90 |   78.5 |   91 |   99.8 |   90 | NE     |   91 | NE authorised |   89 | NE       |   0.011 |

Abbreviations: CEC = concomitant emetogenic therapy; CINV = chemotherapy-induced nausea and vomiting; N/C = not calculated; N/A = not applicable; NE =not estimable; VAS = visual analogue scale Across cycles 2-6 the 200-mg dose maintained the treatment effect of 200 mg vs placebo for no emesis seen in Cycle 1. In each of Cycles 2-6, a higher proportion of rolapitant-treated subjects reported no emesis or nausea compared with subjects who received placebo. 2.5.2. Main studies HEC Studies P04832 and P04833 Methods The two studies were efficacy studies of identical design and shared the following common design features. Both protocols included the same methodological approach for the inclusion and exclusion criteria, rolapitant dosing regimen, comparator regimen, primary and secondary efficacy variables and assessments and statistical methodology. Study Participants The studies included outpatients, aged ≥18 years with a wide range of solid tumours, who had never been treated with cisplatin and were scheduled to receive the first course of cisplatin-based chemotherapy (≥60 mg/m2). They had to have a Karnofsky performance score of ≥60 and a predicted life expectancy of ≥4 months. Patients with significant bone marrow suppression and renal and liver impairment were excluded. Medicinal product no longer authorised

Treatment within 48 hours prior to commencing study drug with the following agents was restricted. Agents that could impact on the anti-emetogenic efficacy of 5-HT3 antagonists e.g. phenothiazines, benzamides, domperidone, cannabinoids, NK1 antagonist (aprepitant) and benzodiazepines (e.g., lorazepam, alprazolam) were prohibited. Palonosetron was not permitted within 7 days prior to the start of study treatment. Systemic

<div style=\"page-break-after: always\"></div>

corticosteroids or sedative antihistamines (e.g. dimenhydrinate, diphenhydramine) were prohibited within 72 hours of Day 1 except as premedication for chemotherapy (e.g., taxanes).

## Treatments

<!-- image -->

A single dose of study drug (4 × 50 mg capsules of rolapitant or matching placebo) was administered 1 to 2 hours prior to administration of the first chemotherapeutic agent on Day 1 Granisetron (10 μ g/kg IV) plus dexamethasone (20 mg PO) was administered approximately 30 minutes before administration of the first chemotherapeutic  agent.  It  is  generally  recommended  that  cisplatin-based  chemotherapy  be  administered over approximately 3 hours on Day 1. Dexamethasone (8 mg PO) was administered PO BID on Days 2, 3, and  4.  Inclusion  of  an  aprepitant  comparator  arm  would  have  been  very  useful  to  demonstrate  the comparative  clinical relevance of this new NK-1 antagonist. There is general agreement that there are no differences  in efficacy between the 5HT3 antagonists dolasetron, granisetron, ondansetron and tropisetron (Roila 2010) so efficacy data using a regimen containing granisetron should be generalizable to antiemetic regimens containing these other agents. Figure 4: Flow Chart for Drug Administration - Days 1-4 Because of the potential for hypersensitivity reactions to taxanes, subjects receiving taxanes received doses of  dexamethasone  according  to  the  respective  taxane  package  insert,  in  lieu  of  the  20  mg  PO  dose  of dexamethasone on Day 1. Objectives Primary Objective The primary objective of this study was to determine whether administration of rolapitant with granisetron and  dexamethasone  improved  CINV  in  the  delayed  phase  (&gt;24  to  120  hours)  during  the  first  cycle  of chemotherapy  compared  with  administration  of  placebo  with  granisetron  and  dexamethasone  in  subjects receiving  HEC.  The  primary  outcome  was  based  on  the  CR,  defined  as  no  emetic  episodes  and  no  use  of rescue medication in the delayed phase. Medicinal product no longer authorised

## Key Secondary Objectives

- Determine the effect of rolapitant on CR rates in the acute (0 to 24 hours) and overall (0 to 120 hours) phases of CINV
- Determine if rolapitant is safe and well tolerated in subjects receiving HEC.

<div style=\"page-break-after: always\"></div>

- Other secondary objectives included the following:
- Determine the effect of rolapitant treatment on the incidences of no emesis in the acute, delayed, and overall phases of CINV.
- Determine the effect of rolapitant treatment on the incidence of no significant nausea in the overall phase of CINV.

· Determine the effect of rolapitant treatment on the time to first emesis or use of rescue medication. Tertiary study objectives included the following: · To determine the effect of rolapitant treatment on the incidences of no significant nausea in the acute and delayed phases of CINV · To determine the effect of rolapitant treatment on the incidences of no nausea and complete protection in the acute, delayed, and overall combined phases of CINV · To evaluate the effect of rolapitant treatment on health-related quality of life as assessed by the FLIE Pharmacokinetic Objective Another study objective was to evaluate the population PK of rolapitant and its primary metabolite M19 in subjects receiving chemotherapy. Outcomes/endpoints Primary Endpoint The primary efficacy endpoint for this study was the complete response rate in the delayed phase of CINV, from  &gt;24  through  120  hours  following  initiation  of  cisplatin-based  chemotherapy.  Complete  response  is defined as no emesis and no use of rescue medication. Key Secondary Endpoint The  key  secondary  endpoints  are  the  complete  response  rates  for  the  acute  (0  through  ≤24  hours)  and overall (0 through ≤120 hours) phases of CINV. Secondary Endpoints and Tertiary Endpoints The secondary efficacy endpoints for this study included: · No emesis (no vomiting, retching, or dry heaves) in the acute, delayed, and overall phases of CINV. · No significant nausea (maximum VAS &lt;25 mm) in the overall phase of CINV. · Time to first emesis or to use of rescue medication. The tertiary efficacy endpoints for this study included: Medicinal product no longer authorised

- No significant nausea in the acute and delayed phases of CINV.
- No nausea (maximum VAS &lt;5 mm) and Complete protection (no emesis, no rescue medication, and maximum nausea VAS &lt;25 mm on a 0 to 100 mm scale) in the acute, delayed, and overall phases of CINV.
- No impact on daily life (total score &gt;108) as assessed by the FLIE Questionnaire.

<div style=\"page-break-after: always\"></div>

A summary of the response criteria used in this study is provided inTable

Table 33: Summary of the Response Criteria for Chemotherapy-Induced Nausea and Vomiting

| Endpoint              | Definition                                                                             | Duration                                                                         |
|-----------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Complete response     | No emesis, no use of rescue medication                                                 | Overall, acute (0 through ≤24 hours) and delayed (>24 through 120 hours) phases  |
| No emesis             | No vomiting, retching, or dry heaves (includes subjects who receive rescue medication) | Overall, acute (0 through ≤24 hours), and delayed (>24 through 120 hours) phases |
| No nausea             | Maximum VAS <5 mm                                                                      | Overall, acute (0 through ≤24 hours), and delayed (>24 through 120 hours) phases |
| No significant nausea | Maximum VAS <25 mm                                                                     | Overall, acute (0 through ≤24 hours), and delayed (>24 through 120 hours) phases |
| Complete protection   | No emesis, no rescue medication, and maximum VAS <25 mm                                | Overall, acute (0 through ≤24 hours), and delayed (>24 through 120 hours) phases |

Sample size calculations and statistical methods were acceptable It was estimated that with 257 subjects per group,  an  absolute  difference  of  15%  in  the  delayed  phase  CR  rates  between  the  rolapitant  and  control groups could be detected at an α = 0.05 level of significance (2-sided) with 93% power, assuming a control group  CR  rate  of  50%.  The  50%  control  response  rate  estimate  was  based  on  the  results  of  a  Phase  3 aprepitant trial with a similar study design. Using this same sample size, the study had 90% power to detect an absolute difference of 12% in the key secondary endpoint of CR in the acute phase of CINV assuming a control response rate of 71%. The sample size assumptions used for CR in the overall phase of CINV were the  same  as  those  used  for  the  delayed  phase,  resulting  in  93%  power  for  this  key  secondary  endpoint. Therefore, a minimum of 530 subjects was planned for randomization to 1 of 2 treatment groups (rolapitant group or control group) in a 1:1 ratio to ensure 257 evaluable subjects per group.

Assessment in Subsequent Cycles (up to 5 Additional Cycles for up to 6 Cycles Total) Subjects were asked the following CINV assessment questions on Days 6, 7, or 8 in each subsequent cycle (Cycles 2 to 6): · Have you had any episode of vomiting or retching since your chemotherapy started in this cycle? · Have you had any nausea since your chemotherapy started in this cycle that interfered with normal daily life? Randomisation Randomization of subjects occurred centrally using an interactive web-based randomization system (IWRS) at Cycle 1. Randomization was stratified by gender. In each stratum, subjects were randomized in a 1:1 ratio to 1 of 2 study drug treatment arms. Blinding (masking) A double-blind technique was used. Sample size Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Statistical methods

Continuous  data  were  summarized  using  n  (number  of  subjects  with  non-missing  observations),  mean, median, standard deviation (SD), minimum value, and maximum value. Categorical data were summarized using  the  frequency  count  and  percentage  of  subjects  in  each  category.  Unless  otherwise  specified,  all statistical hypothesis tests were 2-sided with a significance level of α = 0.05.

Adverse  events  and  medical  histories  were  coded  using  the  Medical  Dictionary  for  Regulatory  Activities (MedDRA)  Version  15.0.  All  medications  were  coded  using  the  World  Health  Organization  (WHO)  Drug Dictionary (March 2012 version). Statistical  analyses  for  the  primary,  secondary,  and  tertiary  endpoints  were  performed  on  the  Modified Intent-to-Treat (MITT) Population. Analyses for the primary, key secondary, and secondary endpoints were repeated  on  the  As-Treated  (AT)  and  PP  Populations.  All  safety  analyses  were  performed  on  the  Safety Population. The primary analysis population (MITT) should be further justified . The MITT  population consisted  of  all  randomized  subjects  who  received  at  least  1  dose  of  study  drug. Subjects were analyzed in the treatment group into which they were randomized. The following criteria were used to exclude subjects from the MITT population: · Subject was enrolled at a noncompliant site with major GCP violations · Subject did not provide informed consent · Subject did not receive at least one dose of study drug (rolapitant or placebo) As-Treated Population (Cycle 1) The AT population consisted of all randomized subjects who received at least 1 dose of study drug. Subjects were analyzed in the group in which they actually received treatment in Cycle 1. Per Protocol Population (Cycle 1) The PP population consisted of all randomized subjects who received at least 1 dose of study drug, received emetogenic chemotherapy (Hesketh Level 5), and did not have protocol deviations significantly affecting the interpretation of the study results. In addition, if a subject had missing diary data and the determination of CR could not be made from the remaining data, this subject was excluded from the respective phase of the efficacy  analysis.  Subjects  were  analyzed  based  on  actual  treatment  received  in  Cycle  1.  Criteria  used  to further exclude subjects from the PP population can be found in the SAP. Safety Population The Safety population consisted of all subjects who were randomized to treatment groups and who received at least 1 dose of study drug. Safety analysis was based on actual treatment received in Cycle 1. The  safety  population  for  subsequent  cycles  consisted  of  Safety  subjects  who  received  at  least  1  dose  of study drug for the respective subsequent cycle. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

Figure. 5: participant flow from randomization through cycle 6 in study PO4832

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 6:. participant flow from randomization through cycle 6 in study PO4833

<!-- image -->

## Recruitment

A total of 532 subjects were randomised into study P04832 at 76 sites, including 266 subjects randomised to receive rolapitant with granisetron and dexamethasone and 266 randomised to receive placebo with granisetron and dexamethasone (control).

Medicinal product no longer authorised

First subject enrolled (date consent signed): 25 April 2012; Last subject completed (date of last assessment): 03 April 2014; Release date of report: 11 August 2014

<div style=\"page-break-after: always\"></div>

A total of 555 subjects were randomised into study P04833 at 79 sites, including 278 subjects randomised to receive rolapitant with granisetron and dexamethasone and 277 randomised to receive placebo with granisetron and dexamethasone (control).

First subject enrolled: 20 February 2012; Last subject completed: 24 January 2014; Release date of report: 04 August 2014

<!-- image -->

|           |         |    | longer   |
|-----------|---------|----|----------|
|           |         | no |          |
|           | product |    |          |
| Medicinal |         |    |          |

Conduct of the study There were no major amendments to the original study protocols of both studies.. Baseline data Table 34: Demographics and Baseline Characteristics (MITT Population) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Demographics and Baseline Characteristics (MITT Population) (Continued)

|    | longer   |
|----|----------|
| no |          |

The most common reason for discontinuation in Cycle 1 in all studies was withdrawal of consent. Compliance with  rolapitant  dosing  was  high  (&gt;99%)  across  both  studies  as  was  compliance  with  adjunct  antiemetic therapy (&gt;99%).

Mean age in the MITT Population in Po4833 was 58.5 years and ranged from 18 to 83; most subjects were &lt;65  years  of  age  (73.2%),  male  (67.8%),  white  (80.5%),  and  did  not  consume  alcohol  (self-reported) (78.9%). The MITT Population included subjects from Europe (62.1%), North America (NA) (United States of America) (6.6%), Asia/South Africa (16.5%) and Central/South America (14.7%). Numbers analysed Overall a total of 1087 subjects were included in the MITT population, including 544 subjects who received rolapitant. Discontinuation during Cycle 1 was uncommon, reported in 4.9% and 6.9% of subjects in the rolapitant and control groups, respectively, in the pooled HEC studies. Medicinal product no longer authorised

Across  both  studies  (&gt;99%)  rolapitant  and  control  subjects  received  at  least  one  dose  of  cisplatin-based chemotherapy during Cycle 1.  The mean and median dose of cisplatin across both studies was &gt;75mg/m 2 . Compliance with administration of HEC agents was high in both studies; &gt;99% of subjects in the HEC studies received at least one HEC agent in Cycle 1.

<div style=\"page-break-after: always\"></div>

The  minimum  duration  per  cycle  was  14  days  .The  median  cycle  duration  across  both  studies  was approximately 22 days. The dosing interval proposed in section 4.2 is 14 days.

## Outcomes and estimation

## CR delayed phase (primary endpoint)

| Endpoint a                      | Rolapitant       | Control                            | Rolapitant 200 mg vs. Control   | Rolapitant 200 mg vs. Control   |
|---------------------------------|------------------|------------------------------------|---------------------------------|---------------------------------|
| Study                           | 200 mg n / N (%) | n / N (%)                          | Odds Ratio (95% CI) b longer    | P-value b                       |
| Complete Response Delayed Phase | -                |                                    | 1.9 (1.3, 2.7)                  | <0.001                          |
| HEC (P04832) HEC (P04833)       | 192/ 264 (72.7)  | 153/ 262 (58.4)                    | 1.4 (1.0, 2.1)                  | 0.043                           |
| HECs Pooled                     | 190/ 271 (70.1)  | 169/ 273 (61.9) 322/ 535 (60.2) no | 1.6 (1.3, 2.1)                  | <0.001                          |
| (P04832/P04833)                 | 382/ 535 (71.4)  |                                    |                                 |                                 |

The rolapitant group achieved a statistically significantly higher CR rate in the delayed phase compared to the control group in study P0483 2 (72.7% vs 58.4%, respectively; p &lt; 0.001) and in study P04833 (70.1% vs 61.9%, respectively; p = 0.043). This higher CR rate in the rolapitant group corresponds to a 34% relative reduction in failure rate with respect to the incidence of emesis or rescue medication use during the delayed phase of CINV. Table  35 :  Complete  Response  in  the  Delayed  Phase  of  CINV:  Summary  and  Between Group Comparison (MITT Population, Study P04832 Study P04833 and pooled analysis) Endpoint a Study Complete Response Delayed Phase HEC (P04832) HEC (P04833) HECs Pooled (P04832/P04833) Abbreviations:  CI  =  confidence  interval;  CMH  =  Cochran-Mantel  Haenszel;  HEC  =  highly  emetogenic  chemotherapy; Analysis  Populations:  MITT  for  P04832,  P04833,  and  a  complete  response  is  defined  as  no  emesis  or  use  of  rescue medication. Key secondary endpoint; Time to First Emesis or Use of Rescue Medication The proportion of subjects with a complete response in the acute and overall phase (no emesis and no use of rescue  medication  due  to  nausea)  during  the  initial  chemotherapy  cycle  (key  secondary  endpoints)  was statistically  significantly  higher  in  the  rolapitant  group  compared  to  the  standard  therapy  group  in  Study P08342 but not Study P08433. CR Acute phase: HEC (Study P04832 (83.7 vs 73.7) OR (95% CI).8 (1.2, 2.8) p=0.005) and (P04833 HEC (83.4% vs 79.5) OR (95% CI) 1.3 (0.8, 2.0) p=0.233). As statistical significance was not achieved for CR (acute phase) in study P04833, based on the statistical hierarchy specified in the SAP,  formal  statistical  significance  of  subsequent  endpoints  within  the  hierarchy  could  not  be  assigned. However, for completeness, the unadjusted p-values are reported but no inference can be made from them, other than that the comparison was non-significant for those endpoints. Medicinal product no longer authorised

Kaplan-Meier Plot of Proportions of Subjects without Emesis or Use of Rescue Medication (MITT Population P04832 and P04833)

## Study P04832

<div style=\"page-break-after: always\"></div>

<!-- image -->

Other secondary endpoints evaluated included no emesis during the acute, delayed, and overall phases of CINV,  and  no  significant  nausea  during  the  overall  phase  and  time  to  first  emesis  or  use  of  rescue medication.  Tertiary  endpoints  (not  formally  tested  for  significance)  included  no  significant  nausea  during acute and delayed phases, no acute, delayed and overall phase nausea, complete protection across all three phases and impact on daily life (FLIE). The results for the secondary and tertiary endpoints are generally

<div style=\"page-break-after: always\"></div>

concordant with the results for the primary and key secondary endpoints across both for HEC study P04832. Statistically significant differences in favour of rolapitant were seen for all endpoints for HEC P08432 but not HEC P08433.

## Nausea

The proportion of subjects with a no significant nausea in the delayed, acute and overall phase during the initial  chemotherapy  cycle  was  statistically  significantly  higher  in  the  rolapitant  group  compared  to  the standard therapy group in Study P08342 but not Study P08433. When the studies were pooled statistical significance was achieved across all three time points.

| Efficacy Variable                 | CINV Phase          | Rolapitant (N=666) a Rate (%   | Control (N=666) Rate (%)   | Unadjusted P-Value b   |
|-----------------------------------|---------------------|--------------------------------|----------------------------|------------------------|
| No Significant Nausea d Medicinal | Acute Phase n (%)   | 547 (82.1) (79.0, 85.0)        | 564 (84.7) (81.7, 87.3)    | 0.193                  |
| No Significant Nausea             | Delayed phase n (%) | 484 (72.7) (69.1, 76.0)        | 462 (69.4) (65.7, 72.9)    | 0.194                  |
| No Nausea e                       | Acute Phase         | 433 (65.0)                     | 439 (65.9)                 | 0.693                  |
|                                   | n (%)               | (61.3, 68.6)                   | (62.2, 69.5)               |                        |

Time to First Emesis or Use of Rescue Medication During the First 120 Hours In  both  studies  P08432  and  P08433  and  the  pooled  analysis,  the  time  to  first  emesis  or  use  of  rescue medication was longer for rolapitant compared to control. A separation in the Kaplan-Meier curves is visually apparent  early  during  the  acute  phase  of  CINV  by  12  hours  after  administration  of  study  drug.  This separation continues to increase during the acute phase (0-24hrs). At 24hrs  the separation of the curves increases  considerably  and  from  48hrs  the  effect  is  maintained  in  the  rolapitant  arm  and  is  sustained throughout the delayed phase of CINV. Subjects achieving CR at 48hrs maintained their control up to 120 hrs.  For  both  Study  P04832  and  P04833  the  incidence  of  subjects  requiring  ≥1  rescue  medication  during Cycle 1 was lower in the rolapitant group than in the control group (13.3% and 21.0%, vs 13.3% and 22.0%, respectively). Effect on daily life Effect on daily life (using FLIE) was the only QoL endpoint evaluated across these studies. It was included as a  tertiary  endpoint  that  was  not  subject  to  formal  statistical  testing.  No  inference  can  be  made  from unadjusted p values calculated for these endpoints, other than that the comparison was non-significant for those endpoints. A higher proportion of subjects treated with rolapitant reported no impact on daily life with respect to both the vomiting and nausea domains of the FLIE compared to control; unadjusted P=0.027. Table 36: Efficacy variables in HEC studies Significant Nausea d No Significant Nausea Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| No Nausea                 | Delayed Phase n (%)   | 323 (48.5) (44.6, 52.4)   | 299 (44.9) (41.1, 48.8)            |   0.201 |
|---------------------------|-----------------------|---------------------------|------------------------------------|---------|
| No Nausea                 | Overall n (%)         | 303 (45.5) (41.7, 49.4)   | 280 (42.0) (38.3, 45.9)            |   0.219 |
| Complete Protection f     | Acute Phase n (%)     | 514 (77.2) (73.8, 80.3)   | 508 (76.3) (72.9, 79.5)            |   0.726 |
| Complete Protection       | Delayed Phase n (%)   | 428 (64.3) (60.5, 67.9)   | 379 (56.9) (53.0, 60.7) authorised |   0.006 |
| Complete Protection       | Overall n (%)         | 413 (62.0) (58.2, 65.7)   | 354 (53.2) (49.3, 57.0)            |   0.001 |
| No Impact on Daily Life g | Overall n (%)         | 443 (73.2) (69.5, 76.7)   | 409 (67.4) (63.5, 71.1)            |   0.027 |

<!-- image -->

<!-- image -->

Abbreviations: CINV = chemotherapy-induced nausea and vomiting; FLIE = Functional Living Index-Emesis; N/C=not calculated; N/A= not applicable; NE=not estimable; VAS = visual analogue scale Repeat efficacy The effect  of  rolapitant  over  repeat  courses  of  HEC  was  evaluated  by  measuring  subject  incidences  of  no emesis or nausea, no emesis, and no nausea from Day 1 to Day 6 of each cycle for additional Cycles 2-6 . Unlike cycle 1 where daily diary entries were used to record events of emesis and nausea, subject recall at day 6-8 (Visit 2) was used to evaluate sustained benefit of rolapitant over multi-cycle use. Figure 7 Subject Response of No Emesis or Nausea by Cycle (MITT Population) Study P04832 Cycle 2-6 Study P04833 Cycle 2-6 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## Subgroup analyses

Exploratory  analyses  of  the  primary,  key  secondary  were  conducted  for  subject  subgroups,  according  to gender, age, race, region, and receipt of CEC. During the delayed and overall phases of CINV, the CR rate favoured  rolapitant  across  all  subgroups  for  the  pooled  HEC  studies.  There  was  some  variability  across subgroups in the acute phase responses.

<!-- image -->

Efficacy  outcomes  by  gender  were  variable  across  the  two  HEC  studies.  Response  rates  for  females  were consistently  higher  compared  to  males  receiving  rolapitant  versus  control  across  all  CINV  phases  (pooled analysis). (e.g.  CR delayed phase females 71.2% vs control 52.3% OR 2.3 (1.5, 3.4) vs males 71.5% vs 64.9% OR 1.4 (1.0, 1.9) respectively. The magnitude of the treatment effect (CR delayed phase)for males was much smaller than that for females (e.g 18.9% difference vs 6.6%. A Gail-Simon test conducted by the applicant indicated that there were no qualitative interactions between treatment and subgroup regardless of gender across all of these endpoints. Figure 8: Complete Response for the Overall Phase by Subgroup (MITT Population) HEC Studies Pooled Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Summary of main studies

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 37 : Summary of efficacy for pivotal HEC trial P04832

| Title: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy- Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC) authorised   | Title: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy- Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC) authorised   | Title: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy- Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC) authorised   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                         | TS-P04832                                                                                                                                                                                                                                                                | TS-P04832                                                                                                                                                                                                                                                                |
| Design                                                                                                                                                                                                                                                                   | Multicenter, Randomized, Parallel-group, Double-Blind, Active-Controlled Study in Patients Receiving Cisplatin Based HEC                                                                                                                                                 | Multicenter, Randomized, Parallel-group, Double-Blind, Active-Controlled Study in Patients Receiving Cisplatin Based HEC                                                                                                                                                 |
| Design                                                                                                                                                                                                                                                                   | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                           | Acute phase (0 to 24 hours) delayed phase (>24 to 120 hours) over all phase (0 to 120 hours) phases of CINV not applicable not applicable longer                                                                                                                         |
| Hypothesis                                                                                                                                                                                                                                                               | Superiority                                                                                                                                                                                                                                                              | Superiority                                                                                                                                                                                                                                                              |
| Treatments groups                                                                                                                                                                                                                                                        | Rolapitant                                                                                                                                                                                                                                                               | Rolapitant 200 mg (50 mg×4)PO on Day 1 + granisetron IV (10 µg/kg on Day 1) + dexamethasone PO (20 mg on Day 1 and 8 mg BID from Day 2 to Day 4) n=264 no                                                                                                                |
| Treatments groups                                                                                                                                                                                                                                                        | Placebo                                                                                                                                                                                                                                                                  | Placebo on Day 1 + granisetron IV (10 µg/kg on Day 1) + dexamethasone PO (20 mg on Day 1 and 8 mg BID from Day 2 to Day 4) n=262                                                                                                                                         |
| Endpoints and definitions Medicinal                                                                                                                                                                                                                                      | Primary endpoint CR delayed phase product                                                                                                                                                                                                                                | Complete response rate (defined as no emetic episodes, no rescue medication) from >24 through 120 hours after the start of the highly emetogenic chemotherapy administration (delayed phase)                                                                             |
| Endpoints and definitions Medicinal                                                                                                                                                                                                                                      | Key Secondary endpoint CR acute phase                                                                                                                                                                                                                                    | Complete response rate (defined as no emetic episodes, no rescue medication) from 0 through ≤ 24 hours after the start of the highly emetogenic chemotherapy administration (acute phase)                                                                                |
| Endpoints and definitions Medicinal                                                                                                                                                                                                                                      | Key Secondary endpoint CR overall phase                                                                                                                                                                                                                                  | Complete response rate (defined as no emetic episodes, no rescue medication) from 0 through ≤ 120 hours after the start of the highly emetogenic chemotherapy administration (overall phase)                                                                             |
| Endpoints and definitions Medicinal                                                                                                                                                                                                                                      | Secondary endpoint No emesis                                                                                                                                                                                                                                             | No emesis (no vomiting, retching or dry heaves) during the acute phase (0 through ≤ 24 hours)                                                                                                                                                                            |
| Endpoints and definitions Medicinal                                                                                                                                                                                                                                      | Acute Secondary endpoint No emesis delayed                                                                                                                                                                                                                               | No emesis (no vomiting, retching or dry heaves) during the delayed phase (>24 through 120 hours)                                                                                                                                                                         |
| Endpoints and definitions Medicinal                                                                                                                                                                                                                                      | Secondary endpoint No emesis overall                                                                                                                                                                                                                                     | No emesis (no vomiting, retching or dry heaves) during the overall phase (0 through 120 hours)                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                                                 | Secondary endpoint                    | No significant nausea               | No significant nausea (nausea <25 mm on VAS) during the overall phase (0 through 120 hours)   | No significant nausea (nausea <25 mm on VAS) during the overall phase (0 through 120 hours)   |
|-------------------------------------------------|---------------------------------------|-------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
|                                                 | Secondary endpoint                    | TTF                                 | Time to the first emetic episode or time to the first rescue medication                       | Time to the first emetic episode or time to the first rescue medication                       |
| Database lock                                   | 03 April 2014                         | 03 April 2014                       | 03 April 2014                                                                                 | 03 April 2014                                                                                 |
| Results and Analysis                            | Results and Analysis                  | Results and Analysis                | Results and Analysis                                                                          | Results and Analysis                                                                          |
| Analysis description                            | Primary Analysis                      | Primary Analysis                    | Primary Analysis                                                                              | Primary Analysis                                                                              |
| Analysis population and time point description  | Modified Intent to treat authorised   | Modified Intent to treat authorised | Modified Intent to treat authorised                                                           | Modified Intent to treat authorised                                                           |
| Descriptive statistics and estimate variability | Treatment group                       | rolapitant                          | rolapitant                                                                                    | control                                                                                       |
| Descriptive statistics and estimate variability | Number of subject                     | 264                                 | 264                                                                                           | 262                                                                                           |
| Descriptive statistics and estimate variability | CR delayed n (% patients)             | 192 (72.7)                          | 192 (72.7)                                                                                    | 153 (58.4)                                                                                    |
| Descriptive statistics and estimate variability | 95% IC a                              | [66.9;78.0] longer                  | [66.9;78.0] longer                                                                            | [52.2;64.4]                                                                                   |
| Descriptive statistics and estimate variability | p-value b                             | < 0.001                             | < 0.001                                                                                       | < 0.001                                                                                       |
| Descriptive statistics and estimate variability | CR acute* n (% patients)              | 221 (83.7) no                       | 221 (83.7) no                                                                                 | 193 (73.7)                                                                                    |
| Descriptive statistics and estimate variability | 95% IC a                              | [78.4;88.0]                         | [78.4;88.0]                                                                                   | [67.9;78.9]                                                                                   |
| Descriptive statistics and estimate variability | p-value c                             | 0.005                               | 0.005                                                                                         | 0.005                                                                                         |
| Descriptive statistics and estimate variability | CR overall* n (% patients) product    | 185 (70.1)                          | 185 (70.1)                                                                                    | 148 (56.5)                                                                                    |
| Descriptive statistics and estimate variability | 95% IC a                              | [64.2;75.5]                         | [64.2;75.5]                                                                                   | [50.2;62.6]                                                                                   |
| Descriptive statistics and estimate variability | p-value c                             | 0.001                               | 0.001                                                                                         | 0.001                                                                                         |
| Descriptive statistics and estimate variability | Other secondary analyses              | Other secondary analyses            | Other secondary analyses                                                                      | Other secondary analyses                                                                      |
| Descriptive statistics and estimate variability | No emesis Delayed phase               | 206/ 264 (78.0)                     | 206/ 264 (78.0)                                                                               | 162/ 262 (61.8)                                                                               |
| Descriptive statistics and estimate variability | Mean difference to control            | 16.2%                               | 16.2%                                                                                         | 16.2%                                                                                         |
| Descriptive statistics and estimate variability | Odds Ratio (95% CI) P-value Medicinal | 2.0 (1.5, 3.2) 0.002                | 2.0 (1.5, 3.2) 0.002                                                                          | 2.0 (1.5, 3.2) 0.002                                                                          |
| Descriptive statistics and estimate variability | No emesis acute phase                 | 228/ 264 (86.4)                     | 228/ 264 (86.4)                                                                               | 199/ 262 (76.0)                                                                               |
| Descriptive statistics and estimate variability | Mean difference to control            | 10.4%                               | 10.4%                                                                                         | 10.4%                                                                                         |
| Descriptive statistics and estimate variability | Odds Ratio (95% CI) P-value           | 2.0 (1.3, 3.2) 0.002                | 2.0 (1.3, 3.2) 0.002                                                                          | 2.0 (1.3, 3.2) 0.002                                                                          |
| Descriptive statistics and estimate variability | No Emesis - Overall Phase             | 199/ 264 (75.4)                     | 199/ 264 (75.4)                                                                               | 155/ 262 (59.2)                                                                               |
| Descriptive statistics and estimate variability | Mean difference to control            | 16.2%                               | 16.2%                                                                                         | 16.2%                                                                                         |

<div style=\"page-break-after: always\"></div>

|       | Odds Ratio (95% CI) P-value                                                                                                                                                                                                                                                                                                                                                                             | 2.1 (1.5, 3.1) <0.001                                                                                                                                                                                                                                                                                                                                                                                   | 2.1 (1.5, 3.1) <0.001                                                                                                                                                                                                                                                                                                                                                                                   |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|       | Significant tertiary analysis                                                                                                                                                                                                                                                                                                                                                                           | Significant tertiary analysis                                                                                                                                                                                                                                                                                                                                                                           | Significant tertiary analysis                                                                                                                                                                                                                                                                                                                                                                           |
|       | FLIE No Impact on Daily Life FLIE total score >108. Denominator was based on the number of subjects with valid questionnaire                                                                                                                                                                                                                                                                            | 72.8                                                                                                                                                                                                                                                                                                                                                                                                    | 67.8                                                                                                                                                                                                                                                                                                                                                                                                    |
|       | Odds Ratio (95% CI) P-value                                                                                                                                                                                                                                                                                                                                                                             | 1.3 (0.9, 1.9) 0.231 authorised                                                                                                                                                                                                                                                                                                                                                                         | 1.3 (0.9, 1.9) 0.231 authorised                                                                                                                                                                                                                                                                                                                                                                         |
| Notes | a p-value from Cochran-Mantel-Haenszel test, stratified by gender b Exact 95% confidence interval (CI) for response rate c Unadjusted p-values are *The key secondary endpoints of CR rate in the acute and overall phases of CINV were analyzed in a stepwise fashion using the same methodology as the primary endpoint. To control for multiplicity within the prespecified secondary endpoints, the | a p-value from Cochran-Mantel-Haenszel test, stratified by gender b Exact 95% confidence interval (CI) for response rate c Unadjusted p-values are *The key secondary endpoints of CR rate in the acute and overall phases of CINV were analyzed in a stepwise fashion using the same methodology as the primary endpoint. To control for multiplicity within the prespecified secondary endpoints, the | a p-value from Cochran-Mantel-Haenszel test, stratified by gender b Exact 95% confidence interval (CI) for response rate c Unadjusted p-values are *The key secondary endpoints of CR rate in the acute and overall phases of CINV were analyzed in a stepwise fashion using the same methodology as the primary endpoint. To control for multiplicity within the prespecified secondary endpoints, the |

| Title: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy- Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC) product   | Title: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy- Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC) product   | Title: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy- Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC) product   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                      | TS-P04833                                                                                                                                                                                                                                                             | TS-P04833                                                                                                                                                                                                                                                             |
| Design                                                                                                                                                                                                                                                                | Multicenter, Randomized, Parallel-group, Double-Blind, Active-Controlled Study in Patients Receiving Cisplatin Based HEC                                                                                                                                              | Multicenter, Randomized, Parallel-group, Double-Blind, Active-Controlled Study in Patients Receiving Cisplatin Based HEC                                                                                                                                              |
| Design                                                                                                                                                                                                                                                                | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                        | Acute phase (0 to 24 hours) delayed phase (>24 to 120 hours) over all phase (0 to 120 hours) phases of CINV not applicable not applicable                                                                                                                             |
| Hypothesis                                                                                                                                                                                                                                                            | Superiority                                                                                                                                                                                                                                                           | Superiority                                                                                                                                                                                                                                                           |
| Treatments groups Medicinal                                                                                                                                                                                                                                           | Rolapitant                                                                                                                                                                                                                                                            | Rolapitant 200 mg (50 mg×4)PO on Day 1 + granisetron IV (10 µg/kg on Day 1) + dexamethasone PO (20 mg on Day 1 and 8 mg BID from Day 2 to Day 4) n=264                                                                                                                |
| Treatments groups Medicinal                                                                                                                                                                                                                                           | Placebo                                                                                                                                                                                                                                                               | Placebo on Day 1 + granisetron IV (10 µg/kg on Day 1) + dexamethasone PO (20 mg on Day 1 and 8 mg BID from Day 2 to Day 4) n=262                                                                                                                                      |

1.3 (0.9, 1.9) 0.231 *The  key  secondary  endpoints  of  CR  rate  in  the  acute  and  overall  phases  of CINV were analyzed in a stepwise fashion using the same methodology as the primary endpoint. To  control  for  multiplicity  within  the  prespecified  secondary  endpoints,  the Bonferroni-Holm multiple comparison procedure was used. Table 38: Summary of efficacy for trial P04833 Title: A  Phase  3,  Multicenter,  Randomized,  Double-Blind,  Active-Controlled  Study  of  the  Safety  and Efficacy  of  Rolapitant  for  the  Prevention  of  Chemotherapy-  Induced  Nausea  and  Vomiting  (CINV)  in Subjects Receiving Highly Emetogenic Chemotherapy (HEC) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| Endpoints definitions   | Primary endpoint       | CR delayed phase      | Complete response rate (defined as no emetic episodes, no rescue medication) from >24 through 120 hours after the start of the highly emetogenic chemotherapy administration (delayed phase)            |
|-------------------------|------------------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                         | Key Secondary endpoint | CR acute phase        | Complete response rate (defined as no emetic episodes, no rescue medication) from 0 through ≤ 24 hours after the start of the highly emetogenic chemotherapy administration (acute phase)               |
|                         | Key Secondary endpoint | CR overall phase      | Complete response rate (defined as no emetic episodes, no rescue medication) from 0 through ≤ 120 hours after the start of the highly emetogenic chemotherapy administration (overall phase) authorised |
|                         | Secondary endpoint     | No emesis Acute       | No emesis (no vomiting, retching or dry heaves) during the acute phase (0 through ≤ 24 hours)                                                                                                           |
|                         | Secondary endpoint     | No emesis delayed     | No emesis (no vomiting, retching or dry heaves) during the delayed phase (>24 through 120 hours)                                                                                                        |
|                         | Secondary endpoint     | No emesis overall     | No emesis (no vomiting, retching or dry heaves) during the overall phase (0 through 120 hours)                                                                                                          |
|                         | Secondary endpoint     | No significant nausea | No significant nausea (nausea <25 mm on VAS) during the overall phase (0 through 120 hours) longer                                                                                                      |
|                         | Secondary endpoint     | TTF                   | Time to the first emetic episode or time to the first rescue medication                                                                                                                                 |
| Database lock           | 03 April 2014          |                       |                                                                                                                                                                                                         |

Analysis description

Analysis population

and time

description

Descriptive and

variability point

statistics estimate

Primary Analysis

Modified Intent to treat

Treatment group rolapitant

Number of

subject

CR delayed n (% patients)

95% IC a p-value b

CR acute*

n (% patients)

Results and Analysis Medicinal product no longer authorised

95% IC a p-value c

CR overall*

n (% patients)

95% IC a

271

190 (70.1)

[64.3;75.5]

0.043

226 (83.4)

[78.4;87.6]

0.233

183 (67.5)

[61.6;73.1]

control

273

169 (61.9)

[55.6;67.7]

217 (79.5)

[74.2;84.1]

165 (60.4)

[54.4;66.3]

<div style=\"page-break-after: always\"></div>

MEC Study P04834

<!-- image -->

| p-value c                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.084                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.084                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Other secondary analyses                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Other secondary analyses                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Other secondary analyses                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Rolapitant 200 mg n / N (%)                                                                                                                                                                                                                                                                                                                                                                                                                                              | Control n / N (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| No emesis Delayed phase                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 198/ 271 (73.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 198/ 271 (73.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Mean difference to control                                                                                                                                                                                                                                                                                                                                                                                                                                               | 7.9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 7.9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Odds Ratio (95% CI) P-value                                                                                                                                                                                                                                                                                                                                                                                                                                              | 1.4 (1.0, 2.1) 0.046 authorised                                                                                                                                                                                                                                                                                                                                                                                                                                          | 1.4 (1.0, 2.1) 0.046 authorised                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| No emesis acute phase                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 232/ 271 (85.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 223/ 273 (81.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Mean difference to control                                                                                                                                                                                                                                                                                                                                                                                                                                               | 3.9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 3.9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Odds Ratio (95% CI) P-value                                                                                                                                                                                                                                                                                                                                                                                                                                              | 1.3 (0.8, 2.1) 0.208                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1.3 (0.8, 2.1) 0.208                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| No Emesis - Overall Phase                                                                                                                                                                                                                                                                                                                                                                                                                                                | 192/ 271 (70.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 175/ 273 (64.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Mean difference to control                                                                                                                                                                                                                                                                                                                                                                                                                                               | 6.7%                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 6.7%                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Odds Ratio (95% CI) P-value                                                                                                                                                                                                                                                                                                                                                                                                                                              | 1.4 (1.0, 1.9) 0.091 longer                                                                                                                                                                                                                                                                                                                                                                                                                                              | 1.4 (1.0, 1.9) 0.091 longer                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Significant tertiary analysis                                                                                                                                                                                                                                                                                                                                                                                                                                            | Significant tertiary analysis                                                                                                                                                                                                                                                                                                                                                                                                                                            | Significant tertiary analysis                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| FLIE No Impact on Daily Life FLIE total score >108. Denominator was based on the number of subjects with valid questionnaire product                                                                                                                                                                                                                                                                                                                                     | 194/ 248 (78.2) no                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 183/ 249 (73.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Odds Ratio (95% CI) P-value                                                                                                                                                                                                                                                                                                                                                                                                                                              | 1.3 (0.9,2.0) 0.206                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1.3 (0.9,2.0) 0.206                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| p-value from Cochran-Mantel-Haenszel test, stratified by gender b Exact 95% confidence interval (CI) for response rate c Unadjusted p-values are *The key secondary endpoints of CR rate in the acute and overall phases of CINV were analyzed in a stepwise fashion using the same methodology as the primary endpoint. To control for multiplicity within the prespecified secondary endpoints, the Bonferroni- Holm multiple comparison procedure was used. Medicinal | p-value from Cochran-Mantel-Haenszel test, stratified by gender b Exact 95% confidence interval (CI) for response rate c Unadjusted p-values are *The key secondary endpoints of CR rate in the acute and overall phases of CINV were analyzed in a stepwise fashion using the same methodology as the primary endpoint. To control for multiplicity within the prespecified secondary endpoints, the Bonferroni- Holm multiple comparison procedure was used. Medicinal | p-value from Cochran-Mantel-Haenszel test, stratified by gender b Exact 95% confidence interval (CI) for response rate c Unadjusted p-values are *The key secondary endpoints of CR rate in the acute and overall phases of CINV were analyzed in a stepwise fashion using the same methodology as the primary endpoint. To control for multiplicity within the prespecified secondary endpoints, the Bonferroni- Holm multiple comparison procedure was used. Medicinal |

## Methods

This  was  a  Phase  3,  multicenter,  randomized,  parallel-group,  double-blind,  active-controlled  study  of rolapitant  in  subjects  receiving  MEC.  Rolapitant  or  placebo  was  administered  orally  1-2  hours  prior  to  the initiation  of  chemotherapy  on  Day  1.  Granisetron  (2  mg  PO)  and  dexamethasone  (20  mg  PO)  were

<div style=\"page-break-after: always\"></div>

administered  approximately  30  minutes  before  initiation  of  chemotherapy  on  Day  1,  except  in  subjects receiving taxanes as part of MEC.

## Study participants

Approximately 1300 evaluable subjects were required to evaluate the primary objective of the study. It was expected that 1350 subjects would be enrolled at approximately 150 investigational sites.

In  this  study  unlike  the  HEC  studies  (cisplatin  but not  chemotherapy  naïve  subjects  were  included  in HEC studies)  participants  were  naive  to  MEC  and  HEC,  and  were  scheduled  to  receive  a  first  course  of  MEC. Cyclophosphamide IV (&lt;1500 mg/m2), doxorubicin, epirubicin, carboplatin, idarubicin, ifosfamide, irinotecan, daunorubicin, or cytarabine IV (&gt;1 g/m 2 ) were the required chemotherapies included in the MEC protocol. The protocol also specified that at least 50% of the study subjects would receive anthracycline in combination with cyclophosphamide (AC) as the MEC regimen. Since 2010 (Roila et al) it has been recognised that CINV associated  with  the  commonly  used  combination  of  the  MEC  agents  cyclophosphamide  and  anthracycline should be treated the same as for HEC. Rolapitant  200  mg  (50mgx4)  or  placebo  was  administered  orally  1  to  2  hours  prior  to  the  initiation  of chemotherapy  on  Day  1.  Granisetron  (2  mg  PO)  and  dexamethasone  (20  mg  PO)  were  administered approximately 30 minutes before initiation of chemotherapy as standard therapy (i.e., 1-2 hours prior to the initiation of chemotherapy on Day 1). In this study, all subjects continued to receive granisetron (2 mg daily) on Days 2 and 3. Treatments Rolapitant (4 × 50 mg capsules) or matching placebo was administered orally 1-2 hours prior to the initiation of chemotherapy on Day 1. Granisetron (2 mg [PO]) and dexamethasone (20 mg oral [PO]) were administered approximately 30 minutes before initiation of chemotherapy on Day 1, except in subjects receiving taxanes as part of MEC. All subjects continued to receive granisetron (2 mg daily) on Days 2 and 3. All subjects were expected to complete Cycle 1; at the end of Cycle 1, eligible subjects, as determined by the site investigator, were offered the opportunity to continue with the same study medication administered in the same manner as in Cycle 1 for up to five additional cycles (a total of 6 cycles). Figure 9 Flow Chart for Drug Administration - Days 1-3 P04834 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

- To determine the effect of rolapitant treatment on the incidences of no emesis (no vomiting, retching, or dry heaves; included subjects who received rescue medication) in the acute, delayed and overall phases of CINV.

The control treatment regime is not in line with the recommended prophylaxis for AC or non-AC MEC in CINV (MASCC /ESMO 2010) that was current the time this study was commenced (2012) or the most recent 2016 guidance.  The  administration  of  5HT-3RA  from  day  2  to  day  3  post  chemotherapy  was  not  and  is  not recommended as part of the EU (MASCC/ESMO) consensus guidelines. The comparator regime recommended in EU consensus guidelines (MASCC/ESMO 2010) from that time for non- AC MEC or AC are different. In the 2010 guidance it was established that for patients receiving non-AC MEC  a  combination  of  a  5HT-3RA  and  dexamethasone  was  considered  standard  antiemetic  prophylaxis whereas patient receiving AC should be treated more like HEC.  Study P04834 was conducted between March 5, 2012, and Sept 6, 2013 so it is unclear why such a high proportion of the study population for the MEC study  comprised  subjects  treated  with  AC  and  why  the  comparator  regime  was  chosen  (i.e.  choice  of granisetron, dosing on day 2,3 of cycle). Subjects in the AC arm were potentially undertreated. Control of CINV in the acute phase has a direct relationship with control of CINV in the delayed phase. The comparator regime in the MEC study should be further justified. Objectives The primary objective of this study was to determine whether administration of rolapitant with granisetron and  dexamethasone  improved  CINV  in  the  delayed  phase  (&gt;24  to  120  hours)  of  CINV  compared  with administration  of  placebo  with  granisetron  and  dexamethasone  in  subjects  receiving  MEC.  The  primary outcome was based on the CR (defined as no emetic episodes and no rescue medication) in the delayed phase. Key Secondary Objectives · To determine the effect of rolapitant treatment on the incidence of CR in the acute (0- ≤24 hours) and overall (0-≤120 hours) phases of CINV. · To determine if rolapitant was safe and well tolerated in subjects receiving MEC. Secondary Objectives Medicinal product no longer authorised

- To determine the effect of rolapitant treatment on the incidence of no significant nausea in the overall phase of CINV.

<div style=\"page-break-after: always\"></div>

- To  determine  the  effect  of  rolapitant  treatment  on  the  time  to  first  emesis  or  use  of  rescue medication.

## Tertiary Objectives

- To determine the effect of rolapitant treatment on the incidences of no significant nausea in the acute and delayed phases of CINV.

· To  determine  the  effect  of  rolapitant  treatment  on  the  incidences  of  no  nausea  and  complete protection in the acute, delayed and overall combined phases of CINV. · To  evaluate  the  effect  of  rolapitant  treatment  on  health-related  quality  of  life  as  assessed  by  the FLIE. · Outcomes/endpoints The  efficacy  of  rolapitant  was  assessed  through  approximately  120  hours  following  initiation  of  MEC.  The primary assessment of efficacy was based on the responses recorded in the NVSD Diary for Cycle 1. The primary efficacy endpoint for this study was the complete response rate in the delayed phase of CINV, from &gt;24 through 120 hours following initiation of MEC. Complete response is defined in as no emesis and no rescue medication. The key secondary efficacy endpoints were · the  incidence  of  CR  during  the  acute  (0-≤24  hours)  and  overall  (0-≤120  hours)  phases  of  CINV following the initiation of MEC. The secondary efficacy endpoints for this study included: · No emesis (no vomiting, retching, or dry heaves) in the acute, delayed, and overall phases of CINV. · No significant nausea (maximum VAS &lt;25 mm) in the overall phase of CINV. · Time to first emesis or to use of rescue medication. The tertiary efficacy endpoints for this study included: · No significant nausea in the acute and delayed phases of CINV. · No nausea (maximum VAS &lt;5 mm) and Complete protection (no emesis, no rescue medication, and maximum nausea VAS &lt;25 mm on a 0 to 100 mm scale) in the acute, delayed, and overall phases of CINV. · No impact on daily life (total score &gt;108) as assessed by the FLIE Questionnaire. Sample size Medicinal product no longer authorised

Approximately 1350 subjects were to be randomized to one of two treatment groups (rolapitant group or control group) in a 1:1 ratio to ensure 650 evaluable subjects per group. With 650 subjects per group, the study was able to detect an absolute difference of 9% in the delayed phase CR rates between the rolapitant and control groups at an α = 0.05 level of significance (2-sided) with 90% power, assuming a control group

<div style=\"page-break-after: always\"></div>

complete response rate  of  49%.  The  sample  size  assumptions  were  based  on  the  results  of  two  Phase  3 aprepitant studies performed in a similar patient population receiving MEC.

Using this same sample size, the study had 91% power to detect an absolute difference of 8% in the key secondary endpoint of complete response in the acute phase assuming a control response rate of 70%. The study had 90% power to detect an absolute difference of 9% in the key secondary endpoint of CR in the overall phase assuming a control response rate of 42%.

<!-- image -->

| Efficacy Variable   | CINV Phase                           | Rolapitant (N a =666) Rate (%)   | Control (N a =666) Rate (%)   | Unadjusted P-Value   |
|---------------------|--------------------------------------|----------------------------------|-------------------------------|----------------------|
| Complete Response   | Delayed Phase (>24- 120 hours) n (%) | 475 71.3% (67.7, 74.7)           | 410 61.6% (57.7, 65.3)        | <0.001               |

Efficacy data and additional analyses Study P04834 Baseline characteristics A  broad  population  of  cancer  subjects  was  enrolled  across  both  studies  based  on  age,  gender,  type  of underlying  malignancy,  and  geographic  region.  Mean  age  in  the  MITT  population  was  56.7  years.  Most subjects were &lt;65 years of age (72.4%), female (80.1%), white (77.0%), and did not consume alcohol (selfreported) (80.6%). Cancer diagnosis was similar between the treatment groups; the most common types of cancer overall were breast cancer (63.4%) and lung cancer (16.5%). All other cancer types were reported in &lt;5% of subjects overall. Greater than 50% of subjects in both the rolapitant and control groups received an anthracycline-cyclophosphamide (AC) chemotherapy. A total of 1369 subjects were randomised into this study at 170 sites, including 684 subjects randomised to receive  rolapitant  with  granisetron  and  dexamethasone  and  685  randomised  to  receive  placebo  with granisetron and dexamethasone (control). Twenty five subjects randomised did not receive study medication. A further 12 subjects were  excluded due to GCP noncompliance at site 181.This data was considered to be unusable and was excluded from the dataset. The MITT Population (primary analysis population) for Cycle 1 comprised a total of 1332 subjects (666 subjects in each treatment group). Discontinuation during Cycle 1 was uncommon, reported in 7% and 6.6% of subjects in the rolapitant and control groups, respectively. The most common reason for discontinuation from Cycle 1 in both rolapitant and control  subjects  was  withdrawal  of  consent  (7.0%  and  8.8%,  respectively).    Compliance  with  rolapitant dosing was high (&gt;99%) across both studies as was compliance with adjunct antiemetic therapy (&gt;99%). Mean and median numbers of chemotherapy cycles administered in the MITT population were 3.7 and 4.0, respectively, in both the rolapitant and control groups. Median duration of each treatment cycle was 21 days in both groups Efficacy results Table 39 : Complete Response in the Delayed Phase of CINV: Summary and Between Group Comparison (MITT Population, Study P04834) Efficacy Variable CINV Phase Complete Medicinal product no longer authorised

Key secondary endpoints

<div style=\"page-break-after: always\"></div>

Table 40 : Complete Response in the Acute and Overall Phases of CINV: Summary and Between-Group Comparisons (MITT Population MEC Study P04834)

| Efficacy Variable                      | CINV Phase                              | Rolapitant (N=666) Rate (%)   | Control (N=666) Rate (%)   | Unadjusted P-Value   |
|----------------------------------------|-----------------------------------------|-------------------------------|----------------------------|----------------------|
| Complete ResponseAcute                 | Phase (0-≤24 hours) (%) (95% CI for %)c | 556 (83.5) (80.4, 86.2)       | 535 (80.3) (77.1, 83.3)    | 0.143                |
| Complete ResponseOverall Phase (0-≤120 | hours) n (%) (95% CI for %)c            | 457 (68.6) (64.9, 72.1)       | 385 (57.8) (54.0, 61.6)    | <0.001               |

| Complete Response   | Rolapitant   | Control       | P-Value a   |
|---------------------|--------------|---------------|-------------|
| Non-AC              | N=322        | N=307         |             |
| Delayed             | 76.1         | 63.8 no       | <0.001      |
| Acute               | 90.7         | 84.4          | 0.016       |
| Overall             | 74.8         | 61.2          | <0.001      |
| AC                  | N=344        | N=359 product |             |
| Delayed             | 66.9         | 59.6          | 0.047       |
| Acute               | 76.7         | 76.9          | N.S.        |
| Overall             | 62.8         | 54.9          | 0.033       |

A pre-specified subgroup analysis was performed for the endpoint of complete response in each CINV phase for subjects who received Non-AC MEC (MEC according to recent guidelines) vs. AC based chemotherapy. Table  41:  Proportion  of  Patients  Receiving  AC  or  non  AC  Chemotherapy  Achieving  Complete Response a  Unadjusted P-values are obtained from Cochran-Mantel-Haenszel test. N.S.=Not significant (p&gt;0.05) Nausea Medicinal product no longer authorised

The proportion of subjects with no significant nausea (maximum VAS of &lt;25 mm) and no nausea (maximum VAS of &lt;5mm) did not achieve statistical significance  for the  rolapitant group compared to the standard therapy group in any of the phases. In fact in the acute phase the control group were numerically higher than the rolapitant group for the no significant nausea endpoint. Rolapitant has very little impact on the treatment of nausea across any of the phases of MEC induced CINV. The results of the other secondary and tertiary

<div style=\"page-break-after: always\"></div>

endpoints were generally in line with those of the primary and key secondary endpoints for the delayed, and overall phases for (no emesis and complete protection).

A  higher  proportion  of  subjects  treated  with  rolapitant  reported  no  impact  on  daily  life  (FLIE  total  score &gt;108) compared with subjects who were treated with control (73.2% and 67.4%, respectively; unadjusted p = 0.027).

## Time to First Emesis or Use of Rescue Medication During the First 120 Hours

<!-- image -->

A  separation  in  the  Kaplan-Meier  curves  is  visually  apparent  early  during  the  acute  phase  of  CINV  by  12 hours after administration of study drug. This separation continues to increase during the acute phase (024hrs) is sustained in the   delayed phase of CINV(&gt;24hrs). For  Study P04834 the incidence of subjects requiring ≥1 rescue medication during Cycle 1 was lower in the rolapitant group than in the control group). (18.3% and 26.3%, respectively). Figure 10: Kaplan-Meier Plot of Proportions of Subjects without Emesis or Use of Rescue Medication (MITT Population, Study P04834) Overall  the  statistically  significant  and  clinically  relevant  changes  in  CR  in  favour  of  rolapitant  was  seen across the delayed phase of CINV in subjects receiving MEC. The treatment effect was more pronounced in subjects receiving g non-AC MEC 12.3% compared with AC MEC 7.3%. Subgroup analyses Exploratory analyses of the primaryand key secondary were conducted for subject subgroups, according to gender, age, race, region, and receipt of CEC. During the delayed and overall phases of CINV, the CR rate favoured rolapitant across all subgroups for the MEC studies. There was some variability across subgroups in the acute phase responses. Medicinal product no longer authorised

Similar  to  the    HEC  studies  efficacy  outcomes  by  gender  were  variable  across  the  MEC  studies    however opposite  to  the    HEC  studies  response  rates  for  males  were  consistently  higher  compared  to  females receiving rolapitant versus control across all CINV phases. (e.g. CR delayed phase females 68.4% vs  control 59.3% OR 1.5 (1.2, 1.9) vs males 83.0% vs 70.8% OR 2.0 (1.1, 3.6) respectively. The magnitude of the treatment effect (CR delayed phase)for males was higher than  that for females (e.g 12.2% difference vs 9.1%. Response rates for males receiving rolapitant were consistently higher than response rates in females

<div style=\"page-break-after: always\"></div>

across all CINV phases . A Gail-Simon test conducted by the applicant indicated that there were no qualitative interactions  between  treatment  and  subgroup  regardless  of  gender  across  all  of  these  endpoints.    The variability in response across gender within studies and across the HEC and MEC studies  has not been fully explained.

Approximately 16% of the study population were under 45 years (age &lt;45 is a risk factor for CINV) and just 6% of the study population were over 75 years. The CR rate was consistently higher in the rolapitant group compared to control in the age subgroups in the 45 -65 age group.  Rolapitant was least effective in &lt;45yrs and &gt;75 yrs age group across all three phases.

<!-- image -->

The CR rate was higher (OR&gt;1) in the rolapitant group compared to the control group for all of the race categories in the MEC studies for all  phases  in the CR analyses except in the acute phase for the Asian population( OR=1). The CR rate was higher in the rolapitant group compared to control in the majority of regions in the pooled analyses across all three phases of CINV.A further subgroup analysis was conducted for the three regions within Europe(Western, Central and Eastern Europe). Across all three phases the odds ratio for CR rate in Western Europe was less than zero (OR 0.9 delayed phase; OR 0.6 Acute phase; OR 0.8 Overall phase. The CR rate across all phases in Central Europe was consistently higher than the other regions. The reason for this variability across Europe is unclear. Figure 11: Complete response for the Delayed phase by subgroup (MITT population) MEC study Medicinal product no longer authorised

Complete response for the Acute phase by subgroup (MITT population) MEC study

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Repeat Efficacy Similar to the HEC studies this study offered an optional multiple-cycle extension of up to 5 additional cycles for MEC. Subjects response of no emesis or nausea based on duration of Cycle 1 ( analysis over cycle duration &lt;21 days versus ≥21 days also conducted for study P04834) for the MITT population was  assessed to evaluate whether repeat dosing demonstrated sustained benefit of the use of rolapitant over multi-cycle use. Note that subjects evaluation of no emesis or nausea was based on subject recall on day 6, 7 or 8 rather than daily diary entries. Similar percentages of patients reported no emesis or nausea  across cycles regardless of Cycle 1 duration and the treatment effect for  rolapitant between Cycles 2 and 6 appears to be maintained. Figure 12: Subject Response of No Emesis or Nausea by Cycle (MITT Population) P04834 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Title: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy- Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderatly Emetogenic Chemotherapy (MEC) no   | Title: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy- Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderatly Emetogenic Chemotherapy (MEC) no                                                                                                                                                                                                                                                                                  | Title: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy- Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderatly Emetogenic Chemotherapy (MEC) no                                                                                                                                                                                                                                                                                  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                    | TS-P04834                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Design                                                                                                                                                                                                                                                              | Multicenter, Randomized, Parallel-group, Double-Blind, Active-Controlled Study in Patients Receiving MEC MEC includes the following agents: cyclophosphamide IV (<1500 mg/m2), doxorubicin, epirubicin, carboplatin, idarubicin, ifosfamide, irinotecan, daunorubicin, or cytarabine IV (>1 g/m2). These were the required chemotherapies included in the MEC protocol. For this study, the protocol specified that at least 50% of the study subjects would receive anthracycline in combination with cyclophosphamide as the MEC regimen product | Multicenter, Randomized, Parallel-group, Double-Blind, Active-Controlled Study in Patients Receiving MEC MEC includes the following agents: cyclophosphamide IV (<1500 mg/m2), doxorubicin, epirubicin, carboplatin, idarubicin, ifosfamide, irinotecan, daunorubicin, or cytarabine IV (>1 g/m2). These were the required chemotherapies included in the MEC protocol. For this study, the protocol specified that at least 50% of the study subjects would receive anthracycline in combination with cyclophosphamide as the MEC regimen product |
| Medicinal                                                                                                                                                                                                                                                           | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Acute phase (0 to 24 hours) delayed phase (>24 to 120 hours) overall (0 to 120 hours) phases of CINV. not applicable not applicable                                                                                                                                                                                                                                                                                                                                                                                                                |
| Hypothesis                                                                                                                                                                                                                                                          | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Treatments groups                                                                                                                                                                                                                                                   | Rolapitant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Rolapitant 200 mg on Day 1 + granisetron PO (2 mg from Day 1 to Day 3) + dexamethasone PO (20 mg on Day 1) n=666                                                                                                                                                                                                                                                                                                                                                                                                                                   |

Table 42: Summary of efficacy for trial P04834 Title: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of  Rolapitant  for  the  Prevention  of  Chemotherapy-  Induced  Nausea  and  Vomiting  (CINV)  in  Subjects Receiving Moderatly Emetogenic Chemotherapy (MEC) not applicable Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                                | Placebo                                 | Placebo                                 | Placebo on Day 1 + granisetron IV (10 µg/kg on Day 1) + dexamethasone PO (20 mg on Day 1 and 8 mg BID from Day 2 to Day 4) n=666                                                                     |
|------------------------------------------------|-----------------------------------------|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions                      | Primary endpoint                        | CR delayed phase                        | Complete response rate (defined as no emetic episodes, no rescue medication) from >24 through 120 hours after the start of the highly emetogenic chemotherapy administration (delayed phase)         |
| Endpoints and definitions                      | Key Secondary endpoint                  | CR acute phase                          | Complete response rate (defined as no emetic episodes, no rescue medication) from 0 through ≤ 24 hours after the start of the highly emetogenic chemotherapy administration (acute phase) authorised |
| Endpoints and definitions                      | Key Secondary endpoint                  | CR overall phase                        | Complete response rate (defined as no emetic episodes, no rescue medication) from 0 through ≤ 120 hours after the start of the highly emetogenic chemotherapy administration (overall phase) longer  |
| Endpoints and definitions                      | Secondary endpoint                      | No emesis Acute                         | No emesis (no vomiting, retching or dyr heaves) during the acute phase (0 through ≤ 24 hours)                                                                                                        |
| Endpoints and definitions                      | Secondary endpoint                      | No emesis delayed                       | No emesis (no vomiting, retching or dyr heaves) during the delayed phase (>24 through 120 hours) no                                                                                                  |
| Endpoints and definitions                      | Secondary endpoint                      | No emesis overall product               | No emesis (no vomiting, retching or dyr heaves) during the overall phase (0 through 120 hours)                                                                                                       |
| Endpoints and definitions                      | Secondary endpoint                      | No significant nausea                   | No significant nausea (nausea <25 mm on VAS) during the overall phase (0 through 120 hours)                                                                                                          |
| Endpoints and definitions                      | Secondary endpoint                      | TTF                                     | Time to the first emetic episode or time to the first rescue medication                                                                                                                              |
| Database lock                                  | Last subject completed: 22 January 2014 | Last subject completed: 22 January 2014 | Last subject completed: 22 January 2014                                                                                                                                                              |
| Results and Analysis Medicinal                 | Results and Analysis Medicinal          | Results and Analysis Medicinal          | Results and Analysis Medicinal                                                                                                                                                                       |
| Analysis description                           | Primary Analysis                        | Primary Analysis                        | Primary Analysis                                                                                                                                                                                     |
| Analysis population and time point description | Modified Intent to treat                | Modified Intent to treat                | Modified Intent to treat                                                                                                                                                                             |
|                                                | Overall patients                        | Overall patients                        | Overall patients                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Descriptive and   | statistics estimate Treatment group                                                                                                                                                                                                                                                                                               | rolapitant                                                                                                                                                                                                                                                                                                                        | placebo                                                                                                                                                                                                                                                                                                                           | placebo                                                                                                                                                                                                                                                                                                                           |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| variability       | Number of subject                                                                                                                                                                                                                                                                                                                 | 666                                                                                                                                                                                                                                                                                                                               | 666                                                                                                                                                                                                                                                                                                                               | 666                                                                                                                                                                                                                                                                                                                               |
|                   | Primary endpoint CR delayed                                                                                                                                                                                                                                                                                                       | 475 (71.3)                                                                                                                                                                                                                                                                                                                        | 410 (61.6)                                                                                                                                                                                                                                                                                                                        | 410 (61.6)                                                                                                                                                                                                                                                                                                                        |
|                   | n (% patients) 95% ICa                                                                                                                                                                                                                                                                                                            | [67.7;74.7]                                                                                                                                                                                                                                                                                                                       | [57.7;65.3]                                                                                                                                                                                                                                                                                                                       | [57.7;65.3]                                                                                                                                                                                                                                                                                                                       |
|                   | p-valueb                                                                                                                                                                                                                                                                                                                          | <0.001                                                                                                                                                                                                                                                                                                                            | <0.001                                                                                                                                                                                                                                                                                                                            | <0.001                                                                                                                                                                                                                                                                                                                            |
|                   | Key secondary endpoint CR acute n (% patients)                                                                                                                                                                                                                                                                                    | 556 (83.5)                                                                                                                                                                                                                                                                                                                        | 535 (80.3) authorised                                                                                                                                                                                                                                                                                                             | 535 (80.3) authorised                                                                                                                                                                                                                                                                                                             |
|                   | 95% ICa                                                                                                                                                                                                                                                                                                                           | [80.4;86.2]                                                                                                                                                                                                                                                                                                                       | [77.7;83.3]                                                                                                                                                                                                                                                                                                                       | [77.7;83.3]                                                                                                                                                                                                                                                                                                                       |
|                   | p-valuec                                                                                                                                                                                                                                                                                                                          | 0.143                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                   |
|                   | As per the SAP, with the hierarchical testing, as statistical significance was not achieved for this endpoint, formal statistical significance of subsequent endpoints within the hierarchy could not be established. The applicant acknowledges this however for completeness the unadjusted p- values are presented here longer | As per the SAP, with the hierarchical testing, as statistical significance was not achieved for this endpoint, formal statistical significance of subsequent endpoints within the hierarchy could not be established. The applicant acknowledges this however for completeness the unadjusted p- values are presented here longer | As per the SAP, with the hierarchical testing, as statistical significance was not achieved for this endpoint, formal statistical significance of subsequent endpoints within the hierarchy could not be established. The applicant acknowledges this however for completeness the unadjusted p- values are presented here longer | As per the SAP, with the hierarchical testing, as statistical significance was not achieved for this endpoint, formal statistical significance of subsequent endpoints within the hierarchy could not be established. The applicant acknowledges this however for completeness the unadjusted p- values are presented here longer |
|                   | Key secondary endpoint CR overall n (% patients) product                                                                                                                                                                                                                                                                          | 457 (68.6) no                                                                                                                                                                                                                                                                                                                     | 385 (57.8)                                                                                                                                                                                                                                                                                                                        | 385 (57.8)                                                                                                                                                                                                                                                                                                                        |
|                   | 95% ICa                                                                                                                                                                                                                                                                                                                           | [64.9;72.1]                                                                                                                                                                                                                                                                                                                       | [54.0;61.6]                                                                                                                                                                                                                                                                                                                       | [54.0;61.6]                                                                                                                                                                                                                                                                                                                       |
|                   | p-value c                                                                                                                                                                                                                                                                                                                         | <0.001                                                                                                                                                                                                                                                                                                                            | <0.001                                                                                                                                                                                                                                                                                                                            | <0.001                                                                                                                                                                                                                                                                                                                            |
|                   | Secondary endpoints No significant nausea during the overall phase of CINV c Medicinal                                                                                                                                                                                                                                            | 470 (70.6)                                                                                                                                                                                                                                                                                                                        | 470 (70.6)                                                                                                                                                                                                                                                                                                                        | 443 (66.5)                                                                                                                                                                                                                                                                                                                        |
|                   | p-value                                                                                                                                                                                                                                                                                                                           | 0.118                                                                                                                                                                                                                                                                                                                             | 0.118                                                                                                                                                                                                                                                                                                                             | 0.118                                                                                                                                                                                                                                                                                                                             |
|                   | Secondary endpoints No Emesis - Delayed Phase                                                                                                                                                                                                                                                                                     | 536 (80.5)                                                                                                                                                                                                                                                                                                                        | 536 (80.5)                                                                                                                                                                                                                                                                                                                        | 465 (69.8)                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| p-value c                                                      | <0.001                              | <0.001                      |
|----------------------------------------------------------------|-------------------------------------|-----------------------------|
| Secondary endpoints No Emesis - Acute Phase                    | 585/666 (87.8)                      | 563/666 (84.5)              |
| p-value c                                                      | 0.085                               | 0.085                       |
| Secondary endpoints No Emesis - Overall Phase                  | 524/666 (78.7)                      | 435/666 (65.3)              |
| p-value c                                                      | <0.001 authorised                   | <0.001 authorised           |
| Tertiary endpoints No Significant Nausea - delayed Phase       | Comparison groups Odds ratio longer | Rolapitant 200mg vs control |
| Tertiary endpoints No Significant Nausea - delayed Phase       |                                     | 1.2                         |
| Tertiary endpoints No Significant Nausea - delayed Phase       | 95% CI                              | (0.9, 1.5)                  |
| Tertiary endpoints No Significant Nausea - delayed Phase       | P-value                             | 0.194                       |
| Tertiary endpoints No Significant Nausea - Acute Phase product | Comparison groups Odds ratio no     | Rolapitant 200mg vs control |
| Tertiary endpoints No Significant Nausea - Acute Phase product |                                     | 1.2                         |
| Tertiary endpoints No Significant Nausea - Acute Phase product | 95% CI                              | (0.9, 1.5)                  |
| Tertiary endpoints No Significant Nausea - Acute Phase product | P-value                             | 0.194                       |
| Tertiary endpoints No Nausea - delayed Phase                   | Comparison groups                   | Rolapitant 200mg vs control |
| Tertiary endpoints No Nausea - delayed Phase                   | Odds ratio                          | 1.2                         |
| Tertiary endpoints No Nausea - delayed Phase                   | 95% CI                              | (0.9, 1.4)                  |
| Tertiary endpoints No Nausea - delayed Phase                   | P-value                             | 0.201                       |
| Tertiary endpoints No Nausea - acute Phase Medicinal           | Comparison groups                   | Rolapitant 200mg vs control |
| Tertiary endpoints No Nausea - acute Phase Medicinal           | Odds ratio                          | 1.0                         |
| Tertiary endpoints No Nausea - acute Phase Medicinal           | 95% CI                              | (0.8, 1.2)                  |
| Tertiary endpoints No Nausea - acute Phase Medicinal           | P-value                             | 0.693                       |

<div style=\"page-break-after: always\"></div>

|                                                           | Tertiary endpoints No Nausea                                  |                                    | Comparison groups                  | Rolapitant 200mg vs control            |                                    |
|-----------------------------------------------------------|---------------------------------------------------------------|------------------------------------|------------------------------------|----------------------------------------|------------------------------------|
|                                                           | -                                                             |                                    | Odds ratio                         | 1.1                                    |                                    |
|                                                           | overall Phase                                                 |                                    | 95% CI                             | (0.9, 1.4)                             |                                    |
|                                                           | Tertiary endpoints No Nausea                                  |                                    | P-value                            | 0.219                                  |                                    |
|                                                           | Tertiary endpoints Complete Protection - Delayed Phase        |                                    | Comparison groups                  | Rolapitant 200mg vs control            |                                    |
|                                                           |                                                               |                                    | Odds ratio                         | 1.5                                    |                                    |
|                                                           |                                                               |                                    | 95% CI                             | (1.2, 2.0)                             |                                    |
|                                                           |                                                               |                                    | P-value                            | <0.001                                 |                                    |
|                                                           | Tertiary endpoints Complete Protection - Acute Phase          |                                    | Comparison groups                  | Rolapitant 200mg vs control authorised |                                    |
|                                                           |                                                               |                                    | Odds ratio                         |                                        |                                    |
|                                                           |                                                               |                                    | 95% CI                             |                                        |                                    |
|                                                           |                                                               |                                    | P-value                            |                                        |                                    |
|                                                           | Tertiary endpoints Complete Protection overall Phase Tertiary | -                                  | Comparison groups longer           | Rolapitant 200mg vs control            |                                    |
|                                                           | Tertiary endpoints Complete Protection overall Phase Tertiary | -                                  | Odds ratio                         | 1.4                                    |                                    |
|                                                           |                                                               | -                                  | 95% CI no                          | (1.2, 1.8)                             |                                    |
|                                                           |                                                               | -                                  | P-value                            | 0.001                                  |                                    |
|                                                           | endpoints No Impact on Daily Life Overall phase product       |                                    | Comparison groups                  | Rolapitant 200mg vs control            |                                    |
|                                                           |                                                               |                                    | Odds ratio                         | 1.3                                    |                                    |
|                                                           |                                                               |                                    | 95% CI                             | (1.0, 1.7)                             |                                    |
|                                                           |                                                               |                                    | P-value                            | 0.027                                  |                                    |
|                                                           | Subgroup analysis Non-AC MEC Group                            | Subgroup analysis Non-AC MEC Group | Subgroup analysis Non-AC MEC Group | Subgroup analysis Non-AC MEC Group     | Subgroup analysis Non-AC MEC Group |
| Descriptive statistics and estimate variability Medicinal | Treatment group                                               |                                    | rolapitant                         | placebo                                |                                    |
| Descriptive statistics and estimate variability Medicinal | Number of subject                                             |                                    | 322                                | 307                                    |                                    |
| Descriptive statistics and estimate variability Medicinal | CR delayed n (% patients)                                     |                                    | 245 (76.1)                         | 196 (63.8)                             |                                    |
| Descriptive statistics and estimate variability Medicinal | Odds Ratio (IC95%) b                                          | 1.8                                | (1.27,2.55) <0.001                 | (1.27,2.55) <0.001                     |                                    |
| Descriptive statistics and estimate variability Medicinal | p-value CR acute n (% patients)                               |                                    | 292 (90.7)                         | 259 (84.4)                             |                                    |

Odds

Ratio

(IC95%)

p-value b

1.80 (1.11,2.63)

P=0.016

CR overall n (% patients)

241 (74.8)

188 (61.2)

Odds

Ratio

(IC95%)

p-value b Subgroup analysis  AC Group Descriptive statistics and estimate variability Treatment group rolapitant placebo Number of subject 344 359 CR delayed n (% patients) 230 (66.9) 214 (59.6) Odds Ratio (IC95%) p-value b 1.37 (1.00,1.86) 0.047 CR acute n (% patients) 264 (76.7) 276 (76.9) Odds Ratio (IC95%) p-value b 0.99 (0.70,1.41) 0.966 CR overall n (% patients) 216 (62.8) 197 (54.9) Odds Ratio (IC95%) p-value b 1.39 (1.03,1.88) 0.033 Notes a p-value from Cochran-Mantel-Haenszel test, stratified by gender b Exact 95% confidence interval (CI) for response rate c Unadjusted p-values Analysis performed across trials (pooled analyses and meta-analysis) Table 43: Pooled results from HEC studies. Medicinal product no longer authorised

1.88 (1.34,2.65) P&lt;0.001

<div style=\"page-break-after: always\"></div>

| Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   |
|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Efficacy Endpoints                                                                                                                           | HEC Study 1                                                                                                                                  | HEC Study 1                                                                                                                                  | HEC Study 1                                                                                                                                  | HEC Study 2                                                                                                                                  | HEC Study 2                                                                                                                                  | HEC Study 2                                                                                                                                  | Study 1 and 2 Combined                                                                                                                       | Study 1 and 2 Combined                                                                                                                       | Study 1 and 2 Combined                                                                                                                       |
| Efficacy Endpoints                                                                                                                           | Rolapitant (N=264) Rate (%)                                                                                                                  | Control (N=262) Rate (%)                                                                                                                     | P-Value b                                                                                                                                    | Rolapitant (N=271) Rate (%)                                                                                                                  | Control (N=273) Rate (%)                                                                                                                     | P-Value b                                                                                                                                    | Rolapitant (N=535) Rate (%)                                                                                                                  | Control (N=535) Rate (%)                                                                                                                     | P-Value c                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   | Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase (Studies 1 and 2 - HEC Individual Results)   |
|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                              | HEC Study                                                                                                                                    | HEC Study                                                                                                                                    | HEC Study                                                                                                                                    | HEC Study 2                                                                                                                                  | HEC Study 2                                                                                                                                  | HEC Study 2                                                                                                                                  | Study 1 and 2 Combined                                                                                                                       | Study 1 and 2 Combined                                                                                                                       | Study 1 and 2 Combined                                                                                                                       |
| Complete Response                                                                                                                            | Complete Response                                                                                                                            | Complete Response                                                                                                                            | Complete Response                                                                                                                            | Complete Response                                                                                                                            | Complete Response                                                                                                                            | Complete Response                                                                                                                            | Complete Response                                                                                                                            | Complete Response                                                                                                                            | Complete Response                                                                                                                            |
| Delayed                                                                                                                                      | 72.7                                                                                                                                         | 58.4                                                                                                                                         | <0.001                                                                                                                                       | 70.1                                                                                                                                         | 61.9                                                                                                                                         | 0.043                                                                                                                                        | 71.4                                                                                                                                         | 60.2                                                                                                                                         | <0.001                                                                                                                                       |
| Acute                                                                                                                                        | 83.7                                                                                                                                         | 73.7                                                                                                                                         | 0.005                                                                                                                                        | 83.4                                                                                                                                         | 79.5                                                                                                                                         | N.S.                                                                                                                                         | 83.6                                                                                                                                         | 76.6                                                                                                                                         | 0.004                                                                                                                                        |
| Overall                                                                                                                                      | 70.1                                                                                                                                         | 56.5                                                                                                                                         | 0.001                                                                                                                                        | 67.5                                                                                                                                         | 60.4                                                                                                                                         | N.S.                                                                                                                                         | 68.8                                                                                                                                         | 58.5                                                                                                                                         | <0.001                                                                                                                                       |
| No Emesis authorised                                                                                                                         | No Emesis authorised                                                                                                                         | No Emesis authorised                                                                                                                         | No Emesis authorised                                                                                                                         | No Emesis authorised                                                                                                                         | No Emesis authorised                                                                                                                         | No Emesis authorised                                                                                                                         | No Emesis authorised                                                                                                                         | No Emesis authorised                                                                                                                         | No Emesis authorised                                                                                                                         |
| Acute                                                                                                                                        | 86.4                                                                                                                                         | 76.0                                                                                                                                         | 0.002                                                                                                                                        | 85.6                                                                                                                                         | 81.7                                                                                                                                         | N.S.                                                                                                                                         | 86.0                                                                                                                                         | 78.9                                                                                                                                         | 0.002                                                                                                                                        |
| Delayed                                                                                                                                      | 78.0                                                                                                                                         | 61.8                                                                                                                                         | <0.001                                                                                                                                       | 73.1                                                                                                                                         | 65.2                                                                                                                                         | 0.046*                                                                                                                                       | 75.5                                                                                                                                         | 63.6                                                                                                                                         | <0.001                                                                                                                                       |
| Overall                                                                                                                                      | 75.4                                                                                                                                         | 59.2                                                                                                                                         | <0.001                                                                                                                                       | 70.8                                                                                                                                         | 64.1                                                                                                                                         | N.S.                                                                                                                                         | 73.1                                                                                                                                         | 61.7                                                                                                                                         | <0.001                                                                                                                                       |
| No Significant Nausea                                                                                                                        | No Significant Nausea                                                                                                                        | No Significant Nausea                                                                                                                        | No Significant Nausea                                                                                                                        | No Significant Nausea                                                                                                                        | No Significant Nausea                                                                                                                        | No Significant Nausea                                                                                                                        | No Significant Nausea                                                                                                                        | No Significant Nausea                                                                                                                        | No Significant Nausea                                                                                                                        |
| Acute                                                                                                                                        | 86.4                                                                                                                                         | 79.4                                                                                                                                         | 0.035                                                                                                                                        | 90.0                                                                                                                                         | 85.7                                                                                                                                         | N.S.                                                                                                                                         | 88.2                                                                                                                                         | 82.6                                                                                                                                         | 0.009                                                                                                                                        |
| Delayed                                                                                                                                      | 73.5                                                                                                                                         | 64.9                                                                                                                                         | 0.034                                                                                                                                        | 74.5                                                                                                                                         | 68.9                                                                                                                                         | N.S.                                                                                                                                         | 74.0                                                                                                                                         | 66.9                                                                                                                                         | 0.011                                                                                                                                        |
| Overall                                                                                                                                      | 71.6                                                                                                                                         | 63.0                                                                                                                                         | 0.037                                                                                                                                        | 72.7                                                                                                                                         | 67.8                                                                                                                                         | N.S.                                                                                                                                         | 72.1                                                                                                                                         | 65.4                                                                                                                                         | 0.017                                                                                                                                        |

|                   | Age < 65 n/N (%)   | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|-------------------|--------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| Controlled Trials |                    |                                                   |                                                   |                                                 |
| P04832            | 392/526 (74.5%)    | 116/526 (22.1%)                                   | 16/526 (3.0%)                                     | 2/526 (0.4%)                                    |

No Emesis Acute Delayed Overall Acute Delayed Overall a  Primary endpoint was complete response in the delayed phase. Delayed phase: &gt;24 to 120 hours post-cisplatin treatment; Acute phase: 0 to 24 hours post-cisplatin treatment; Overall phase: 0 to 120 hours post-cisplatin treatment b Unadjusted P-values are obtained from Cochran-Mantel Haenszel test, stratified for sex. c Unadjusted P-values are obtained from Cochran-Mantel-Haenszel test, stratified by study and sex. N.S.=Not significant (p&gt;0.05) *Not significant after applying pre-specified multiplicity adjustment. Efficacy in repeat cycles In order to address the potential concern that the numerical improvements observed with rolapitant over multiple cycles were due to control in Cycle 1, an exploratory analysis of time to emesis for those patients who had no emesis in Cycle 1 was performed . By limiting the analysis to patients with no emesis in Cycle 1, the two treatment groups are comparable for the assessment of effect in subsequent cycles. This analysis accounts for patient drop outs via censoring. Data from the HEC studies were pooled to provide a more robust sample size for this subset analysis. For the subset of patients without emesis in Cycle 1, the time to emesis in subsequent cycles was significantly extended (pooled HECs: p=0.0167; P04834: p=0.0027). Discontinuation across cycles due to 'lack of efficacy' was analysed. Across all six cycles in the 3 Phase 3 clinical studies, discontinuation rates due to lack of efficacy were as follows (rolapitant vs. control): 4832: 1.1% vs. 1.5%; 4833: 3.2% vs. 2.5%; 4834: 2.0% vs. 4.4%. Clinical studies in special populations Table 44: Number of older patients in clinical efficacy studies. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|        | Age < 65 n/N (%)   | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|--------|--------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| P04833 | 398/544 (73.2%)    | 128/544 (23.5%)                                   | 18/544 (3.3%)                                     | 0/544 (0%)                                      |
| P04834 | 965/1332 (72.4%)   | 283/1332 (21.2%)                                  | 81/1332 (6.1%)                                    | 3/1332 (0.2%)                                   |
| Total  | 1755/2402 (73.1%)  | 527/2402 (21.9%)                                  | 115/2402 (4.8%)                                   | 5/2402(0.2%)                                    |

The  study  design  chosen  for  MEC  study  was  add-on  of  NK-1  RA  to  dexamethasone  and  5HT3  receptor antagonist with further doses of 5HT3 receptor antagonist on days 2, 3. The protocol specified that at least 50% of the study subjects would receive anthracycline in combination with cyclophosphamide as the MEC regimen.  Since  this  study  was  designed  anthracycline  in  combination  with  cyclophosphamide  has  been designated as HEC. However since 2010 antiemetic prophylaxsis for AC and non-AC MEC have been different recognising the higher emetogenicity of AC. The administration of oral granisetron from day 2 to day 3 post chemotherapy is not recommended as part of the MASCC/ESMO consensus  guidelines for the prevention of CINV with non- AC  MEC. In subjects treated with AC chemotherapy, the guidelines recommend use of a 5HT3 receptor antagonist plus a corticosteroid Plus an NK-1 RA on day 1 followed by NK-1 RA on day 2 and 3. The comparator regimen is not in line with the recommended prophylaxis for AC or non-AC MEC in CINV (MASCC /ESMO 2010) but reflects treatment guidelines that were available at the time of the study design.

Total Supportive study(ies) No additional studies were assessed as supportive. A phase II study was initiated in 2006 while phases III were initiated in 2012 where only 91 patients were included in the 200 mg rolapitant group. Considering the difference of sample size between the phase II and the 3 phases III and the possible changes in standard of care, the assessment has focused on results from the 3 phase III studies. 2.5.3. Discussion on clinical efficacy Design and conduct of clinical studies All  3  phase  III  studies  were  multicentre,  randomised,  parallel-group,  double-blind,  and  placebo-controlled studies with objective to determine whether the administration of rolapitant on add-on therapy with a 5-HT3 receptor antagonist and dexamethasone improves protection from CINV in the delayed phase (&gt;24 to 120 hours) compared  to  administration  of placebo  on add-on  with a  5-HT3  receptor  antagonist  and dexamethasone, in cycle 1, in subjects receiving highly or moderately emetogenic chemotherapy. Two phase III HEC studies (P04832 and P04833) were conducted in subjects receiving for treatment of their underlying  malignancy ≥ 60  mg/m2  of  cisplatin-based  chemotherapy  which  is  generally  regarded  as  a relevant  model  of  highly  emetogenic  chemotherapy  (HEC).  Since  2010  consensus  clinical  guidelines (MASCC/ESMO) recommend a combination of aprepitant plus a 5HT3 receptor antagonist and dexamethasone to prevent acute nausea and vomiting in subjects receiving cisplatin based chemotherapy. Data comparing the longer-acting NK-1 receptor antagonist rolapitant with first-generation NK-1 receptor antagonists such as aprepitant would have helped clarify rolapitant's place in antiemetic management for CINV associated with HEC. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

The decision to include more than 50% of subjects on AC chemotherapy in both the rolapitant and control groups was based on the study designs conducted for other earlier NK-1 RAs.

The  subjects  recruited  to  the  MEC  study  were  chemotherapy  naïve.  The  HEC  study  participants  were  not required to be chemotherapy naïve. The current EMA guidance on CINV recommends that subjects should be stratified at baseline according to prior chemotherapy. Subjects were stratified according to gender only in the pivotal efficacy studies. The primary endpoint for those studies was the rate of complete response (CR) defined as no emesis and no use of rescue medication during the delayed phase (&gt; 24 through 120 hours). This  endpoint  is  considered  to  be  appropriate  Indeed,  the  NK1  receptor  antagonists  are  expected  to  be mainly effective  in  the  delayed  phase  of  emesis,  while  5-HT3  antagonists  have  been  proven  to be  mainly effective in the acute phase. The primary analysis was conducted using the MITT.

In all phase III studies, patients had the possibility to participate up to 5 additional cycle (a total of 6 cycles). However,  the  primary  endpoint  differed  for  the  subsequent  cycles.  Indeed,  instead  of  CR  in  the  delayed phase subjects were recall and asked if they had no vomiting/retching and no nausea that interfered with quality of life. Furthermore, the data was not collected in a diary as in cycle 1 but via a telephone call around 7 days after chemotherapy which less rigorous. No  re-randomization  was  planned  after  cycle  1  and  patients  continued  with  the  same  study  medication administered in the same manner as in cycle 1. In these three studies, subjects were randomised 1:1 to receive rolapitant 200 mg administered orally or placebo, randomization was stratified by gender but not by age. Efficacy data and additional analyses In both HEC Studies, the demographics were generally well-balanced between the treatment groups in this study.  However,  there  were  some  differences  in  demographic  characteristics  noted  across  the  two  pivotal studies.  Study  P04832  had  more  females,  more  subjects  of  Asian  origin,  more  non-drinkers  and  more subjects with ovarian cancer than study P04833.There were more white subjects more subjects with lung and stomach cancer, more subjects from Europe included in study P04833. Although the differences across the populations in the two HEC studies are small, they occur across a diverse range of variables. Onset of CINV can be impacted by a number of variables (age, sex , level of alcohol consumption, history of pregnancyrelated nausea and vomiting, prior response to CINV with previous cycles of chemotherapy,  susceptibility to motion sickness, and cisplatin dose) and there is some evidence that this effect can be cumulative (Warr et al 2014). The impact of this variability may account for the difference in outcomes for the pivotal studies. The demographic differences that were noted reflect the broad patient population recruited in terms of location, tumour type, chemotherapy regimen etc. A number of the variables that are recognised as risk factors for onset of CINV are missing from the baseline characteristics presented for the pivotal studies, in particular prior  response  to  CINV  with  previous  cycles  of  chemotherapy,  for  subjects  in  the  HEC  studies.  A  similar picture was seen for patients who had received medication or pre-medication for nausea and vomiting during previous  chemotherapy  or  a  history  of  nausea  or  vomiting  during  the  previous  chemotherapy.  However, overall the proportion of patients involved was relatively small and the distribution of patients in the three subgroups was well balanced across treatment groups. Medicinal product no longer authorised

Less than 9% of the study population were under 45 years (age &lt;45 is a risk factor for CINV) and just 3% of the study population were over 75 years. A sufficient number of young (&lt;45yrs) and elderly subjects &gt;75yrs have not been included in the confirmatory studies to provide a firm basis for the assessment of safety and efficacy  in  these  age  groups.  The  majority  of  participants  were  white  (approx.75%  across  HEC  and  MEC

<div style=\"page-break-after: always\"></div>

studies). Low numbers in the other race categories make it difficult to draw clear conclusion on efficacy in these subgroups.

In  the  MEC  study,  the  demographics  were  generally  well-balanced  between  the  treatment  groups  in  this study. However there was a preponderance of female participants reflecting the fact that breast cancer was the commonest cancer subtype. Other baseline characteristics previously identified as risk factors for CINV such as alcohol consumption (self-reported), and age were well balanced across treatment groups. Clinical experience  with  NK-1  RA  in  clinical  practice  and  this  has  not  resulted  in  differential  clinical  guidelines  for males  being  treated  with  MEC  (MASCC  ESMO  2016,  NCCN2016)  and  the  findings  in  the  MEC  study  are generalizable to men.

In the HEC studies, subgroup analyses showed some variability in response rates between men and women. Women had a consistently more favourable response than men across all phases of CINV. The magnitude of the  treatment  effect  (CR  delayed  phase)  for  males  was  much  smaller  than  that  for  females  (e.g  18.9% difference vs 6.6%. The less favourable results in the HEC setting for males has not been fully explained. Less than 9% of the study population were under 45 years (age &lt;45 is a risk factor for CINV) and just 3% of the study population were over 75 years. The CR rate was higher in the rolapitant group compared to control in the majority of age subgroups in the pooled HEC analyses and the treatment effect is consistently in favour of  rolapitant  across  age  groups  tending  to  increase  with  age.  However  subject  &lt;45yrs  and  &gt;75  are  not adequately represented in these studies.

Results  of  the  studies  showed  a  statistical  superiority  of  rolapitant  (plus  granisetron  and  dexamethasone) over placebo (plus granisetron and dexamethasone PO) in terms of complete response (CR), defined by the absence  of  emesis  and  use  of  rescue  medication,  during  the  delayed  phase  (i.e.  &gt;  24h  -120h)  following initiation  of  chemotherapy.  CR  in  the  delayed  phase  for  each  clinical  study  were:  72.7%  vs  58.4% (  =14.3%) p &lt; 0.001in P04832 HEC; 70.1% vs 61.9% (  =8.2%) p 0.043 in  04833 HEC; 71.3% vs 61.6% (  = 9.7%) p &lt; 0.001 in P04834 MEC as defined by the applicant; 66.9% vs 59.6 (  = 7.3%) p= 0.047 P04834 AC regimen; 76.1% vs 63.8% (  =12.3%) p&lt; 0.001 in P04834 MEC (AC regimen excluded). The proportion of subjects, who had no emesis and no use of rescue medication was significantly higher in the  rolapitant  group  versus  the  placebo  group,  in  both  studies  in  patients  receiving  highly  emetogenic chemotherapy regimen (HEC) including cisplatin and the study in patients receiving moderately emetogenic chemotherapy (MEC) regimen or a combination of anthracycline plus cyclophosphamide regimen (AC). The  results  in  key  secondary  endpoints  in  P04832  HEC  study  were  clinically  and  statistically  significant, however in the P04833 HEC and P04834 MEC studies key secondary endpoints did not achieved statistical significance. In the HEC studies, Kaplan-Meier curves for time to first emesis or use of rescue medication for both pooled HEC studies the separation was widest from 24hs and plateaued at 48hrs. If CR was achieved at 48hrs complete response was maintained throughout the 120 hour period. In the MEC study, Kaplan-Meier curves for time to first emesis or use of rescue medication for both studies separated for the rolapitant and the control curves around the 10 hour mark (in the acute phase) and was maintained throughout the 24 to 120 hour period. The incidence of subjects requiring ≥1 rescue medication during Cycle 1 was lower in the rolapitant group than in the control group (18.3% and 26.3%, respectively) but was higher than that seen for the HEC studies. No impact was seen in terms of reduction or prevention of nausea across any of the phases in the MEC study. The proportion of subjects who experienced no significant nausea and no nausea in the acute and delayed phase were not significantly higher in the rolapitant group compared to the control group. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

In  the  MEC  Study,  a  further  subgroup  analysis  by  region  in  Europe  indicated  that  there  was  considerable regional variation across Western Eastern and Central Europe. In particular the CR response rate was lower in Western Europe across all phases of treatment compared with the other regions.

In  this  study,  at  least  50%  of  the  study  subjects  would  receive  anthracycline  in  combination  with cyclophosphamide  IV  which  is  considered  to  be  a  highly  emetogenic  regimen.  The  comparator  control regimen is not in line with current standard of care as outlined in the MASCC/ESMO consensus guidelines current at the time the study or the most recent version for AC chemotherapy.

Key secondary endpoints (complete response in acute and overall CINV phases) were numerically in favour of rolapitant arm but not statistically significant in study P048033in subject receiving HEC regimen.

The efficacy of rolapitant compared with control in the delayed phase (71.3% vs, 61.6%) OR 95% CI 1.6 (1.2, 2.0) p&lt;0.001 is slightly less than that seen in the HEC studies pooled. The treatment effect (rolapitant compared to control) for CR delayed phase was 9.7% in the MEC study  for the combined AC and non AC MEC populations compared with 11.2% in the pooled HEC studies. Rolapitant was less effective in AC MEC subgroup compared with non-AC MEC. Non-AC MEC Delayed phase: 76.1%vs 63.8% OR 1.8 95%CI (1.27, 2.55) p&lt;0.001 compared with AC Delayed phase: 66.9% vs 59.6 OR 1.37 95% CI (1.00, 1.86) p= 0.047. Across both HEC and MEC studies efficacy data from subsequent cycles were a very fluctuating with a low amplitudes regarding benefit of the use of rolapitant over multi-cycle use. This analysis is difficult to interpret because different endpoints were used in the repeat cycles and the methodology for collection the nausea and vomiting data was different. Furthermore subjects are not re-randomised prior to subsequent cycle of chemotherapy. The choice of a different endpoint for subsequent endpoint (compared to first cycle) in order to limit patient burden indeed completing comprehensive diaries over 6 cycles can be demanding for patients with cancer is justified. An analysis of efficacy over multiple cycles in patients without emesis in cycle 1 was presented. The time-to-emesis or rescue med across cycles in patients with no emesis at cycle 1 show a statistically significant benefit in rolapitant patients compared to the control group suggesting that efficacy in subsequent cycles was maintained. This differentiation in the KM curves for the time to emesis analysis in patients who had no emesis in cycle 1 across following repeat treatment, the lack of differential drop-outs across treatment groups and the low levels of discontinuation due to lack of efficacy gives support to the claim for efficacy over repeat cycles of chemotherapy. The maintenance of efficacy over multiple cycles is considered useful clinical information and is included in section 5.1.of the SmPC. As recommended by current guidelines in combination NK1 inhibitors should be used in combination with a 5HT3 inhibitor and dexamethasone in order to prevent emesis and nausea in both acute and delayed phase. The CR treatment effect in the acute phase achieved statistical significance in only one of the 2 HEC studies but not the MEC study. The treatment effect of rolapitant in the acute phase as demonstrated by the CR, no emesis, no nausea and no significant nausea endpoints was modest, therefore the clinical significance of the treatment effect for rolapitant in the acute phase has not been (only historical comparisons) up to the level of other KN1 antagonists aprepitant and netupitant - in association with palonosetron. Medicinal product no longer authorised

Regarding repeat course, due to the change of primary end point and the way it is collected, to the absence of re randomisation after cycle 1, weaknesses in methodology are considered however the effect of rolapitant in repeat course is sufficiently shown and is described in section 5.1.

The  only  measure  of  impact  of  rolapitant  on  quality  of  life  used  in  all  three  studies  was  the  FLIE questionnaire.  This  was  only  evaluated  as  an  exploratory  tertiary  endpoint.  An  inconsistent  response  was

<div style=\"page-break-after: always\"></div>

seen across studies. The MEC study subjects reported experiencing less interference with normal daily life. A higher proportion of subjects treated with rolapitant reported no impact on daily life compared with subjects who were treated with control. Unlike the HEC studies where there was no difference across the treatment groups in the proportion of subjects reporting no impact on daily life.

No direct comparative data with any of the currently approved NK1RA are available. Indirect comparison of CR rates in delayed phase with aprepitant suggest that the treatment effect with rolapitant is smaller than that seen with aprepitant but exceeds the &gt;10% difference considered to be clinically relevant.

2.5.4. Conclusions on the clinical efficacy Results  from  clinical  studies  showed  efficacy  of  rolapitant  as  add  on  to  a  standard  therapy  compared  to standard therapy plus placebo in the prevention of chemotherapy induced delayed nausea and vomiting in adults  receiving  initial  course  of  highly  and  moderately  emetogenic  chemotherapy  regimen.  The  primary endpoint CR for the treatment effect in the acute phase achieved statistical significance in one of the HEC studies but was numerically higher (although modest) vs control across studies. As recommended by current guidelines in combination NK1 inhibitors should be used in combination with a 5HT3 inhibitor and dexamethasone in order to prevent emesis and nausea in both acute and delayed phase. 2.6. Clinical safety The  oral  rolapitant  clinical  development  program  consists  of  20  completed  studies,  including  13  Phase  1 studies in healthy adults and one Phase 1 study in adults with mild or moderate hepatic impairment; two Phase 2 studies, one each in subjects at risk for chronic idiopathic cough (CIC), and Post-Operative Nausea and Vomiting (PONV); and four studies in subjects at risk for CINV. In order to review the data, pooling groups were constructed: Pooling Group 1 consists of the four clinical studies supporting the proposed indication in CINV. Pooling Group 2 represents a second integrated analysis on safety data from healthy subjects receiving a single dose (doses ranged from 5 mg to 800 mg) of rolapitant as monotherapy. Other Phase 1 studies and Phase 1 study cohorts with potential confounding effects (eg, co-administration of concomitant medications, hepatic impairment), and Phase 2 studies that studied indications other than the target indication, were not included in the pooled analyses. Patient exposure Medicinal product no longer authorised

## Pooling Group 1 (CINV studies)

A total of 2868 subjects received at least one dose of study drug in the CINV studies, of which 1567 subjects received  rolapitant  at  any  dose  and  1301  received  control.  Among  rolapitant-treated  subjects,  1294  were assigned to receive the proposed dose of 200 mg across these studies.

<div style=\"page-break-after: always\"></div>

A high percentage of subjects completed Cycle 1 of the studies (95.1%, 94.9%, and 94.2% in the 200 mg rolapitant, all rolapitant dose, and control groups, respectively).

Participation in Cycles 2 to 6 was voluntary. A similar percentage of subjects in the control group (76.9%), rolapitant  200  mg  group  (78.4%),  and  rolapitant  overall  group  (76.7%)  continued  to  Cycle  2.  The  most common reason for not continuing into Cycle 2 was study completion in the overall rolapitant group (7.0%), and withdrawn consent in the rolapitant 200 mg group (4.3%) and control group (5.4%). Within the HEC group, 22.3% of subjects receiving &lt;200 mg rolapitant completed Cycle 1 but did not continue to the next cycle  because  of  study  completion,  compared  with  4.8%  and  6.4%  in  the  control  and  rolapitant  200  mg groups,  respectively.  Overall  only  367  subjects  in  the  CINV  trials  completed  6  cycles  of  therapy  and  319 completed 6 cycles at the proposed dose of 200mg.

|                    | Patients enrolled   |   Patients exposed |   Patients exposed to the proposed dose range | Patients with long term* safety data   |
|--------------------|---------------------|--------------------|-----------------------------------------------|----------------------------------------|
| Placebo-controlled | 1568                |               1567 |                                          1294 | 367                                    |
| Other studies^     |                     |               1231 |                                           730 | -                                      |
| Post marketing     | 0                   |                  0 |                                             0 | 0                                      |
| Compassionate use  | 0                   |                  0 |                                             0 | 0                                      |

Pooling Group 2 (single dose in healthy subjects) A  total  of  606  healthy  subjects  were  enrolled  in  the  Phase  1  studies  included  in  Pooling  Group  2  and randomized to receive a single dose of rolapitant (n = 550) or placebo (n = 56) Overall, a high percentage of subjects completed the studies (rolapitant, 97.8%; placebo, 96.4%) in Pooling Group  2.  The  most  common  reason  for  premature  discontinuation  in  the  overall  rolapitant  group  was withdrawn consent (0.7%). No subjects discontinued from study treatment due to AEs. Individual Studies or Study Cohorts not Included in Pooling Group 1 or 2 Phase 1 Studies A  total  of  268  subjects  were  enrolled  in  Phase  1  studies  or  study  cohorts  during  the  rolapitant  oral development that were not included in Pooling Group 1 or Pooling Group 2 and they received rolapitant (n = 258) or control (n = 10). The reasons for discontinuation were AEs unrelated to study treatment (n = 2), loss to follow-up (n = 1), protocol noncompliance (n = 1), and withdrawn consent (n = 1). Phase 2 Studies A total of 644 subjects were enrolled in Phase 2 studies not included in Pooling Group 1 or Pooling Group 2 and received rolapitant (n = 423) and/or placebo (n = 135) or active control (n = 104). Due to the crossover design  of  Study  P04888,  27  subjects  received  both  rolapitant  and  placebo.  Most  subjects  completed  the Phase  2  studies  with  data  described  individually.  There  was  no  relationship  between  discontinuations  and increasing dose. The most common reasons for discontinuation were subject decision and loss to follow-up. Table 45 : Patient exposure Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Adverse events

POOLING GROUP 1 (CINV patients)

Pooling Group 1 is the primary analysis set that allows for a comparison of rolapitant to control in subjects in the CINV studies. It includes all subjects from the controlled, double-blind, randomized, parallel comparison studies conducted in subjects at risk for CINV.

|                  | HEC (P04832 and P04833)   | HEC (P04832 and P04833)   | MEC (P04834)   | MEC (P04834)     | ALL CINV    | ALL CINV         |
|------------------|---------------------------|---------------------------|----------------|------------------|-------------|------------------|
|                  | Control                   | Rolapitant 200mg          | Control        | Rolapitant 200mg | Control     | Rolapitant 200mg |
| N                | 537                       | 535                       | 674 no         | 670              | 1211        | 1205             |
| ≥ 1 TEAE         | 427 (79.5%)               | 428 (80%)                 | 551 (81.8%)    | 547 (81.6%)      | 978 (80.8%) | 975 (80.9%)      |
| ≥ 1 TRTEAE       | 27 (5%)                   | 26 (4.9%)                 | 92 (13.6%)     | 80 (11.9%)       | 119 (9.8%)  | 106 (8.8%)       |
| ≥ 1 Grade 3 TEAE | 178 (33.1%)               | 179 (33.5%) product       | 174 (25.8%)    | 179 (26.7%)      | 352 (29.1%) | 358 (29.7%)      |
| ≥ 1 TESAE        | 119 (22.2%)               | 117 (21.9%)               | 103 (18.7%)    | 89 (13.3%)       | 222 (18.3%) | 206 (17.1%)      |
| ≥ 1 TRTESAE      | 0                         | 1 (0.2%)                  | 0              | 0                | 0           | 1 (0.1%)         |
| TEAE DC          | 65 (12.1%)                | 61 (11.4%)                | 37 (5.5%)      | 34 (5.1%)        | 102 (8.4%)  | 95 (7.9%         |
| Death            | 21 (3.9%)                 | 20 (3.7%)                 | 7 (1%)         | 13 (1.9%)        | 28 (2.3%)   | 33 (2.7%)        |

The safety assessment included analysis of AEs, clinical laboratory parameters, vital signs, ECGs, neurological parameters, and concomitant medications. The effect of intrinsic factors (age, gender, body weight, race, and ethnicity)  and  extrinsic  factors  (geographic  region  and  cycle  length)  were  evaluated.  Potential  drug interactions with substrates of CYP2D6 and BCRP were assessed. The  overall  incidence  of  TEAEs  across  subjects  in  the  CINV  studies  who  received  rolapitant  200  mg  or rolapitant  at  any  dose  in  Cycle  1  was  64.0%  and  65.2%,  respectively,  which  was  similar  to  the  overall incidence  in  subjects  who  received  control  (64.6%).  Across  all  cycles  combined,  the  overall  incidence  of TEAEs  for  subjects  with  CINV  who  received  rolapitant  200  mg  or  rolapitant  at  any  dose  was  81.5%  and 82.3%, respectively, similar to the incidence reported in subjects who received control (80.9%). Table  46: Summary  adverse  events  in  CINV  studies  P04832  (HEC),  P04833  (HEC)  and P04834 (MEC) The  most  common  TEAEs  in  cycle  1  in  subjects  receiving  200  mg  rolapitant  were  fatigue  (11.8%), constipation (9.0%), neutropenia (8.2%), decreased appetite (7.8%), and alopecia (7.6%). The incidence of these common TEAEs was similar in the rolapitant 200 mg group, all rolapitant and control groups. Medicinal product no longer authorised

For  all  cycles  combined,  the  most  common  TEAEs  in  subjects  receiving  200  mg  rolapitant  were  fatigue (19.8%), alopecia (15.8%), and neutropenia (15.2%). The incidence of these common TEAEs was similar in the rolapitant 200 mg, all rolapitant dose, and control groups.

Within the HEC group in Cycle 1 and across all cycles combined, the incidence of the most common TEAEs was similar to or slightly higher in the &lt;200 mg rolapitant group compared with the 200 mg rolapitant and control groups.

<div style=\"page-break-after: always\"></div>

In Cycle 1, the incidence of treatment-related TEAEs was comparable in the 200 mg rolapitant group, the all rolapitant doses group, and the control group. The most commonly reported treatment-related events in the overall  rolapitant  200  mg  group  were  fatigue  (1.9%),  constipation  (1.5%),  and  headache  (1.5%);  the incidence of these events was similar in the all rolapitant doses group (1.8%, 2.0%, and 1.8%, respectively) and  the  control  group  (1.4%,  1.5%  and  1.4%,  respectively).  In  all  cycles  combined,  the  incidence  of treatment-related TEAEs was comparable in the 200 mg rolapitant group, the all rolapitant doses group, and the control group.

|                                | Overall CINV       | Overall CINV         | Overall CINV           |
|--------------------------------|--------------------|----------------------|------------------------|
|                                | Control N =1301    | Rolipant 200mg =1294 | N All Rolipant N =1567 |
| Subjects ≥ 1 incidence         | 840 (64.6%)        | 828 (64%)            | 1021 (65.2%)           |
| Fatigue                        | 146 (11.2%)        | 153 (11.8%)          | 187 (11.9%) longer     |
| Constipation                   | 151 (11.6%)        | 117 (9%)             | 149 (9.5%)             |
| Neutropenia                    | 88 (6.8%)          | 106 (8.2%)           | 122 (7.8%)             |
| Decreased appetite             | 100 (7.7%)         | 101 (7.8%) no        | 122 (7.8%)             |
| Alopecia                       | 112 (8.6%)         | 98 (7.6%)            | 111 (7.1%)             |
| Diarrhoea                      | 89 (6.8%)          | 87 (6.7%)            | 116 (7.4%)             |
| Headache                       | 101 (7.8%)         | 81 (6.3%)            | 108 (6.9%)             |
| Asthenia                       | 100 (7.7%) product | 76 (5.9%)            | 99 (6.3%)              |
| Nausea                         | 104 (8%)           | 72 (5.6%)            | 127 (8.1%)             |
| Dizziness                      | 41 (3.2%)          | 61 (4.7%)            | 79 (5%)                |
| Dyspepsia                      | 35 (2.7%)          | 52 (4%)              | 67 (4.3%)              |
| Mucosal inflammation Medicinal | 43 (3.3%)          | 48 (3.7%)            | 60 (3.8%)              |
| Stomatitis                     | 29 (2.2%)          | 42 (3.3%)            | 49 (3.1%)              |
| Hiccups                        | 32 (2.5%)          | 41 (3.2%)            | 49 (3.1%)              |
| Anaemia                        | 35 (2.7%)          | 40 (3.1%)            | 50 (3.2%)              |
| UTI                            | 33 (2.5%)          | 39 (3%)              | 42 (2.7%)              |
| Vomiting                       | 61 (4.7%)          | 19 (1.5%)            | 51 93.3%)              |

Table  47 :  TEAEs by MedDRA Preferred Term with Incidence of ≥ 3% of Subjects in the Overall Rolapitant 200mg group or ≥ 10% of subjects in any group. Cycle 1 all subjects in CINV trials Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table  48 :  TEAEs by MedDRA Preferred Term with Incidence of ≥ 3% of Subjects in the Overall Rolapitant 200mg group or ≥ 10% of subjects in any group all cycles combined, all subjects in CINV trials

|                          | Overall CINV    | Overall CINV           | Overall CINV         |
|--------------------------|-----------------|------------------------|----------------------|
|                          | Control N =1301 | Rolipant 200mg N =1294 | All Rolipant N =1567 |
| Subjects ≥ 1 incidence   | 1053 (80.9%)    | 1055 (81.5%)           | 1289 (82.3%)         |
| Fatigue                  | 253 (19.4%)     | 256 (19.8%)            | 310 (19.8%)          |
| Alopecia                 | 227 (17.4%)     | 204 (15.8%)            | 227 (14.5%)          |
| Neutropenia              | 173 (13.3%)     | 197 (15.2%)            | 240 (15.3%)          |
| Constipation             | 215 (16.5%)     | 186 (14.4%)            | 234 (14.9%)          |
| Asthenia                 | 190 (14.6%)     | 182 (14.1%)            | 217 (13.8%)          |
| Decreased appetite       | 172 (13.2%)     | 174 (13.4%)            | 215 (13.7%)          |
| Diarrhoea                | 160 (12.3%)     | 164 (12.7%)            | 207 (13.2%) longer   |
| Nausea                   | 201 (15.4%)     | 151 (11.7%)            | 246 (15.7%)          |
| Anaemia                  | 113 (8.7%)      | 136 (10.5%)            | 168 (10.7%)          |
| Headache                 | 143 (11%)       | 115 (8.9%) no          | 152 (9.7%)           |
| Dizziness                | 91 (7%)         | 97 (7.5%)              | 120 (7.7%)           |
| Mucosal inflammation     | 74 (5.7%)       | 86 (6.6%) product      | 106 (6.8%)           |
| Dyspepsia                | 71 (5.5%)       | 79 (6.1%)              | 98 (6.3%)            |
| UTI                      | 69 (5.3%)       | 76 (5.9%)              | 85 (5.4%)            |
| Leukopenia               | 72 (5.5%)       | 75 (5.8%)              | 108 (6.9%)           |
| Hypomagnesaemia          | 54 (4.2%)       | 70 (5.4%)              | 71 (4.5%)            |
| Stomatitis               | 76 (5.8%)       | 69 (5.3%)              | 77 (4.9%)            |
| Abdominal pain Medicinal | 56 (4.3%)       | 64 (4.9%)              | 83 (5.3%)            |
| Cough                    | 66 (5.1%)       | 59 (4.6%)              | 81 (5.2%)            |
| Dyspnoea                 | 46 (3.5%)       | 58 (4.5%)              | 69 (4.4%)            |
| Dehydration              | 76 (5.8%)       | 57 (4.4%)              | 70 (4.5%)            |
| Pyrexia                  | 58 (4.5%)       | 55 (4.3%)              | 69 (4.4%)            |
| Hiccups                  | 32 (2.5%)       | 53 (4.1%)              | 63 (4%)              |
| Dysgeusia                | 51 (3.9%)       | 50 (3.9%)              | 58 (3.7%)            |

<div style=\"page-break-after: always\"></div>

| Vomiting            | 117 (9%)   | 50 (3.9%)   | 113 (7.2%)   |
|---------------------|------------|-------------|--------------|
| Insomnia            | 82 (6.3%)  | 49 (3.8%)   | 62 (4%)      |
| Bone pain           | 52 (4%)    | 46 (3.6%)   | 49 (3.1%)    |
| Back pain           | 36 (2.8%)  | 45 (3.5%)   | 54 (3.4%)    |
| Thrombocytopenia    | 39 (3%)    | 43 (3.3%)   | 55 (3.5%)    |
| Febrile neutropenia | 49 (3.8%)  | 42 (3.2%)   | 52 (3.3%)    |
| Hypokalaemia        | 47 (3.6%)  | 40 (3.1%)   | 53 (3.4%)    |
| Pain in extremity   | 30 (2.3%)  | 40 (3.1%)   | 49 (3.1%)    |
| Peripheral oedema   | 42 (3.2%)  | 39 (3%)     | 45 (2.9%)    |

Across all cycles combined, the incidence of anemia was 10.5%, 10.7%, and 8.7% in the 200 mg rolapitant, all rolapitant, and control groups, respectively. All other TEAEs related to anemia were reported in &lt;0.5% of subjects who received rolapitant 200 mg with similar incidence, in both Cycle 1 and all cycles combined, as that reported in the control group. Most of these events were assessed as unrelated to study treatment

Febrile neutropenia Hypokalaemia Pain in extremity Peripheral oedema Nervous System Events The incidence of TEAEs in the Nervous system disorders SOC in Cycle 1 was similar in the rolapitant 200 mg group the all rolapitant doses group and the control group (14.7%, 15.6%, and 14.6%, respectively). Results were also similar for the all cycles combined analysis (25.1%, 25.4%, and 24.5%, respectively). The most common TEAEs in the Nervous system disorders SOC in both Cycle 1 and all cycles combined were headache, dizziness, and dysgeusia. Across all cycles combined, the incidence of headache was 8.9%, 9.7%, and 11.0% in  the  rolapitant  200  mg,  all  rolapitant  doses,  and  control  groups,  respectively;  dizziness  was  reported  in 7.5%, 7.7%, and 7.0% of subjects, respectively; and dysgeusia in 3.9%, 3.7%, and 3.9%, respectively. Across all cycles combined, convulsion occurred at a similar frequency in the rolapitant 200 mg and control groups (0.2% each); one additional subject in the rolapitant 200 mg group experienced partial seizures. Two subjects  who  received  &lt;200  mg  rolapitant  experienced  convulsions.  In  4  of  8  subjects,  seizures  occurred during Cycle 1 of treatment. All cases were reported as recovered/resolved and 3 events were associated with  discontinuation.  All  subjects  who  experienced  events  of  convulsion/partial  seizure  had  multiple confounding factors. For the rolapitant subjects, four subjects had metastatic disease to the central nervous system that was not known to be present prior to the event. Haematopoietic Leukopenia Events Overall across all cycles combined, 21.6% of subjects in the 200 mg rolapitant group and 21.8% of subjects in  the  all  rolapitant  doses  group  experienced  at  least  one  TEAE  derived  from  the  SMQ  for  Haematopoietic leukopenia, compared with 19.7% of subjects in the control group. Most of these events were assessed as unrelated to study treatment Anemia Events Medicinal product no longer authorised

## Acute Renal Failure

<div style=\"page-break-after: always\"></div>

Overall across all cycles combined, 3.5% of subjects in the 200 mg rolapitant group and 3.9% of subjects in the all rolapitant doses group experienced at least one TEAE derived from the SMQ for acute renal failure, compared with 4.0% of subjects in the control group. Most of these events were assessed as unrelated to study treatment

## Hepatic Dysfunction

Overall across all cycles combined, 2.3% of subjects in the 200 mg rolapitant group and 2.6% of subjects in the all rolapitant doses group experienced at least one TEAE derived from the SMQ for hepatic dysfunction, compared with 2.5% of subjects in the control group.

5 cases met Hy's law criteria. One case occurred in a subject in the 10 mg dose group in Study P04351. In this  subject,  mild  to  moderate  elevations  in  ALT  (4.9  x  ULN)  and  bilirubin  (2.9  x  ULN)  with  AST  and  ALP within normal limits observed at Cycle 1 Visit 2; these elevations resolved spontaneously to within normal limits by the next visit. This subject received a total of 4 cycles of therapy with no further elevations in liver function tests that met Hy's law laboratory criteria. The remaining 4 cases occurred in the control group in HEC studies Cardiac Arrhythmias Overall across all cycles combined, the incidence of cardiac arrhythmia events was similar in the rolapitant 200  mg  group  (4.6%),  the  all  rolapitant  doses  group  (4.5%),  and  the  control  group  (4.5%).  The  most common TEAEs in this analysis were syncope, with an overall incidence across all cycles of 1.3%, 1.1%, and 1.1% in the 200 mg rolapitant, all rolapitant, and control groups, respectively, and tachycardia (1.1%, 1.0%, and 0.7%, respectively). The incidence of all other events in Cycle 1 and across all cycles combined was &lt;1% and did not differ remarkably across all treatment groups. Rhabdomyolysis/Myopathy Events Overall  across  all  cycles  combined,  the  incidence  of  rhabdomyolysis/myopathy  events  was  7.7%  in  the rolapitant 200 mg group and 7.8% in the all rolapitant doses group compared with 9.3% and the control group.  The  most  common  TEAEs  in  this  analysis  were  myalgia.  Most  of  these  events  were  assessed  as unrelated to study treatment; the only treatment-related TEAEs related to rhabdomyolysis/myopathy events reported in more than 1 subject in the rolapitant 200 mg group were blood creatinine increased (0.2% of subjects each in the 200 mg rolapitant and control groups), and myalgia and muscular weakness (0.2% and &lt;0.1% in the rolapitant 200 mg and control groups, respectively). POOLING 2 (healthy subjects who received single doses of rolapitant.) The  overall  incidence  of  TEAEs  across  the  550  healthy  subjects  who  received  single-dose  rolapitant  was 30.7%; the incidence was highest among subjects who received &gt;200 mg rolapitant (54.2%) compared with those  who  received  200  mg  (28.7%)  or  &lt;200  mg  (23.2%)  doses.  Among  the  56  subjects  who  received placebo in these studies, the incidence of TEAEs was 51.8%. Medicinal product no longer authorised

The  most  commonly  reported  TEAEs  in  Pooling  Group  2  were  in  the  SOC Nervous  system  disorders and occurred  with  increasing  incidence  across  rolapitant  dose.  The  most  commonly  reported  TEAEs  were headache (8.9%, 4.3%, 5.7%, and 6.8% of subjects in the placebo and &lt;200, 200 and &gt;200 mg rolapitant groups,  respectively),  somnolence  (1.8%,  5.8%,  5.5%,  and  3.4%,  respectively),  and  dizziness  (1.8%,  0, 3.3%, and 16.9%, respectively.

<div style=\"page-break-after: always\"></div>

The  most  common  SOCs  in  which  treatment-related  TEAEs  were  reported  in  subjects  receiving  200  mg rolapitant and placebo were Nervous system disorders (11.8% and 8.9%), Gastrointestinal disorders (3.3% and 3.6%), and General disorders and administration site conditions (1.2% and 5.4%), respectively.

The incidence of some treatment-related TEAEs possibly increased with rolapitant dose, particularly dizziness and nausea. The incidence of these events in the rolapitant &lt; 200 mg, 200 mg, and &gt; 200 mg dose groups compared with placebo was as follows: dizziness (0, 2.8%, 15.3% and 1.8%, respectively) and nausea (0, 0.5%, 6.8% and 0, respectively)

<!-- image -->

## Table 49: Pooled data on SAEs from PO4351 (HEC), PO4832(HEC) and PO4834 (MEC)

Serious adverse event/deaths/other significant events Deaths Pooling 1 (CINV population) Overall  a  total  of  79  patients  had  a  TEAEs  leading  to  death  including  48  (3.1%)  patients  who  received rolapitant  at  any  dose,  38  (2.9%)  of  whom  received  200  mg  of  rolapitant  and  31  (2.4%)  patients  who received control. None of these events were considered to be related to study drug. Pooling 2 (healthy subjects who received single doses of rolapitant) No deaths were reported in any of the Phase 1 studies included in Pooling Group 2. Serious adverse events In  all  cycles  combined,  the  most  common  SOCs  in  which  TESAEs  were  reported  in  the  overall  200  mg rolapitant group were Blood and lymphatic system disorders (4.6%), Infections and infestations (3.6%), and Respiratory, thoracic and mediastinal disorders (2.6%). In general, the incidence of TESAEs was similar in the  200  mg  rolapitant  group,  the  all  rolapitant  doses  group,  and  the  control  group.  Within  each  PT,  the overall incidence of TESAEs was ≤ 3.0%. The most commonly reported TESAEs in the overall rolapitant 200 mg  group  with  corresponding  incidence  in  the  overall  control  group  were  febrile  neutropenia  (2.6%  and 3.0%, respectively) and neutropenia (1.2% and 2.0%, respectively); all other TESAEs were reported in &lt;1% of rolapitant subjects. Across cycles, the incidence of febrile neutropenia was highest in Cycles 1 and 2 in all groups,  with  lower  incidence  in  individual  subsequent  cycles;  for  neutropenia  the  incidence  varied  across cycles with no apparent trend POOLING 2 (healthy subjects who received single doses of rolapitant.) Three TESAEs were reported in 2 subjects, both of whom received rolapitant 200 mg in Study PR-10-5014-. Subject 001045 experienced an SAE of rhabdomyolysis and Subject 001068 experienced SAEs of moderate syncope and bradycardia. Medicinal product no longer authorised

| System Organ Class   | Control     | Rolipant 200mg   | All Rolipant   |
|----------------------|-------------|------------------|----------------|
| Preferred Term       | N =1301     | N =1294          | N =1567        |
| All                  | 244 (18.8%) | 227 (17.5%)      | 290 (18.5%)    |

<div style=\"page-break-after: always\"></div>

| Blood and lymphatic system disorders                 | 73 (5.6%)        | 59 (4.6%)        | 83 (5.3%)   |
|------------------------------------------------------|------------------|------------------|-------------|
| Febrile neutropenia                                  | 39 (3%)          | 32 (2.6%)        | 42 (2.7%)   |
| Neutropenia                                          | 26 (2%)          | 16 (1.2%)        | 27 (1.7%)   |
| Anaemia                                              | 8 (0.6%)         | 8 (0.6%)         | 10 (0.6%)   |
| Thrombocytopenia                                     | 3 (0.2%)         | 5 (0.4%)         | 8 (0.5%)    |
| Infections and infestations                          | 45 (3.5)         | 47 (3.6%)        | 60 (3.8%)   |
| Pneumonia                                            | 14 (1.1%)        | 11 (0.9%)        | 14 (0.9%)   |
| Respiratory, thoracic and mediastinal disorders      | 25 (1.9%)        | 33 (2.6%)        | 40 (2.6%)   |
| Pulmonary embolism                                   | 10 (0.8%)        | 10 (0.8%)        | 11 (0.7%)   |
| Gastrointestinal disorders                           | 34 (2.6%)        | 27 (2.1%) longer | 41 (2.6%)   |
| Vomiting                                             | 9 (0.7%)         | 2 (0.2%)         | 7 (0.4%)    |
| Dysphagia                                            | 1 (< 0.1%)       | 1 (<0.1%) no     | 4 (0.3%)    |
| Nausea                                               | 6 (0.5%)         | 1 (<0.1%)        | 5 (0.3)     |
| General disorders and administration site conditions | 27 (2.1%)        | 25 (1.9%)        | 32 (2%)     |
| Asthenia                                             | 6 (0.5%)         | 6 (0.5%)         | 7 (0.4%)    |
| Nervous system disorders                             | 8 (0.6%) product | 21 (1.6%)        | 26 (1.7%)   |
| Metabolism and nutrition disorders Medicinal         | 20 (1.5%)        | 19 (1.5%)        | 27 (1.7%)   |
| Dehydration                                          | 14 (1.1%)        | 12 (0.9%)        | 17 (1.1%)   |
| Vascular disorders                                   | 16 (1.2%)        | 18 (1.4%)        | 25 (1.6%)   |
| Cardiac disorders                                    | 11 (0.8%)        | 15 (1.2%)        | 19 (1.2%)   |
| Renal and urinary disorders                          | 11 (0.8%)        | 7 (0.5%)         | 13 (0.8%)   |
| Renal failure acute                                  | 6 (0.5%)         | 3 (0.2%)         | 6 (0.4%)    |
| Investigations                                       | 11 (0.8%)        | 5 (0.4%)         | 6 (0.4%)    |

<div style=\"page-break-after: always\"></div>

## Laboratory findings

Hematology results (actual and change from baseline/predose) were collected for Pooling Group 1

Mean red cell parameters,  including  hemoglobin,  hematocrit,  and  red  blood  cell  count  decreased  between Visit 1 and Visit 3 of each cycle; the mean changes were similar in the overall rolapitant 200 mg and control groups.Mean WBC count decreased from baseline to Visit 2 and to Visit 3 in Cycle 1 and the mean changes were similar in the overall rolapitant 200 mg and control groups. No notable differences were noted between the groups at any cycle.

|                                       | Overall CINV        | Overall CINV                  | Overall CINV            |
|---------------------------------------|---------------------|-------------------------------|-------------------------|
|                                       | Control N = 1301    | Rolapitant 200 mg N = 1294 no | All Rolapitant N = 1567 |
| Subjects with ≥ 1 incidence           | 562 (43.2%)         | 569 (44%)                     | 689 (44%)               |
| ALP > 1.5 X ULN                       | 205 (15.8%) product | 214 (16.5%)                   | 242 (15.4%)             |
| ALT >3 X ULN                          | 70 (5.4%)           | 75 (5.8%)                     | 99 (6.3%)               |
| AST > 3 X ULN                         | 32 (2.5%)           | 29 (2.2%)                     | 35 (2.2%)               |
| Total bilirubin > 1.5 X ULN Medicinal | 78 (6%)             | 93 (7.2%)                     | 121 (7.1%)              |
| BUN > 3 X ULN                         | 26 (2%)             | 18 (1.4%)                     | 22 (1.4%)               |
| Creatinine > 1.5 X ULN                | 22 (1.7%)           | 12 (0.9%)                     | 17 (1.1%)               |
| HgB < 80 G/L                          | 35 (2.7%)           | 44 (3.4%)                     | 60 (3.8%)               |
| WBC < 2.0 X 10 9 /L                   | 167 (12.8%)         | 163 (12.6%)                   | 193 (12.3%)             |
| Neutrophils < 1.0 X 10 9 /L           | 278 (21.4%)         | 260 (20.1%)                   | 322 (20.5%)             |

Serum chemistry results (actual and change from baseline/predose) were collected for Pooling Group 1. Small increases from baseline in mean creatinine values were observed in all treatment groups across cycles, with comparable (or smaller) increases seen in the rolapitant 200 mg group compared with the control and rolapitant &lt;200 mg groups. Mean changes in glucose values were small and comparable across treatment groups and cycles. In general, mean total bilirubin, AST, and ALT levels increased from baseline to Visit 2, then returned toward (or below) baseline levels at Visit 3. Similar changes were observed in all treatment groups. Table  26 :  Post  baseline  PCS  abnormal  laboratory  results,  all  cycles  combined  all  CINV studies Medicinal product no longer authorised

## Electrocardiogram

<div style=\"page-break-after: always\"></div>

The  percentage  of  subjects  with  postdose  QTcF  &gt;450  msec  in  Cycle  1  was  approximately  6%  across  all treatment groups. This decreased to between 2.2% and 2.7% of subjects at Visit 2. No subjects in the 200 mg rolapitant group or the all rolapitant doses group had QTcF &gt;500 msec postdose or at Visit 2.

Overall in all  cycles  combined at the post-dose assessment, 35.6% of subjects of subjects in the 200 mg rolapitant group and 32.3% of subjects in the all rolapitant doses group had a QTcB &gt;450 msec, compared with 37.8% of subjects in the control group. The percentage of subjects QTcB &gt;500 msec ranged from 1.0% to 1.4% across treatment groups.

<!-- image -->

| MedDRA Terms                                       | Age <65 number (percentage) N =971   | Age 65-74 number (percentage) N = 265   | Age 75-84 number (percentage) N = 58 aged > 75 longer   | Age 85+ number (percentage)   |
|----------------------------------------------------|--------------------------------------|-----------------------------------------|---------------------------------------------------------|-------------------------------|
| Total AEs                                          | 781(80.4%)                           | 228 (86%)                               | 46 (79.3)                                               |                               |
| Serious AEs - Total                                |                                      |                                         |                                                         |                               |
| - Fatal                                            |                                      |                                         |                                                         |                               |
| - Hospitalization/prolong existing hospitalization | product                              | no                                      |                                                         |                               |
| - Life-threatening                                 |                                      |                                         |                                                         |                               |
| - Disability/incapacity                            |                                      |                                         |                                                         |                               |
| - Other (medically significant)                    |                                      |                                         |                                                         |                               |
| AE leading to drop-out                             |                                      |                                         |                                                         |                               |
| Psychiatric disorders                              | 75 (7.7%)                            | 19 (7.2%)                               | 7 (12.1%)                                               |                               |
| Nervous system disorders Medicinal                 | 233 (24%)                            | 77 (29.1%)                              | 15 (25.9%)                                              |                               |
| Accidents and injuries                             |                                      |                                         |                                                         |                               |
| Cardiac disorders                                  | 35 (4.6%)                            | 12 (4.5%)                               | 6 (10.3%)                                               |                               |
| Vascular disorders                                 | 93 (9.6%)                            | 30 (11.3%)                              | 9 (15.5%)                                               |                               |
| Cerebrovascular disorders                          | 0                                    | 3 (1.1%)                                | 0                                                       |                               |
| Infections and infestations                        | 225 (23.2%)                          | 54 (20.4%)                              | 16 (27.6%)                                              |                               |
| Anticholinergic syndrome                           |                                      |                                         |                                                         |                               |

<div style=\"page-break-after: always\"></div>

| Quality of life decreased                                                             |
|---------------------------------------------------------------------------------------|
| Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures |
| <other AE appearing more frequently in older patients>                                |

During Cycle 1 and across all cycles combined the overall incidence of TEAEs was higher in North America and Asia/South Africa compared with Central/South America and Europe in both the rolapitant and control groups. This was generally the case across the SOCs, particularly for North America. However, there was no difference in the overall incidence of TEAEs in the rolapitant group compared with the control group in any of the geographic regions for Pooling Group 1

The incidence of TEAEs in Cycle 1 were generally similar between rolapitant and control for all age groups. The exception was in the &gt;75 y population where dizziness was higher in the rolapitant compared to control group (10.3% and 1.5%, respectively) as was alopecia (10.3% and 3.0%, respectively). Individual TEAEs reported in subjects ≥ 75 years of age at higher incidence (&gt;5% difference) in the rolapitant group compared with control included diarrhea (20.7% and 13.6%), peripheral edema (10.3% and 3.0%), anemia (17.2% and 6.1%), leukopenia (10.3% and 4.5%), dizziness (12.1% and 4.5%), alopecia (15.5% and 7.6%), dyspnea (12.1% and 4.5%) and hypotension (10.3% and 0). Generally, across all cycles, in both treatment  groups,  the  elderly  population  experienced  a  higher  rate  of  TEAEs  than  those  subjects  &lt;75  y, driven largely by fatigue and asthenia. Gender During Cycle 1, the overall incidence of TEAEs was similar between rolapitant and control subjects in Pooling Group 1, regardless of gender. Within the SOC of Nervous system disorders ,  the  incidence of headache in control and rolapitant groups was higher in female subjects (10.4% and 7.6%) than in male subjects (3.9% and 4.2%).Similarly, the incidence of alopecia was  higher in female subjects (11.5% and 10.3%) than in male subjects (4.2% and 3.5%) in both control and rolapitant subjects, respectively Similar  to  Cycle  1,  evaluations  of  TEAEs  across  all  cycles  combined  revealed  no  significant  differences between the rolapitant and control groups for either gender. Race The  number  of  non-white  participants  in  the  CINV  studies  was  small,  making  up  just  over  25%  of participants,  of  which  about  14%  were  categorised  as  Asian.  This  is  a  broad  category  that  could  cover  a number of ethnic groups. Only 2.3% were Black or African American. Geographic Region Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Cycle Length

The overall incidence of TEAEs in Cycle 6 for subjects who received chemotherapy at intervals &lt;21 days, 21 to  &lt;28  days,  and ≥ 28  days  at  Cycle  1  was  higher  in  control  subjects  than  in  subjects  who  received rolapitant;  however  the  subgroups  &lt;21  days  and  to  &gt;28  days  contained  few  subjects  for  the  Cycle  6 analysis.

The Cycles 2-6 analysis showed that the incidence of TEAEs was similar in the 200 mg rolapitant and control group for subjects who received chemotherapy at intervals &lt;21 days, 21 to &lt;28 days, and ≥ 28 days.

The  most  common  SOCs  in  which  TEAEs  leading  to  study  discontinuation  were  in  the  overall  200  mg rolapitant group were Gastrointestinal disorders (1.6%) and Blood and lymphatic system disorders (1.1%) they were similar in the 200 mg rolapitant group, the all rolapitant doses group, and the control group. The incidence  of  TEAEs  leading  to  study  discontinuation  was  similar  in  the  200  mg  rolapitant  group,  the  all rolapitant doses group, and the control group. Within each PT, the overall incidence of TEAEs leading to study discontinuation was &lt;1%. TEAEs leading to discontinuation in more than 2 subjects in any treatment group across Cycles 1-6 in the 200 mg rolapitant, all rolapitant, and control groups were nausea (0.5%, 0.6%, and 0.2%,  respectively),  stomatitis  (0.4%,  0.3%,  and  0,  respectively),  vomiting  (0.2%,  0.3%,  and  0.5%, respectively), dysphagia (0.2%, 0.2%, and 0, respectively), anaemia (0.4%, 0.3%, and 0.3%, respectively), febrile neutropenia (0.2%, 0.3%, and 0.5%, respectively), leukopenia (0.2%,  0.4%,  and  &lt;0.1%, respectively),  neutropenia  (0.2%,  0.1%,  and  0.3%,  respectively),  disease  progression  (0.2%,  0.1%,  and 0.2%, respectively), respiratory tract infection (0.2%, 0.2%, and 0, respectively), pneumonia (0.2%, 0.2%,

Pregnancy and lactation: The use of rolapitant in pregnant or lacting women has not been studied. Safety related to drug-drug interactions and other interactions Rolapitant is a mild to moderate inhibitor of CYP2D6 and a mild inhibitor of BCRP. TEAEs and select TESAEs for subjects who did and did not receive CYP2D6 and BCRP substrates during the same treatment cycle as the study drug were reported. The overall incidence of TEAEs and TESAEs in Cycle 1 was higher among subjects who received concomitant treatment  with  CYP2D6  and  BCRP  substrates  compared  with  those  who  did  not;  however,  the  rates  were generally similar between the respective rolapitant and control groups. There  were  no  remarkable  differences  in  the  incidence  of  TESAEs  in  subjects  who  received  rolapitant  or control concomitantly with a BCRP substrate compared with subjects who did not. This analysis was done for all individual cycles and no significant differences were observed between rolapitant and control. Discontinuation due to AES In  Cycle  1,  the  overall  incidence  of  TEAEs  leading  to  treatment  discontinuation  was  reported  in  3.1%  of subjects who received 200 mg rolapitant, 3.1% of subjects who received any dose of rolapitant and 3.7% of subjects in the control group. Overall, in all cycles combined, 8.1% of subjects who received 200 mg rolapitant experienced at least 1 TEAE that lead to study discontinuation, compared with 8.2% of subjects who received any dose of rolapitant and 8.7% of subjects in the control group. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

and  0.3%,  respectively),  blood  creatinine  increased  (0.3%,  0.3%,  and  0.6%,  respectively),  and  drug hypersensitivity (0.3%, 0.3%, and &lt;0.1%, respectively).

## Post marketing experience

Rolapitant was launched into the US market in November 2015. As of the cutoff date of 01 December 2015 approximately 331 patients have been exposed based on the number of doses distributed by 01 December 2015.

2.6.1. Discussion on clinical safety Clinical safety was assessed through the 4 studies that were performed in the target population: prevention of CINV in patient receiving HEC and MEC but also in post-operative nausea and vomiting population and in healthy volunteers as recommended in European guideline. However the data is difficult to interpret given that the study populations may have differed and the number of placebo subjects in the pooled group was only  56  out  of  a  total  of  550.  Three  case  of  presyncope  and  one  of  rhabdomyolysis  were  noted  in  those exposed to rolapitant. However specific analysis conducted across the CINV studies failed to show any signal for rhabdomyolysis/myopathic events or cardiac arrhythmias. Overall a total of 2798 subjects were exposed to oral rolapitant at any dose, including 1567 subjects at risk for CINV among them 1294 received the recommended dose of 200 mg. The overall incidence of TEAEs in subjects at risk for CINV receiving rolapitant 200 mg was around 65 % (n=828)  in  cycle  1  and  80%  (n=1055)  in  all  cycles  and  was  similar  in  all  groups.  The  most  commonly reported  events  were  as  expected  for  a  cancer  population  with  underlying  comorbidities  undergoing myelosuppressive chemotherapy. Across  cycles,  the  most  commonly  reported  TEAEs  in  the  CINV  studies  were  fatigue,  alopecia,  and neutropenia with similar incidence in the rolapitant 200 mg and control groups. The most common treatment related TEAEs in the 200 mg group were fatigue (2.4%), constipation (2.2%) and headache (1.9%). Serious TEAEs rates were similar in CINV patient groups. In all cycles combined, 17.5% (n=227) of subjects who  received  200  mg  rolapitant  experienced  at  least  1  serious  TEAE,  compared  with  18.8%  (n=244)  of subjects in the control group. The most common SOCs in which Serious TEAEs in 200 mg rolapitant group were observed were Blood and lymphatic disorders (4.6% n= 59), infectious and infestations (3.6% n=47) and respiratory, thoracic and mediastinal disorders (2.6% n= 21). Most of serious TEAEs were considered to be unrelated to study drug. In all cycles combined, the overall incidence of TEAEs leading to treatment discontinuation were reported in 8.1%  of  subjects  who  received  200  mg  rolapitant,  and  8.7%  of  subjects  in  the  control  group.  The  most common  SOCs  leading  to  discontinuation  were  gastrointestinal  disorder  (1.6%  n=  21)  and  Blood  and lymphatic disorders (1.1% n=14). Medicinal product no longer authorised

Of the 2868 subjects treated in CINV studies, 79 died: 48 (3.1%) in the rolapitant group and 31 (2.9%) in the placebo group. None of the deaths were considered to be related to treatment with study drug.

A  research  on  the  following  TEAEs  was  realised:  hematopoietic  leucopenia,  anemia,  acute  renale  failure hepatic  dysfunction,  cardiac  arrhythmia,  embolic  and  thrombotic  events  and  rhabdomyolysis/myopathy events.

<div style=\"page-break-after: always\"></div>

Regarding adverse events related to the central nervous system, the most common TEAEs in CINV studies were headache (8.9%), dizziness (7.5%) and dysgeusia (3.9%). Rates were similar between rolapitant, and control groups. Review by cycle did not show an increase in the incidence or severity with repeated dose.

Pre-clinical  data  raised  a  potential  proconvulsivant  effect  of  rolapitant.  In  CINV  studies,  the  TEAEs  of seizure/convulsions were reported at the same incidence (0.2%) in the rolapitant 200 mg (n=4) and control groups  (n=2)  and  occurred  in  subjects  with  known  risk  factors  (mostly  unknown  brain  metastasis).  Two others  subjects  receiving  lower  dose  of  rolapitant  experienced  convulsion.  None  were  reported  in  healthy volunteers.

No  convulsions were  reported  in healthy subjects.  No  death  and  no  TEAES  leading  to  treatment discontinuation occurred.

Analyses of haematologic events (leukopenia, anemia), acute renal failure, cardiac arrhythmia, thrombothic events and rhabdomyolysis/myopathy events did not show a signal for rolapitant compared to placebo over multiple cycles of chemotherapy. Regarding hepatic toxicity, overall, 5 patients met the Hy's law criteria. One case occurred in a patient taking 10 mg of rolapitant and 4 in patients taking placebo. In CINV studies, there were no patterns of changes for hematology, blood chemistry, and vital signs in Cycle 1  and  across  multiple  cycles  they  were  comparable  between  rolapitant  and  control  groups  across  all  time points. Most changes were expected in cancer patients receiving myelosuppressive chemotherapy. There was no evidence of a treatment-related effect on clinical laboratory or ECG parameters. In studies in healthy volunteers, 550 subjects received single doses of rolapitant, including 69, 422, and 59 subjects who received &lt;200 mg rolapitant, 200 mg rolapitant, and &gt;200 mg rolapitant, respectively. The  overall  incidence  of  TEAEs  was  30.7%  (n=169)  in  patients  receiving  rolapitant  and  51.8%  (n=29)  in placebo groups. The incidence raised with rolapitant doses (8.7%,16.6% and 30.5% respectively). In placebo group the incidence was 21.4%. At  200  mg  dose,  the  most  commonly  reported  treatment-related  TEAEs  (rates  in  rolatipant  and  placebo groups)  were  somnolence  (5.2%,  1.8%),  headache  (4.3%,  4.6%),  dizziness  (2.8%,  1.8%)  and  diarrhoea (1.4%,0%). Only dizziness seems to occur at an increasing frequency with dose. In patients receiving rolapitant dose &gt; 200mg , the most common treatment-related TEAEs were dizziness (15.3%  and  1.8%),  nausea  (6.8%  and  0),  headache  (5.1%  and  3.6%),  somnolence  (3.4%  and  1.8%), fatigue (3.4% and 5.4%), and polyuria (3.4% and 0) in the rolapitant and control groups, respectively. A case of rhabdomyolysis reported as a TESAE in Pool 2 was judged to be related to rolapitant or not and if not what alternative explanations might account for this episode of rhabdomyolysis. Following assessmsnt of D120 Applicant's response, the Applicant cannot exclude the possibility that the incident of rhabdomyolyis in a healthy volunteer participating in a bioequivalence study was related to rolapitant. As rhabdomyolyis is at least possibly related to rolapitant in this incident, rhabdomyolysis should be included in section 4.8 of the SmPC. Medicinal product no longer authorised

There are no adequate and well-controlled studies on the use of rolapitant in pregnant or lactating women: no  clinical  studies  has  been  conducted  in  these  subpopulations,  and  it  is  not  known  whether  rolapitant  is excreted  in  human  milk.  Overall,  given  the  claimed  indication,  and  the  preclinical  data,  rolapitant  should should  not  be  used  during  pregnancy  unless  clearly  necessary,  and  lactation  is  not  recommended  during treatment. (See SmPC section 4.6.)

<div style=\"page-break-after: always\"></div>

From the safety database all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics.

## 2.6.2. Conclusions on the clinical safety

Overall, the safety profile of rolapitant used in prevention of CINV appears sufficiently investigated. No major safety issues have been identified in the course of the CINV trials with most of adverse events appearing manageable, and in line with the adverse events usually observed with anti-emetic products.

| Summary of safety concerns   |                                                                                                                                                                                                                              |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Interaction with CYP2D6 substrates with narrow therapeutic index e.g. thioridazine, pimozide Neutropenia longer                                                                                                              |
| Important potential risks    | Seizures Other than CYP2D6 related drug interaction                                                                                                                                                                          |
| Missing information          | Use in pregnancy Use in patients <18 years old Use in patients with severe hepatic impairment Use in patients with severe renal impairment and patients with end stage of renal diseases undergoing haemodialysis product no |

2.7. Risk Management Plan Safety concerns Summary of safety concerns Having considered the data in the safety specification the CHMP agrees that the safety concerns listed by the applicant are appropriate and has added one important identified risk, which is the interaction with CYP2D6 substrates with narrow therapeutic index e.g. thioridazine, pimozide. Pharmacovigilance plan Table of on-going and planned additional PhV studies/activities in the Pharmacovigilance Plan: Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| product   | no   | longer   |
|-----------|------|----------|
| Medicinal |      |          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| 20 pM, 3                                                                  | rolapitant with OCT1 substrates e.g. oxaliplating. metformin, and aciclovir                     | interactions                        |                             |         |
|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------|-----------------------------|---------|
| In vivo study assessing the ability for rolapitant on CYP1A2 substrate.,3 | The objective of this study is to assess the ability for rolapitant on CYP1A2 substrate in vivo | Other than CYP2D6 drug interactions | Planned to start in Q2 2017 | Q1 2018 |

<!-- image -->

The safety profile of rolapitant in the prevention of nausea and vomiting associated with initial and repeat courses of highly and moderately emetogenic cancer chemotherapy in adults will be evaluated through the routine pharmacovigilance system of TESARO UK Ltd. Routine pharmacovigilance activities are fully described in the Pharmacovigilance System Master File (PSMF). The Applicant has updated Part III regarding all safety concerns. Risk minimisation measures Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

|            | longer   |
|------------|----------|
| product no |          |
| Medicinal  |          |

## Conclusion

The CHMP and PRAC considered that the risk management plan version 1.7 (28 Feb 2017) is acceptable.

<div style=\"page-break-after: always\"></div>

## 2.8. Pharmacovigilance

## Pharmacovigilance system

The  CHMP  considered  that  the  pharmacovigilance  system  summary  submitted  by  the  applicant  fulfils  the requirements of Article 8(3) of Directive 2001/83/EC.

2.9. New Active Substance The applicant compared the structure of rolapitant with active substances contained in authorised medicinal products in the European Union and declared that it is not a salt, ester, ether, isomer, mixture of isomers, complex or derivative of any of them. 2.10. Product information 2.10.1. User consultation The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use. 2.10.2. Additional monitoring Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Varuby (rolapitant) is included in the additional monitoring list as it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU. 3. Benefit-Risk Balance 3.1. Therapeutic Context 3.1.1. Disease or condition Chemotherapy-induced  nausea  and  vomiting  (CINV)  can  interfere  with  treatment  adherence,  functional activity and quality of life in patients treated with cytotoxic chemotherapy. It is defined as acute and delayed emesis, both phases being mediated by neurotransmitter- driven mechanisms. Medicinal product no longer authorised

The  acute  phase,  which  represents  the  first  24  hours  following  chemotherapy,  is  mediated  in  part  by chemotherapy-induced  increases  in  serotonin  (5-HT)  release  and  activation  of  5-HT3  receptors  on  vagal afferent neurons located primarily in the gastrointestinal tract. The delayed phase of CINV, which occurs 2 to 5 days following the initiation of chemotherapy involves the production of substance P, which binds to NK1 receptors in the vomiting centre of the brain, leading to nausea and vomiting. Although NK-1 signalling has some role in acute chemotherapy-induced nausea and vomiting (≤24 h), delayed emesis has primarily been

<div style=\"page-break-after: always\"></div>

linked  with  substance  P  mediated  stimulation  of  neurokinin  1  receptors  within  the  central  and  peripheral nervous systems.

## 3.1.2. Available therapies and unmet medical need

Three categories of drugs are routinely used for the management of CINV: type three 5-hydroxytryptamine (5-HT3) receptor antagonists, the neurokinin-1 receptor antagonists (NK1 RA), and glucocorticoids to prevent acute nausea and vomiting following chemotherapy of high emetic risk.

A three-drug regimen including single doses of a 5-HT3 receptor antagonist, dexamethasone and aprepitant given before chemotherapy is recommended. A number of agents are licensed for the prevention of CINV including  the  first-  and  second  generation  5HT3  receptor  antagonists  ondansetron,  granisetron  and palonosetron and NK1 receptor antagonists aprepitant, fosaprepitant, and netupitant. Evidence-based  guidelines  for  CINV  prophylaxis  have  been  published  by  different  contemporary  sources, (ESMO/MASCC  2010;  NCCN  2016;ASCO0  generally  recommending  a  5HT3  receptor  antagonists  plus corticosteroid  for  patients  receiving    moderately  emetogenic  chemotherapy  (  MEC),  and  combination treatment with an NK-1RA and 5HT3 receptor antagonist plus a corticosteroid for patients receiving HEC.  No differences between the 5-HT3 receptor antagonists, dolasetron, granisetron, ondansetron, tropisetron have been shown in terms of efficacy. There is no consensus on the dose of dexamethasone to be used in delayed emesis. A single 20-mg dose before chemotherapy is recommended based on the observations that the 20mg dose had the highest numerical efficacy. NK1  receptor  antagonists,  aprepitant  and  netupitant  are  inhibitors  of  cytochrome  P450  (CYP)  3A4,  with aprepitant also having CYP3A4 and CYP2C9 induction potential and inhibition of other CYP enzymes induction potential. Dosage adjustment of concomitantly administered drugs is required including dexamethasone. Although  antiemetic  prophylaxis  has  been  improving  continuously,  significant  numbers  of  patients  still continue  to  experience  CINV.  Compliance  with  current  emetic  guidelines  can  be  suboptimal.  Treatment  of nausea remains a challenge. 3.1.3. Main clinical studies The efficacy of rolapitant for the prevention of CINV was initially evaluated in one phase 2 dose ranging study and 3 pivotal studies in subjects at risk for CINV including: -Study  P04351 :  multicentre,  randomised,  double-blind,  parallel-group  study  evaluated  rolapitant  doses ranging from 10 to 200 mg, in patient receiving HEC chemotherapy. -Studies  P04832  and  P04833  : multicentre,  randomised,  parallel-group,  double-blind  studies  designed  to evaluate the efficacy of a single dose of rolapitant 200 mg administered PO with a 5-HT3 receptor antagonist and dexamethasone compared to placebo administered with a 5-HT3 receptor antagonist and dexamethasone for the prevention of delayed phase CINV (&gt;24 to 120 hours) in patient receiving HEC chemotherapy. Medicinal product no longer authorised

-Study  P04834  : multicentre,  randomised,  parallel-group,  double-blind  study  designed  to  evaluate  the efficacy  of  a  single  dose  of  rolapitant  200  mg  administered  PO  with  a  5-HT3  receptor  antagonist  and dexamethasone compared to placebo administered with a 5-HT3 receptor antagonist and dexamethasone for the prevention of delayed phase CINV (&gt;24 to 120 hours) in patient receiving MEC chemotherapy.

<div style=\"page-break-after: always\"></div>

## 3.2. Favourable effects

All  three  studies  enrolled  a  broad  population  of  subjects  based  on  age,  gender,  race  and  region  with considerable comorbidities who were undergoing myelosuppressive chemotherapy for a variety of cancers.

## HEC phase III studies (Study P04832 and Study P04833)

In  both  studies,  the  primary  efficacy  endpoint  was  reached,  the  rolapitant  in  combination  with  a  5-HT3 inhibitor  and  dexamethasone group achieved a statistically  significantly  higher  Complete  Response  CR  (no emesis and no rescue medication) rate in the delayed phase compared to the in placebo combination with a 5-HT3 inhibitor and dexamethasone group (72.7% versus 58.4%, respectively; p &lt; 0.001 in the first study and 70.1 versus 61.9% p=0.43 in the second study). Statistical significance was reached in both key secondary endpoints (CR in acute and overall phases) in only one of the HEC study P04832: Acute phase: OR 1.8 95%CI (1.2, 2.8) p=0.005) and Overall phase: OR 1.8 95%CI (1.3, 2.8) p=0.001. MEC study (Study P04834) This study included patients naive to moderately or highly emetogenic chemotherapy and were scheduled to receive a first course of MEC. At least 50% of the study subjects would receive anthracycline in combination with cyclophosphamide IV (AC MEC). In the MEC study, a pre-specified subgroup analysis was performed for the endpoint of complete response in each CINV phase for subjects who received Non-AC MEC (MEC according to recent guidelines) vs. AC based chemotherapy (considered HEC according to recent guidelines). The primary efficacy endpoint of complete response in the delayed phase of CINV (&gt;24 through 120 hours following initiation of MEC) was achieved; specifically, a statistically significant higher complete response rate was observed in the rolapitant group compared to the control group (71.3% versus 61.6% OR 1.6 95% CI (1.2,2.0) p&lt;0.001 respectively). The treatment effect for rolapitant compared to placebo was 9.7%. Complete response in acute and overall CINV phases were numerically in favour of rolapitant arm but not statistically significant in one of the studies in subject receiving HEC regimen (P048033).  Complete response over the overall phase (0-120 h at-risk period) was demonstrated in favour of the rolapitant treatment arm in Study P04834 (Overall phase OR 1.6 95%CI (1.3, 2.0) p&lt;0.001) but not for the acute phase OR 1.2 95%CI (0.9,1.6 =p 0.143) In this study the rates of CR in the delayed phase were significantly higher for rolapitant group compared with subjects who received control in the overall population (71.3%, 61.6% respectively), in the non-AC MEC population (76.1%, 63.8% respectively) and in the AC population (66.9%, 59.6% respectively). Efficacy in repeat phases across studies has been shown and is reflected in the SmPC. Medicinal product no longer authorised

## 3.3. Uncertainties and limitations about favourable effects

The CR treatment effect in the delayed phase has been demonstrated as discussed above whereas in the acute phase there was a numerical effect that achieved statistical significance in only one of the 2 HEC and in the pooled analysis HEC studies compared with control is 7%. In the MEC study however complete protection (a composite score defined as no emesis, no rescue medication and maximum nausea VAS&lt;25mm) was in favour of rolapitant in both the delayed and overall phases of CINV. Therefore the indication was revised to

<div style=\"page-break-after: always\"></div>

state the benefit of the product is on the prevetion of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.

## 3.4. Unfavourable effects

Clinical safety was assessed through the 4 studies that were performed in the target population: prevention of CINV in patient receiving HEC and MEC but also in post-operative nausea and vomiting population and in healthy volunteers as recommended in European guideline.

Overall 2798 individuals have been exposed to rolapitant at any dose in a variety of clinical trials. In CINV trials 1657 patients have been exposed to rolapitant and 1294 have been exposed to the proposed dose, of whom 319 have been exposed to 6 cycles of treatment. TEAEs across CINV trials (P04832, P04833, P04834) were reported in 80.9% of the rolapitant 200mg group and 80.8% of the control group. TEAEs occurred at a similar rate in the HEC and MEC populations and there were no differences between the rolapitant 200 mg and control groups. The  most  commonly  reported  types  of  events  in  the  CINV  studies  were  gastrointestinal  disturbances (constipation, diarrhoea and nausea). Other commonly reported events were fatigue, asthenia, neutropenia, anaemia, alopecia and decreased appetite. A  slightly  higher  frequency  of  occurrence  was  recorded  for  a    number  of  TEAES  in  the  rolapitant  group compared to  the  control  group  in  Cycle  1:  neutropenia  (6.8%  control,  8.2%  rolapitant);  dizziness  (3.2% control,  4.7%  rolapitant);  dyspepsia  (2.7%  control,  4%  rolapitant),  stomatitis  (2.2%  control,  3.3% rolapitant); hiccups 2.5% control, 3.2% rolapitant) and anaemia (2.7% control, 3.1% rolapitant). For cycles 1 to 6 a difference in frequency was maintained for neutropenia, anaemia, dyspepsia, hiccups and mucosal inflammation. There were also small excesses noted for hypomagnesaemia, abdominal pain, dyspnoea and thrombocytopenia across the 6 cycles of treatment. In all cycles combined, 17.5% (n=227) of subjects who received 200 mg rolapitant experienced at least 1 serious TEAE, compared with 18.8% (n=244) of subjects in the control group. The most commons SOCs in which  Serious  TEASs  in  200  mg  rolapitant  group  were  Blood  and  lymphatic  disorders  (4.6%  n=  59), infectious and infestations (3.6% n=47) and respiratory, thoracic and mediastinal disorders (2.6% n= 21). There were 79 deaths during the CINV studies, including 48 (3.1%) in rolapitant group and 31 (2.4%) in control group but none of the deaths were considered to be related to treatment with study drug. In healthy subjects, the most commonly reported treatment-related TEAEs (rates in rolatipant and placebo groups)  were  somnolence  (5.2%,  1.8%),  headache  (4.3%,  4.6%),  dizziness  (2.8%,  1.8%)  and  diarrhoea (1.4%, 0%). 3.5. Uncertainties and limitations about unfavourable effects Medicinal product no longer authorised

The vast majority (75%) of those participating in the pivotal CINV studies were aged under 65, just over 20% were aged between 65 and 74 and only 4.5% were aged over 75 and ony 5  many patients were aged over 85. Overall the proportion of those in the under 65 age-group experiencing TEAEs across all 6 cycles combined was similar to that in the over 75 population. No patients in the studies have been exposed to greater than 6 cycles of treatment so there is no data on longer term treatment. Limited data are available in patients  who  were  aged  over  75  and  in  non-white  populations  other  racial/ethnic  groups  in  the  studies,

<div style=\"page-break-after: always\"></div>

however  additional  safety  data  are  expected  from  studies  included  in  the  RMP  and  from  post-marketing phase (see RMP).

Further drug - drug interaction studies are to be provided post authorisation and are described in the RMP.

## 3.6. Effects Table

| Effect                                                      | Short Description                                                           | Unit               | Rolapitant 200 mg   | placebo            | Uncertainties/ Strength of evidence Referenc es                                                                                  | Uncertainties/ Strength of evidence Referenc es   |
|-------------------------------------------------------------|-----------------------------------------------------------------------------|--------------------|---------------------|--------------------|----------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|
| Favourable Effects                                          | Favourable Effects                                                          | Favourable Effects | Favourable Effects  | Favourable Effects | Favourable Effects                                                                                                               | Favourable Effects                                |
| Prevention of nausea and vomiting following HEC regimen     | % of patients with no emesis, no rescue medication during: 25-120h          | %                  | 72.7 a 70.1 b       | 58.4 a 61.9 b      | P<0.001 P=0.043 longer                                                                                                           | Studies P04832 P04833                             |
| Prevention of nausea and vomiting following HEC regimen     | 0-24h                                                                       |                    | 83.7 a              | 73.7 a no          | Key secondary endpoint                                                                                                           | Studies P04832                                    |
| Prevention of nausea and vomiting following HEC regimen     | 0-120h                                                                      | %                  | 70.1 a product      | 56.5 a             | Key secondary endpoint Significant difference between treatment and placebo could be observed only in study P04832               | Studies P04832                                    |
| Prevention of nausea and vomiting following MEC +AC regimen | % of patients with no emesis, no rescue medication during 25-120h Medicinal | %                  | 71.3                | 61.6               | Primary endpoint Statistically significant superior to placebo 50% of subjects did not receive MEC regimen as currently defined. | Study P04834                                      |
| Prevention of nausea and vomiting following HEC regimen     | % of patients with no emesis, no rescue medication during: 0-24h            | %                  | 83.4 b              | 79.5 b             | Key secondary endpoint not statistically significant vs placebo                                                                  | Studies P04833                                    |
|                                                             | 0-120h                                                                      | %                  | 67.5 b              | 60.4 b             | Improvement not statistically significant vs control                                                                             |                                                   |

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Effect                                                                 | Short Description                                                | Unit                 | Rolapitant 200 mg    | placebo              | Uncertainties/ Strength of evidence                             | Referenc es          |
|------------------------------------------------------------------------|------------------------------------------------------------------|----------------------|----------------------|----------------------|-----------------------------------------------------------------|----------------------|
| Prevention of nausea and vomiting following HEC regimen Studies P04833 | % of patients with no emesis, no rescue medication during: 0-24h | %                    | 83.5                 | 80.3                 | Key secondary endpoint not statistically significant vs placebo |                      |
|                                                                        | 0-120h                                                           | %                    | 68.6                 | 57.8                 |                                                                 |                      |
| Unfavourable Effects                                                   | Unfavourable Effects                                             | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                            | Unfavourable Effects |
|                                                                        | Headache                                                         |                      |                      |                      | authorised                                                      | See Clinical Safety  |
|                                                                        | Fatigue                                                          |                      |                      |                      |                                                                 | section              |
|                                                                        | Dizzines                                                         |                      |                      |                      |                                                                 |                      |

Unfavourable Effects Notes: a Study   P04832 b Study   P04833 3.7. Benefit-risk assessment and discussion 3.7.1. Importance of favourable and unfavourable effects Results from clinical studies showed statistically significant efficacy of rolapitant in combination with a 5-HT3 inhibitor and dexamethasone over placebo in combination with a 5-HT3 inhibitor and dexamethasone in the prevention  of  chemotherapy  induced  in  delayed  nausea  and  vomiting  in  adults  receiving  initial  course  of highly and moderately emetogenic chemotherapy regimen. The most important effects observed are 14.3% and 8.2% improvement in CR in the delayed phase in the both HEC studies and 9.7% improvement in the MEC study. This represents a clinically relevant improvement in the number subjects who did not experience emesis or use rescue medications during the delayed phase. A 10% difference has been described in the literature as clinically relevant (Olver 2004, Roila 2010) for the HEC studies.  The  CR  rate  in  MEC  was  further  analysed  for  subjects  who  received  non-AC  MEC  vs.  AC chemotherapy across all phases of CINV. Although the complete response rates were significantly higher for both the  AC  and  non  AC  chemotherapy  populations,  the  treatment  effect  in  the  delayed  phase  was  more pronounced  for  the  Non  AC  MEC  group  compared  to  the  AC  group  (treatment  effect  12.3%  and  7.3% respectively). Medicinal product no longer authorised

Rolapitant  reduces  emesis  and  the  requirement  for  rescue  medication  in  the  delayed  phase  for  patients experiencing  CINV  following  an  initial  cycle  of  cisplatin  based  chemotherapy.  Similarly  an  improvement  in nausea was seen across the pooled studies in the delayed phase.

<div style=\"page-break-after: always\"></div>

Persistence of effect over repeat treatments is considered satisfactory with the accepted limitations identified such  as  use  of  different  endpoints,  use  of  6  day  recall  for  nausea  and  vomiting  data  and  lack  of  re randomisation following cycle 1, and clinically relevant information has been described in the SmPC.

Side effects are in line with what is expected from this type of products in this indication. Overall the safety profile of rolapitant appears favourable and no significant safety issue has been identified.

3.7.2. Balance of benefits and risks Prevention of vomiting and reduction in the use of rescue medication in the delayed phase has been clearly established for initial courses of highly emetogenic cisplatin based chemotherapy and non -AC moderately emetogenic  chemotherapy  in  adults.  Improvement  in  nausea  was  less  consistent  across  the  two  study populations. There was a clinically meaningful improvement in nausea for the delayed phase of CINV for the HEC population and in the non-AC MEC or AC subgroup. Overall rolapitant appears to have been well tolerated in the CINV population and there were no clinically meaningful differences in the incidence of commonly reported events between the rolapitant group and the control group in the CINV studies and there was no evidence for cumulative toxicity over multiple cycles for any TEAE and most of the common TEAEs reported were as expected based on a population of subjects with cancer undergoing chemotherapy. 3.7.3. Additional considerations on the benefit-risk balance Collectively, data show that rolapitant is active in prevention of chemotherapy-induced delayed nausea and vomiting following cisplatin based HEC and non-AC MEC. The treatment effect associated with rolapitant in terms of controlling symptoms of nausea and vomiting in the acute phase of CINV following treatment with HEC is modest in one of the HEC studies and non-statistically significant in the other HEC study. Rolapitant has shown adequate efficacy in terms of reducing rates of emesis and use of rescue medicine in patients treated with MEC in the delayed and overall phases but not the acute phase and the treatment effect in favour of rolapitant was inconsistent across the non-AC MEC and AC subgroups. Data on repeat efficacy over chemotherapy cycles have been considered adequate and described in section 5.1 of the SmPC. The originally applied indication Prevention of nausea and vomiting associated with initial and repeat courses of highly and moderately emetogenic cancer chemotherapy in adults was revised as follows: Prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults. Varuby is given as part of combination therapy. 3.8. Conclusions The overall B/R of Varuby is positive. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the risk-benefit balance of Varuby is favourable in the following indication:

Prevention of delayed nausea and vomiting associated with initial and repeat courses of highly and moderately emetogenic cancer chemotherapy in adults

- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

Varuby is given as part of combination therapy. The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions: Conditions or restrictions regarding supply and use Medicinal product subject to medical prescription. Other conditions and requirements of the marketing authorisation Periodic Safety Update Reports The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation. Conditions or restrictions with regard to the safe and effective use of the medicinal product Risk Management Plan (RMP) The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP. An updated RMP should be submitted: · At the request of the European Medicines Agency; Medicinal product no longer authorised

## New Active Substance Status

Based on the CHMP review of the available data, the CHMP considers that rolapitant is considered to be a new active substance.